Use these links to rapidly review the document
TABLE OF CONTENTS
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
|
|
|
Filed by the Registrant ý
|
Filed by a Party other than the Registrant o
|
Check the appropriate box:
|
o
|
|
Preliminary Proxy Statement
|
o
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
ý
|
|
Definitive Proxy Statement
|
o
|
|
Definitive Additional Materials
|
o
|
|
Soliciting Material Pursuant to §240.14a-12
|
|
|
|
|
|
Boston Scientific Corporation
|
(Name of Registrant as Specified in its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
|
Payment of Filing Fee (Check the appropriate box):
|
ý
|
|
No fee required.
|
o
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
(5)
|
|
Total fee paid:
|
o
|
|
Fee paid previously with preliminary materials.
|
o
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
(3)
|
|
Filing Party:
|
|
|
(4)
|
|
Date Filed:
|
Table of Contents
March 25,
2020
Dear
Boston Scientific Stockholder:
You
are cordially invited to attend the Annual Meeting of Stockholders of Boston Scientific Corporation (the Company) to be held on Thursday, May 7, 2020, at 8:00 a.m. Eastern Time, at
the Company's
Corporate Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752 (Annual Meeting).
This
year you are being asked to:
-
1.
-
elect
to the Board of Directors ten nominees for director;
-
2.
-
approve,
on a non-binding, advisory basis, named executive officer compensation;
-
3.
-
approve
an amendment and restatement of our 2011 Long-Term Incentive Plan, as amended (2011 LTIP);
-
4.
-
ratify
the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2020 fiscal year;
-
5.
-
consider
and vote upon a stockholder proposal described in this Proxy Statement, if properly presented at the Annual Meeting; and
-
6.
-
consider
and vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
These
matters are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement. Our Board of Directors urges you to read the accompanying Proxy Statement and recommends that
you vote "FOR" all of the director nominees, the named executive officer compensation, the amendment and restatement of our 2011 LTIP, and the ratification of the appointment of Ernst &
Young LLP as our independent registered public accounting firm and "AGAINST" the stockholder proposal described in this Proxy Statement. At the meeting, you will be provided with the
opportunity to ask questions.
On
or about March 25, 2020, we will mail to our stockholders of record at the close of business on Friday, March 13, 2020, the record date for our Annual Meeting, an Important Notice of
Internet Availability of Proxy Materials (Notice) containing instructions on how to access our Proxy Statement and Annual Report for the year ended December 31, 2019 (Annual Report) on the
Internet and also how to vote their shares via the Internet. If you received a Notice by mail, you will not receive printed proxy materials unless you specifically request them. Both the Notice and
the Proxy Statement contain instructions on how you can request a paper copy of the Proxy Statement and Annual Report.
The
Board of Directors appreciates and encourages stockholder participation in the Company's affairs. Whether or not you plan to attend the Annual Meeting, we encourage you to vote your shares.
Accordingly, we request that as soon as possible, you vote via the Internet or, if you have received printed proxy materials, you vote via the Internet, by telephone or by mailing your completed proxy
card or voter instruction form.
We currently intend to hold our Annual Meeting in person. However, we are actively monitoring the coronavirus (COVID-19) situation and are sensitive to the public health and
travel concerns you may have and the protocols that federal, state and local governments may impose. In the event it is not possible or advisable to hold our Annual Meeting in person, we will announce
alternative arrangements for the meeting as promptly as practicable, which may include holding the meeting solely by means of remote communication. Please monitor http://investors.bostonscientific.com
for updated information. If you are planning to attend our meeting, please check the website one week prior to the meeting date. As always, we encourage you to vote your shares prior to the Annual
Meeting.
Thank
you for your continuing support.
Michael F. Mahoney
Chairman of the Board of Directors
President and Chief Executive Officer
Table of Contents
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
Marlborough,
Massachusetts
March 25, 2020
The
Annual Meeting of Stockholders of Boston Scientific Corporation (Annual Meeting) will be held on Thursday, May 7, 2020, at 8:00 a.m. Eastern Time, at the Company's Corporate
Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, for the following purposes:
-
1.
-
to
elect to the Board of Directors ten nominees for director;
-
2.
-
to
approve, on a non-binding, advisory basis, named executive officer compensation;
-
3.
-
to
approve an amendment and restatement of our 2011 Long-Term Incentive Plan, as amended (2011 LTIP);
-
4.
-
to
ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2020 fiscal year;
-
5.
-
to
consider and vote upon a stockholder proposal described in the attached Proxy Statement, if properly presented at the Annual Meeting; and
-
6.
-
to
consider and vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
Only
stockholders of record at the close of business on Friday, March 13, 2020, are entitled to notice of and to vote at the meeting or any adjournments or postponements thereof.
It
is important that your shares be represented and voted at the Annual Meeting. Whether or not you plan to attend the Annual Meeting in person, we encourage you to submit your proxy as soon as
possible. For specific instructions, please refer to your Important Notice of Internet Availability of Proxy Materials or to the question on page 3 of the accompanying Proxy Statement entitled "How do I vote by
proxy?"
At
the direction of the Board of Directors,
Desiree Ralls-Morrison
Corporate Secretary
Table of Contents
TABLE OF CONTENTS
i
Table of Contents
300 Boston Scientific Way
Marlborough, Massachusetts 01752
March 25, 2020
PROXY STATEMENT
Information About the Annual Meeting and Voting
The
Annual Meeting of Stockholders of Boston Scientific Corporation (Annual Meeting) will be held on Thursday, May 7, 2020, at 8:00 a.m. Eastern Time, at the Company's
Corporate Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752. At this meeting, stockholders will be asked to elect ten nominees for director, approve, on a
non-binding,
advisory basis, named executive officer compensation, approve an amendment and restatement of our 2011 Long-Term Incentive Plan, as amended (2011 LTIP), ratify the appointment of Ernst &
Young LLP as our independent registered public accounting firm for the 2020 fiscal year, and consider and vote upon a stockholder proposal described in this Proxy Statement, if properly
presented at the Annual Meeting. Management will also respond to questions from stockholders. Our principal executive offices are located at 300 Boston Scientific Way, Marlborough, Massachusetts
01752, and our telephone number is (508) 683-4000. When used in this Proxy Statement, the terms "we," "us," "our," "Boston Scientific" and "the Company" mean Boston Scientific Corporation and
its businesses and subsidiaries.
Why am I receiving these materials?
In connection with its solicitation of proxies for use at our Annual Meeting, our Board of Directors (Board) (i) has made these materials available to
you via the Internet or, upon your request, via email, or (ii) upon your request, has delivered or will deliver printed versions of these materials to you by mail. As a stockholder of record of
our common stock at the close of business on March 13, 2020, the record date for our Annual Meeting, you are invited to attend the Annual Meeting, and are entitled to and requested to vote on
the items of business described in this Proxy Statement.
Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a
full set of printed proxy materials?
Pursuant to rules adopted by the Securities and Exchange Commission (SEC), we are making this Proxy Statement and our Annual Report for the year ended
December 31, 2019 (Annual Report and, together with this Proxy Statement, the proxy materials) available to stockholders electronically via the Internet. Stockholders will be able to access the
proxy materials on the website referred to in the Important Notice of Internet Availability of Proxy Materials (Notice) or request to receive printed copies of the proxy materials and a proxy card.
Instructions on how to access the proxy materials via the Internet or to request a printed copy may be found in the Notice and in this Proxy Statement. We
1
Table of Contents
believe
that this electronic process expedites your receipt of the proxy materials and reduces the cost and environmental impact of printing proxy materials for our Annual Meeting.
On
or about March 25, 2020, stockholders of record and beneficial owners of our common stock at the close of business on March 13, 2020 will be sent a Notice instructing them as to how
to receive their proxy materials via the Internet. The proxy materials will be available on the Internet as of March 25, 2020.
How can I electronically access the proxy materials?
Beginning March 25, 2020, you can access the proxy materials and vote your shares online at www.proxyvote.com. The proxy materials are also available on our own website
(www.bostonscientific.com).
How can I obtain a full set of printed proxy materials?
If you prefer to receive paper copies of the proxy materials and a proxy card, you may still do so. You may request printed materials by (i) calling
(800) 579-1639; (ii) sending an email to sendmaterial@proxyvote.com; or (iii) logging onto www.proxyvote.com using the credentials provided
on your Notice or proxy card.
Who is entitled to vote at the Annual Meeting?
Stockholders who held shares of our common stock at the close of business on Friday, March 13, 2020, are entitled to vote at the Annual Meeting. Each
share of our common stock is entitled to one vote.
How many shares are eligible to be voted and how many shares are required to hold the Annual Meeting?
A quorum is required to hold the Annual Meeting and conduct business. The presence at the Annual Meeting, in person or by proxy, of stockholders holding a
majority of our common stock outstanding as of the close of business on Friday, March 13, 2020, the record date, will constitute a quorum for purposes of holding and conducting business at the
Annual Meeting. As of March 13, 2020, we had 1,399,199,786 shares of our common stock outstanding each entitled to one vote at the Annual Meeting
meaning that 699,599,894 shares of common stock must be represented in person or by proxy to have a quorum. Our common stock is our only outstanding class of voting securities. For purposes of
determining whether a quorum exists, broker non-votes (as described further below) and proxies received but marked "ABSTAIN" will be counted.
What am I voting on?
You are voting on proposals to:
-
1.
-
elect
to the Board ten nominees for director;
-
2.
-
approve,
on a non-binding, advisory basis, named executive officer compensation;
-
3.
-
approve
an amendment and restatement of our 2011 LTIP;
2
Table of Contents
-
4.
-
ratify
the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2020 fiscal year;
-
5.
-
consider
and vote upon a stockholder proposal described in this Proxy Statement, if properly presented at the Annual Meeting; and
-
6.
-
consider
and vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
How does the Board recommend that I vote?
The Board recommends that you vote:
-
1.
-
FOR the election of each of the ten director nominees;
-
2.
-
FOR the named executive officer compensation;
-
3.
-
FOR the amendment and restatement of our 2011 LTIP;
-
4.
-
FOR the ratification of the appointment of Ernst & Young LLP as our independent registered public
accounting firm for the 2020 fiscal year; and
-
5.
-
AGAINST the stockholder proposal described in this Proxy Statement
How do I vote by proxy?
Your vote is very important. Whether or not you plan to attend the Annual Meeting in person, you may give a proxy to be voted at the Annual Meeting
either:
-
-
via the Internet pursuant to the instructions provided in the Notice; or
-
-
if you received printed proxy materials, via the Internet or by telephone or mail pursuant to the instructions provided on the proxy card.
If
you vote by mail, no postage is required if your proxy card is mailed in the United States. If you properly vote pursuant to the instructions provided in the Notice or properly complete and deliver
your proxy card (whether electronically, by mail or by telephone) and our Inspector of Election receives your instructions in time to vote at the Annual Meeting, your "proxy" (one of the individuals
named on your proxy card) will vote your shares as you have directed. If you sign and return your proxy card, but do not make specific selections, your proxy will vote your
shares as recommended by the Board. If any other matter is properly presented at the Annual Meeting, including a proposal to postpone or adjourn the meeting, your proxy will vote your shares in
accordance with his or her discretion. At present, the Board knows of no other business that is intended to be brought before or acted upon at the Annual Meeting.
3
Table of Contents
What if I need assistance with voting or have questions regarding the Annual Meeting?
If you need assistance with the voting of your shares or have questions regarding the Annual Meeting, please contact our proxy solicitation advisor:
Alliance
Advisors, LLC
200 Broadacres Drive, 3rd Floor
Bloomfield, NJ 07003
(844) 866-9429 (Toll Free in the United States)
How are votes counted?
In the election of directors, your vote may be cast "FOR" one or more of the nominees or your vote may be "WITHHELD" with respect to one or more of the
nominees. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.
In
the advisory vote to approve named executive officer compensation, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you "ABSTAIN," it will not count as a share actually voted and
will have no effect on the determination of this proposal. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.
In
the proposal to amend and restate our 2011 LTIP, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you "ABSTAIN," it will not count as a share actually voted with respect to
determining if a majority vote is obtained under our By-Laws. However, to the extent that stockholder approval requirements under the listing standards of the New York Stock Exchange (NYSE) are also
applicable, your abstention will be treated as a vote cast with respect to determining if approval is obtained under the NYSE voting standards, and will have the effect of a vote "AGAINST" the
proposal under such standards. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.
In
the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you
"ABSTAIN," it will not count as a share actually voted and will have no effect on the determination of this proposal. If you sign your proxy card with no further instructions, your shares will be
voted in accordance with the recommendation of the Board.
In
the stockholder proposal described in this Proxy Statement, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you "ABSTAIN," it will not count as a share actually voted with respect
to determining if a majority vote is obtained under our By-Laws and will have no effect on the determination of this proposal. If you sign your proxy card with no further instructions, your shares
will be voted in accordance with the recommendation of the Board.
How many votes are required to approve each proposal?
-
1.
-
Under
our By-Laws, except as otherwise required by law, each nominee for director shall be elected to the Board by the affirmative vote of the majority of votes cast,
in person or by proxy, by the holders of shares entitled to vote at a meeting at which a quorum is present; provided, however, that if the number of nominees exceeds the number of directors to be
elected at any such meeting, as determined by the Secretary of the Corporation as of the record date for such meeting, the directors shall be elected by a plurality of the votes cast, in
4
Table of Contents
person
or by proxy. A majority of the votes cast means that the number of shares voted "for" exceeds fifty percent (50%) of the number of votes cast with respect to such nominee. In the event that a
director nominee fails to receive an affirmative majority of the votes cast in an election where the number of nominees is less than or equal to the number of directors to be elected, the Board of
Directors, within its powers, may decrease the number of directors, fill the vacancy, or take other appropriate action. An abstention will not count as a vote cast with respect to a director. If
directors are to be elected by a plurality of the votes cast, stockholders shall not be permitted to vote against a nominee.
-
2.
-
The
affirmative vote of a majority of shares with voting power present in person or represented by proxy and which have actually voted on the proposal is required to
approve, on an advisory basis, the named executive officer compensation. The vote is advisory and non-binding in nature, but the Executive Compensation and Human Resources Committee of our Board
(Compensation Committee) will take into consideration the outcome of the vote when considering future executive compensation arrangements. You may vote "FOR," "AGAINST" or "ABSTAIN." If you "ABSTAIN,"
it will be counted for the purpose of determining whether a quorum is present for conducting the Annual Meeting, but it will not count as a share actually voted and will have no effect on the
determination of this proposal.
-
3.
-
Under
our By-laws, the affirmative vote of a majority of shares with voting power present in person or represented by proxy and which have actually voted on the
proposal is required to approve the amendment and restatement of our 2011 LTIP. You may vote "FOR," "AGAINST" or "ABSTAIN." If you "ABSTAIN," it will be counted for the purpose of determining whether
a quorum is present for conducting the Annual Meeting, but it will not count as a share actually voted with respect to determining if a majority vote is obtained under our By-Laws. However, to the
extent that stockholder approval requirements under the listing standards of the NYSE are also applicable, your abstention will be treated as a share actually voted with respect to determining if
approval is obtained under the NYSE voting standards, and will have the effect of a vote against the proposal under such standards. Under the stockholder approval requirements of the NYSE, if
applicable, approval of a majority of votes cast on this proposal is required (that is, votes cast "for" must exceed votes cast "against" plus abstentions).
-
4.
-
The
affirmative vote of a majority of shares with voting power present in person or represented by proxy and which have actually voted on the proposal is required to
ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2020 fiscal year. You may vote "FOR," "AGAINST" or "ABSTAIN." If you "ABSTAIN,"
it will be counted for the purpose of determining whether a quorum is present for conducting the Annual Meeting, but it will not count as a share actually voted and will have no effect on the
determination of this proposal.
-
5.
-
The
affirmative vote of a majority of shares with voting power present in person or represented by proxy and which have actually voted on the proposal is required to
approve the stockholder proposal described in this Proxy Statement. You may vote "FOR," "AGAINST" or "ABSTAIN." If you "ABSTAIN," it will be counted for the purpose of determining whether a quorum is
present for conducting the Annual Meeting, but your vote will not count as a share actually voted with respect to determining if a majority vote is obtained and will have no effect on the
determination of this proposal.
At
present, the Board knows of no other matters to be presented for stockholder action at the Annual Meeting.
5
Table of Contents
What is the difference between holding shares as a stockholder of record and as a beneficial owner?
Most of our stockholders hold their shares through a broker, trustee, bank, other financial intermediary or other nominee rather than directly in their own
name. As summarized below, there are some differences between stockholders of record and beneficial owners.
Stockholders of Record
If your shares are registered directly in your name with our transfer agent, Computershare Shareowner Services, as of the close of business on Friday,
March 13, 2020, you are considered the stockholder of record with respect to those shares, and the Notice or proxy materials are being made
available, electronically or otherwise, directly to you by the Company. As the stockholder of record, you have the right to grant your voting proxy directly to the Company or a third party, or to vote
in person at the Annual Meeting. The Company has made available a proxy card or electronic voting means for you to use for voting purposes.
Beneficial Owners
If your shares are held through a brokerage firm, trustee, bank, other financial intermediary or other nominee, as of the close of business on Friday,
March 13, 2020, you are considered the beneficial owner of those shares held in street name, and the Notice or proxy materials are being made available, electronically or otherwise, by the
Company to your broker, trustee, bank,
other financial intermediary or other nominee (the intermediary) and they will forward these materials to you, together with a voting instruction form if furnished via paper copy to your intermediary.
As the beneficial owner, you have the right to direct your intermediary on how to vote and are also invited to attend the Annual Meeting; however, since you are not the stockholder of record, you may
not vote these shares in person at the Annual Meeting, unless you request, complete and deliver a legal proxy from your
intermediary. If you requested printed proxy materials, your intermediary will enclose a voting instruction form for you to use in directing the intermediary regarding how to vote your shares.
What discretion does my broker have to vote my shares held in "street name?"
The NYSE rules allow your broker to vote your shares in its discretion on "routine" proposals when it has not received instructions from you at least ten days
prior to the Annual Meeting. The proposal regarding the ratification of the appointment of our independent registered public accounting firm is a matter considered routine under applicable rules and,
therefore, your broker may vote on your behalf for this matter if you do not otherwise provide instructions. The election of directors, the advisory vote on the named executive officer compensation,
the vote to amend and restate the 2011 LTIP, and the stockholder proposal described in this Proxy Statement are not considered routine matters. If you do not instruct your broker how to vote your
shares on the non-routine matters, your broker will not be permitted to vote your shares on such matters. This is referred to as a "broker non-vote."
Broker
non-votes (shares held by brokers that do not have discretionary authority to vote on the matter and that have not received voting instructions from their clients) are counted for purposes of
determining whether a quorum is present, but are not counted or deemed to be present, represented or voted for the purpose of determining whether stockholders have approved a proposal. A broker
non-vote will have no effect on the outcome of the election of directors, the vote to amend and restate the 2011 LTIP or the advisory vote on the named executive officer compensation.
6
Table of Contents
How do I vote my 401(k) shares?
If you participate in our 401(k) Retirement Savings Plan, as amended and restated (401(k) Plan), you will receive a single proxy card (together with the proxy
materials) or Notice that covers all shares credited to your plan account(s) and shares that you own of record that are registered in the same name. If your plan account(s) are registered in different
names, you will receive separate proxy cards or Notices for your record and plan holdings. You may vote your shares by following the instructions provided in your proxy card or Notice and utilizing
the credentials provided therein. Your vote will serve to instruct the trustees and fiduciaries of our 401(k) Plan how to vote any shares of our common stock held in our 401(k) Plan on your behalf.
Shares of our common stock held in our 401(k) Plan must be voted on or before 11:59 p.m. Eastern Time on May 2, 2020. The trustee and fiduciaries of our 401(k) Plan will vote shares for
which timely instructions are not received in the same proportion as other plan shares that were voted.
What happens if I don't specify how I want my shares voted on one or all of the proposals?
If you are the stockholder of record and you sign, date and return your proxy and do not mark how you want to
vote, your proxy will be counted as a vote "FOR" all of the nominees for directors, "FOR" the named executive officer compensation, "FOR" the amendment and restatement of the 2011 LTIP, "FOR" the
ratification of our independent registered public accounting firm, Ernst & Young, and "AGAINST" the stockholder proposal described in this Proxy Statement. If you hold your shares in street name, please see the discussion on "What discretion does my broker have to vote my shares held in 'street
name?'," above.
Can I change my vote or revoke my proxy after I have already voted or given my proxy?
Yes. If you are a stockholder of record, you may change your vote or revoke your proxy at any time before the
proxy is voted at the Annual Meeting. To change your vote, you may:
-
-
mail a written notice "revoking" your earlier vote to Broadridge Financial Solutions, Inc. (Broadridge), 51 Mercedes Way, Edgewood, NY
11717;
-
-
submit to Broadridge a properly completed and signed proxy card with a later date;
-
-
vote again telephonically or electronically (available until 11:59 p.m. Eastern Time on May 6, 2020); or
-
-
vote in person at the Annual Meeting; however, your attendance at the Annual Meeting alone will not revoke your proxy.
Your
last dated proxy, properly completed and timely received prior to, or vote cast at, the Annual Meeting will be counted.
If
you own your shares in street name, please contact your broker or other intermediary for instructions on changing your vote or revoking your proxy.
Can I vote in person at the meeting?
Yes. If you are the stockholder of record of the shares, you can vote in person by coming to the Annual
Meeting, and we will give you a ballot or a new proxy card when you arrive with proper identification. However, since a beneficial owner holding shares in street
name is not the stockholder of record, if you
7
Table of Contents
are
such a beneficial owner of shares, you may not vote your shares in person at the Annual Meeting unless you obtain a legal proxy from the broker or other intermediary that holds your shares giving
you the right to vote the shares at the Annual Meeting. Please bring the legal proxy with you to the Annual Meeting. If you plan to attend the Annual Meeting in person, you must provide proper
identification. Please visit our website, www.bostonscientific.com, for directions to the Annual Meeting.
Who will count the votes?
Broadridge has been engaged as our independent agent to tabulate stockholder votes and act as Inspector of Election for the meeting.
Is voting confidential?
Proxy instructions, ballots and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote
will not be disclosed either within the Company or to third parties, except:
-
-
as necessary to meet applicable legal requirements;
-
-
to allow for the tabulation and certification of votes; and
-
-
to facilitate a successful proxy solicitation.
Occasionally,
stockholders provide written comments on their proxy cards, which may be forwarded to the Company's management and the Board.
What happens if the Annual Meeting is adjourned or postponed?
Your proxy will still be effective and will be voted at the rescheduled Annual Meeting. You will still be able to change or revoke your proxy until it is
voted, provided such new proxy or revocation is properly completed and timely received.
Will any other business be considered or presented at the Annual Meeting?
Our By-Laws provide that a stockholder may present business to be considered at the Annual Meeting only if proper prior written notice was timely received by
us. Other than the items of business described in this Proxy Statement, our Board is not aware of any other business to be acted upon at the Annual Meeting; however, if any other business does
properly come before the Annual Meeting, the persons named as proxies on the proxy card will vote your shares in accordance with their discretion.
How can I find the results of the Annual Meeting?
We will report the final voting results on a Current Report on Form 8-K filed with the SEC within four business days after the Annual Meeting. The
Form 8-K will be available on the SEC's website, www.sec.gov, as well as on our own website, www.bostonscientific.com, under the "Investor Relations" section.
Who is soliciting my vote pursuant to this Proxy Statement?
Our Board is soliciting your vote.
8
Table of Contents
Is there a list of stockholders entitled to vote at the Annual Meeting?
A list of stockholders entitled to vote at the Annual Meeting will be available at the Annual Meeting and for ten days prior to the Annual Meeting, between
the hours of 8:30 a.m. and 5:00 p.m. Eastern Time, at our Corporate Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752. If you would like to view
the stockholder list, please contact our Corporate Secretary to schedule an appointment by calling (508) 683-4000 or writing to her at 300 Boston Scientific Way, Marlborough, Massachusetts
01752.
9
Table of Contents
Internet Availability of Proxy Materials
Under rules adopted by the SEC, we are furnishing proxy materials to our stockholders primarily via the Internet instead of mailing printed
copies of those materials to each stockholder. On or about March 25, 2020, we will mail to our stockholders (other than those who previously requested electronic or paper delivery) an Important
Notice of Internet Availability of Proxy Materials containing instructions on how to access our proxy materials, including our Proxy Statement and our Annual Report. The Notice also instructs
stockholders on how to vote via the Internet.
This
process is designed to expedite stockholders' receipt of proxy materials, lower the cost of the Annual Meeting and help conserve natural resources; however, if you would prefer to receive printed
proxy materials and a proxy card, please follow the instructions included in the Notice and in this Proxy Statement. If you have previously elected to receive our proxy materials electronically, these
materials will continue to be made available to you via email until you elect otherwise. If you have
previously elected to receive printed proxy materials, you will continue to receive these materials and a proxy card in paper format until you elect otherwise.
Cautionary Statement Regarding Forward-Looking and Other Statements
This Proxy Statement contains forward-looking statements within the meaning of the federal securities laws.
Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "may," "estimate," "intend" and other similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. Factors that may cause actual
results to differ materially from those contemplated by the statements in this Proxy Statement can be found in our most recent Annual Report on Form 10-K filed with the SEC and in the Quarterly
Reports on Form 10-Q that we have filed or will file hereafter under the heading "Risk Factors" and "Safe Harbor for Forward-Looking Statements." The forward-looking statements speak only as of
the date of this Proxy Statement and undue reliance should not be placed on these statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements. This
cautionary statement is applicable to all forward-looking statements contained in this document.
This Proxy Statement contains statements regarding individual and Company performance objectives and targets. These objectives and targets are disclosed in the limited context
of our compensation plans and programs and should not be understood to be statements of management's future expectations or estimates of future results or other guidance. We specifically caution
investors not to apply these statements to other contexts.
10
Table of Contents
PROPOSAL 1: ELECTION OF DIRECTORS
Our
entire Board is elected annually by our stockholders and currently consists of ten members. All of our current directors have been nominated by our Board, upon the recommendation
of our Nominating and Governance Committee, to stand for election at the Annual Meeting for a one-year term, to hold office until the 2021 Annual Meeting of Stockholders and until their successors
have been elected and qualified. The nominees for election at the Annual Meeting are: Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P.
MacMillan, Michael F. Mahoney, David J. Roux, John E. Sununu and Ellen M. Zane.
Each
of the director nominees is willing and able to stand for election at the Annual Meeting, and we know of no reason why any of the nominees would be unable to serve as a director. Should such a
situation arise, however, the Board may designate a substitute nominee or, alternatively, reduce the number of directors to be elected. If a substitute nominee is selected, the persons named as
proxies will vote for that substitute nominee. Any vacancies not filled at the Annual Meeting may be filled by the Board.
Director Nominees at a Glance
|
The
biographies of each of the nominees are listed below and contain information regarding the person's service as a director, business experience, public company director positions
currently held or held at any time during the last five years, information regarding involvement in certain legal or administrative proceedings (if applicable), and the experiences, qualifications,
attributes or skills that caused the Nominating and Governance Committee and the Board to determine that the person should serve as a director in light of our business and structure. Each of the
director nominees listed below exemplifies how our Board values professional experience in business, education, policy and governmental fields as well as strong moral character and diversity in terms
of viewpoint as well as age, ethnicity and gender. Our Board believes that these strong backgrounds and sets of skills provide the Board as a whole with a strong foundation of technical expertise and
a wealth of diverse experience in a wide variety of areas.
11
Table of Contents
|
|
|
|
|
|
|
Nelda J. Connors
|
|
Independent Director
|
|
Founder, Chairwoman and Chief Executive Officer of Pine Grove Holdings, LLC
|
|
|
|
Director Since: December 2009
Age: 54
Committees:
Executive Compensation and
Human Resources; Finance
|
|
Other Public Company Boards: EnerSys Inc.;
Delphi Technologies
Education: University of Dayton, B.S. and M.S.
in Mechanical Engineering
|
Executive Highlights:
Ms. Connors is the founder, chairwoman and chief executive officer of Pine Grove Holdings, LLC, a privately held investment company that acquires
and operates small-to-middle market businesses primarily focused in power generation, construction equipment, advanced material and aftermarket automotive end-markets. She served as president and
chief executive officer of Atkore International Inc., formerly the Electrical and Metal Products division of Tyco International, before it became a privately held company in December 2010.
Prior to joining Tyco, she served as vice president at Eaton Corporation where she held several positions in operations, continuous improvement, and general management. Prior to joining Eaton,
Ms. Connors was employed in a number of executive and management capacities in the automotive industry. Her work over 25 years has involved responsibilities in the U.S., Europe, and
Asia. Ms. Connors previously served as a Class B director of the Federal Reserve Bank of Chicago, and on the boards of Atkore, Blount International, Clarcor, Inc., Echo Global
Logistics and Vesuvius plc. She was formerly an appointed member for the Takata Independent Quality Assurance Panel to investigate the airbag inflator recall. Ms. Connors will stand for
election at the 2020 annual meetings of Baker Hughes Company and CNH Industrial, N.V.
Select Skills and Qualifications:
Ms. Connors' qualifications to serve on our Board include her executive leadership skills and her global experience in the areas of operations and
financial management, quality, M&A and business strategy, as well as her knowledge of public company matters resulting from her service on other public company boards. She also brings to our Board her
experience in National Association of Corporate Directors leadership and governance fellowships.
|
|
|
|
|
|
|
Charles J. Dockendorff
|
|
Independent Director
|
|
Former Executive Vice President and Chief Financial Officer of Covidien plc
|
|
|
|
Director Since: April 2015
Age: 65
Committees:
Audit (Chair, Financial
Expert); Finance
|
|
Other Public Company Boards: Haemonetics
Corporation; Hologic, Inc.; Keysight
Technologies, Inc.
Education: University of Massachusetts
at Amherst, B.B.A. in Accounting; Bentley
College, M.S. in Finance
|
Executive Highlights:
Mr. Dockendorff
was executive vice president and chief financial officer of Covidien plc, a publicly traded medical device and supplies company, and its predecessor, Tyco
Healthcare, from 1995 to 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as controller and was named vice president
and controller in 1994. He was appointed chief financial officer of Tyco Healthcare in 1995. Prior to joining Kendall/Tyco Healthcare,
Mr. Dockendorff was the chief financial officer, vice president of finance and treasurer of Epsco Inc. and Infrared Industries, Inc.
Select Skills and Qualifications:
Mr. Dockendorff's
qualifications to serve on our Board include his executive leadership experience at public medical device companies, as well as his extensive expertise in accounting, finance
and business strategy.
12
Table of Contents
|
|
|
|
|
|
|
Yoshiaki Fujimori
|
|
Independent Director
|
|
Senior Executive Advisor of Japan to CVC Capital Partners
|
|
|
|
Director Since: July 2016
Age: 68
Committees: Finance
|
|
Other Public Company Boards: Oracle
Corporation Japan; Takeda Pharmaceutical
Company; Toshiba Corporation; Shiseido
Company, Limited
Education: Tokyo University of Science, B.A.
in Petroleum Engineering; Carnegie
Mellon Graduate School of Business, M.B.A.
|
Executive Highlights:
Mr. Fujimori
is currently senior executive advisor of Japan to CVC Capital Partners, a position he has held since February 2017. He was an advisor to the LIXIL Group Corporation from June 2016
to December 2019 and was the president and chief executive officer of the LIXIL Group Corporation from August 2011 to June 2016. Prior to joining LIXIL, he was chairman, president and chief executive
officer of GE Japan from January 2008 to June 2011. In his 25 years at GE, beginning in October 1986, he held a variety of positions including senior vice president and chief executive officer
of a number of Asian and global business divisions, including Medical Systems, Plastics, and Capital. Mr. Fujimori also served as a member of the GE Corporate Executive Council from 2001 to
2010. He formerly served as
a director of the Japan Construction Material & Housing Equipment Industries Federation and Tokyo Electric Power Company Holdings.
Select Skills and Qualifications:
Mr. Fujimori's
qualifications to serve on our Board include his expertise in international business, including developing markets, with a particular emphasis on operations and manufacturing in
Japan and Asia, as well as his service on other public company boards.
|
|
|
|
|
|
|
Donna A. James
|
|
Independent Director
|
|
Founder, President and Managing Director of Lardon & Associates LLC
|
|
|
|
Director Since: July 2015
Age: 62
Committees:
Executive Compensation and
Human Resources (Chair);
Nominating and Governance
|
|
Other Public Company Boards: L Brands,
Inc.
Education: North Carolina A&T State
University, B.S. in Accounting
|
Executive Highlights:
Ms. James
is the founder of Lardon & Associates LLC, a business development and executive advisory services firm, where she has served as president and managing director since
April 2006. Ms. James has more than 30 years of diverse management and leadership experience, including her experience at Nationwide Insurance and Financial Services, beginning in 1981.
In her 25 years at Nationwide, she served in several leadership roles, including president of Nationwide Strategic Investments, a division of Nationwide Insurance Company, from 2003 to 2006, at
which time she had direct responsibility for developing and executing strategies for several U.S. and global financial services subsidiaries and affiliates. Ms. James also is the founder of The
Center for Healthy Families, a non-profit in Columbus, Ohio, and the former chair of the National Women's Business Council by presidential appointment.
Ms. James currently serves as a director of the FIS Group, a privately held asset management and investment advisory firm. She formerly served as a director of Time Warner Cable Inc. and
Marathon Petroleum, Inc., where she is currently serving as a board advisor.
Select Skills and Qualifications:
Ms. James's
qualifications to serve on our Board include her expertise in business strategy, finance, accounting and human resources. In addition, her service on other public company boards
contributes to her knowledge of public company matters.
13
Table of Contents
|
|
|
|
|
|
|
Edward J. Ludwig
|
|
Independent Director
|
|
Former Chairman of the Board and Chief Executive Officer of Becton, Dickinson and Company
|
|
|
|
Director Since: March 2014
Age: 68
Committees: Audit (Financial
Expert); Executive
Compensation and Human
Resources
|
|
Other Public Company Boards: CVS Health Corporation
Education: The College of the Holy Cross,
B.A. in Economics and Accounting;
Columbia University, M.B.A.
|
Executive Highlights:
Mr. Ludwig
is the former chairman of the board of Becton, Dickinson and Company (BDX), a global medical technology company, having served in that position from February 2002
through June 2012. He also served as BDX's chief executive officer from January 2000 to September 2011 and as its president from May 1999 to December 2008. Mr. Ludwig joined BDX as a senior
financial analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers), where he earned his CPA, and as a financial and
strategic analyst at Kidde, Inc. He formerly served as a director of Xylem, Inc. and as vice chair of the board of trustees of the Hackensack University Medical Center Network.
Select Skills and Qualifications:
Mr. Ludwig's
qualifications to serve on our Board include his executive leadership experience, specifically his service as a director and executive of a public medical
technology company, along with his extensive expertise in business strategy, finance, management and manufacturing.
|
|
|
|
|
|
|
Stephen P. MacMillan
|
|
Independent Director
|
|
Chairman of the Board, President, and Chief Executive Officer of Hologic, Inc.
|
|
|
|
Director Since: April 2015
Age: 56
Committees:
Executive Compensation and
Human Resources;
Nominating and Governance
|
|
Other Public Company Boards: Hologic,
Inc.
Education: Davidson College, B.A. in
Economics; Harvard Business
School Advanced Management Program
|
Executive Highlights:
Mr. MacMillan
is currently the chairman, president and chief executive officer of Hologic, Inc., a position he has held since June 2015, and he served as president and
chief executive officer of Hologic, Inc., since December 2013. Prior to assuming his role with Hologic, Mr. MacMillan was the chief executive officer of sBioMed, LLC, a medical
research company, from October 2012 to December 2013. From 2003 to 2012, Mr. MacMillan served in various roles at Stryker Corporation, including chief operating officer from June 2003 to
January 2005, president from June 2003 to February 2012, chief executive officer from January 2005 to February 2012 and chairman from January 2010 to February 2012. Prior to 2003, Mr. MacMillan
was a senior executive with Pharmacia Corporation, where he oversaw five global businesses. Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson & Johnson in a
variety of senior roles both in the U.S. and Europe, including president of the joint venture between Johnson & Johnson and Merck. Mr. MacMillan began his career with Procter &
Gamble in 1985. Mr. MacMillan formerly served as a director of Texas Instruments Inc. and Alere Inc. Mr. MacMillan also serves on the board of directors of AdvaMed, a
medical device trade association.
Select Skills and Qualifications:
Mr. MacMillan's
qualifications to serve on our Board include his executive leadership experience, specifically his service as a director and chief executive officer of public
medical technology companies.
14
Table of Contents
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
CEO, Chairman of the Board
|
|
President and Chief Executive Officer of Boston Scientific Corporation
|
|
|
|
Director Since: November 2012
Age: 55
|
|
Other Public Company Boards: Baxter
International, Inc.
Education: University of Iowa, B.B.A. in
Finance; Wake Forest University, M.B.A.
|
Executive Highlights:
Michael
F. Mahoney joined the Company as our president in October 2011, and became our president and chief executive officer and a director in November 2012. Mr. Mahoney became
our chairman of the Board in May 2016. Prior to joining the Company, he was worldwide chairman of the Medical Devices and Diagnostics division of Johnson & Johnson from January 2011 to
September 2011, overseeing 50,000 employees and seven franchises. Prior to assuming this position, Mr. Mahoney served as worldwide group chairman of Johnson & Johnson's DePuy franchise,
an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, Mr. Mahoney served as president and chief executive officer of Global
Healthcare Exchange, a provider of supply chain solutions and services that brings together hospitals, manufacturers, distributors and group purchasing organizations. Mr. Mahoney began his
career at General Electric Medical Systems, where he spent 12 years, culminating in the role of general manager of the Healthcare Information Technology business. Mr. Mahoney also serves
on the board of the Boys & Girls Club of Boston, is the chair of the board of governors of Boston College CEO Club, and a member of the American Heart Association CEO roundtable.
Select Skills and Qualifications:
Mr. Mahoney's
qualifications to serve on our Board, in addition to being our Chief Executive Officer, include his management experience leading complex organizations in medical
device and other healthcare-related businesses, expertise in building strong leadership teams, developing international markets, and a proven ability to execute successful business strategies and
drive operational excellence.
|
|
|
|
|
|
|
David J. Roux
|
|
Independent Director
|
|
Chairman of the Board of Trustees of Jackson Laboratories
|
|
|
|
Director Since: January 2014
Age: 63
Committees:
Audit, Finance (Chair)
|
|
Other Public Company Boards: None
Education: Harvard College; Harvard
University, M.B.A.; King's College,
Cambridge University, M. Phil.
|
Executive Highlights:
Mr. Roux
is chairman of Jackson Laboratories, an independent biomedical research institute. He is the co-founder and was the chairman, co-chief executive officer and managing
partner of Silver Lake, a private equity firm focused on technology investing, from January 2014 to December 2017. Prior to that, Mr. Roux was chairman and chief executive officer of Liberate
Technologies, executive vice president at Oracle Corporation and senior vice president at Lotus Development. He is also chairman of Bristol Seafoods and vice chairman of the National Audubon Society.
He previously served as a
director of Avaya Inc., Avaya Holdings Corp. and Intelsat S.A. Mr. Roux is co-founder of The Roux Institute, an educational partnership with Northeastern University.
Select Skills and Qualifications:
Mr. Roux's
qualifications to serve on the Board include his extensive experience in operations, technology, management and business strategy, and his financial expertise and
background as an entrepreneur, executive and director.
15
Table of Contents
|
|
|
|
|
|
|
John E. Sununu
|
|
Independent Director
|
|
Former United States Senator from New Hampshire
|
|
|
|
Director Since: April 2009
Age: 55
Committees: Audit (Financial
Expert); Nominating and
Governance (Chair)
|
|
Other Public Company Boards: None
Education: Massachusetts Institute of
Technology, B.S. and M.S. in
Mechanical Engineering; Harvard
University, M.B.A.
|
Executive Highlights:
Senator
Sununu served as a U.S. Senator from New Hampshire from 2003 to 2009. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was
appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a member of the U.S. House of Representatives
from New Hampshire's 1st District from 1996 to 2002, where he was vice chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he
drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress,
Senator Sununu served as chief financial officer for Teletrol Systems, a manufacturer of building control systems. Senator Sununu formerly served as a director of Time Warner Cable Inc.
Select Skills and Qualifications:
Senator
Sununu complements our Board with his experience in government and corporate leadership. Senator Sununu provides important insights on government relations, public policy and
other matters relevant to our Company due to his extensive experience in both the public and private industry sectors.
|
|
|
|
|
|
|
Ellen M. Zane
|
|
Independent Director
|
|
CEO Emeritus and Vice Chair of the Board of Trustees at Tufts Medical Center and Floating Hospital for Children
|
|
|
|
Director Since: April 2016
Age: 68
Committees:
Audit (Financial Expert);
Nominating and Governance
|
|
Other Public Company Boards: Brooks
Automation; Haemonetics Corporation; Synchrony Financial
Education: George Washington University, B.A.;
Catholic University of America, M.A.
in Audiology and Speech-Language Pathology
|
Executive Highlights:
Ms. Zane
is chief executive officer emeritus and vice chair of the board of trustees at Tufts Medical Center and Floating Hospital for Children, and previously, she served as
its president and chief executive officer. Ms. Zane also served as Network President for Partners Healthcare System, a physician/hospital network sponsored by the Harvard-affiliated
Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as chief executive officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane
currently is a director of nThrive, a Georgia-based private company involved with healthcare revenue cycle management; Fiduciary Trust Company, a privately owned wealth management company; and AgNovos
Healthcare, LLC a privately held medical device company, focused on bone health. Ms. Zane previously served as a director of Century Capital Management, Parexel International
Corporation, Lincare Holdings Inc. and Press Ganey Holdings. Ms. Zane holds a Professional Director Advanced Certification from the American College of Corporate Directors.
16
Table of Contents
Select Skills and Qualifications:
Ms. Zane's
qualifications to serve on our Board include her executive experience in the healthcare industry, specifically as the chief executive officer of a large urban
academic (teaching and research) medical center, in addition to her experience as a director at other public companies.
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE ELECTION OF ALL TEN OF THESE NOMINEES FOR DIRECTOR.
17
Table of Contents
CORPORATE GOVERNANCE
To
guide the operation and direction of the Board and its committees, our Board has established our Corporate Governance Guidelines, charters for its standing committees and our Code
of Conduct to reflect our commitment to good corporate governance and to comply with Delaware law, the rules and listing standards of the NYSE, the rules and regulations of the SEC and other legal
requirements. These materials are available under "Governance Overview" in the "Investor Relations"
section of our website at www.bostonscientific.com. These materials are also available in print free of charge to stockholders, upon written request to
Boston Scientific Corporation, Investor Relations, 300 Boston Scientific Way, Marlborough, Massachusetts 01752.
Our
Board believes that good corporate governance is fundamental to the overall success of our business. To that end, our Board evaluates our corporate governance practices in light of applicable
changes in Delaware law, the rules and listing standards of the NYSE, the rules and regulations of the SEC, and the rules and regulations under the Internal Revenue Code of 1986, as amended (the
Code), as well as best practices suggested by recognized governance authorities, and makes modifications to our corporate governance practices that it determines are warranted.
Under
the NYSE's Corporate Governance Standards, a majority of the Board must qualify as independent directors. However, our Corporate Governance Guidelines require that a
significant majority of the Board qualify as independent directors. The NYSE Corporate Governance Standards define specific relationships that disqualify directors from being independent and further
require that for a director to qualify as independent, the Board must affirmatively determine that the director has no material relationship with our Company (either directly or as a partner,
stockholder or officer of an organization that has a relationship with our Company).
In
making determinations regarding independence, the Board applies the NYSE standards and broadly considers all relevant facts and circumstances known to it. For directors who will serve on the
Compensation Committee, the Board considers all factors specifically relevant to determining whether a director has a relationship with our Company that is material to that director's ability to be
independent from management in connection with the duties of a Compensation Committee member, including, but not limited to: (i) the source of compensation of such director, including any
consulting, advisory or other compensatory fee paid by our Company to such director, and (ii) whether such director is affiliated with our Company, a subsidiary of our Company or an affiliate
of a subsidiary of our Company as required by the NYSE independence standards for compensation committee members.
The
Board has determined that the following directors are independent under the independence standards set forth in the NYSE Corporate Governance Standards: Nelda J. Connors, Charles J.
Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David J. Roux, John E. Sununu and Ellen M. Zane.
The
Board monitors its compliance with NYSE requirements for director independence on an ongoing basis, including through an annual review of director questionnaires and consideration of transactions
and relationships between each director or any member of his or her immediate family and the Company as well as other relevant facts and circumstances. The Board and the Nominating and Governance
Committee considered the directors' responses to a questionnaire asking about their
18
Table of Contents
relationships
with the Company (and their immediate family members' relationships with the Company) and other potential conflicts of interest, as well as material provided by management related to
transactions, relationships or arrangements between the Company and the directors or parties related to the directors. The Board made its determination as to whether any relationship between a
director and our Company is a material relationship based on the facts and circumstances of the relationship, the amounts involved in the relationship, the director's interest in such relationship, if
any, and such other factors as the Board, in its judgment, deemed appropriate.
Director Nomination Process
|
The
Nominating and Governance Committee is responsible for determining the appropriate skills and characteristics required of new Board members in the context of the current make-up
of the Board. In so doing, the Nominating and Governance Committee considers, with input from the Board, those factors it deems appropriate, such as independence, experience, strength of character,
judgment, technical skills, diversity, years of experience and the extent to which the individual would fill a present need on the Board. The aim is to assemble a Board that is strong in its
collective knowledge and that consists of individuals who bring a variety of complementary attributes and who, taken together, have the appropriate skills and experience to oversee the Company's
business. The Nominating and Governance Committee considers diversity as one of a number of factors in identifying nominees for director. It does not, however, have a formal policy in this regard. The
Nominating and Governance Committee views diversity broadly to include diversity of experience, skills and viewpoint, as well as other diversity concepts such as ethnicity and gender.
Director
nominees must, at a minimum, meet the general criteria outlined in our Corporate Governance Guidelines. Generally, directors should be individuals who have succeeded in their particular field
and who demonstrate integrity, reliability, knowledge of corporate affairs and an ability to work well with others, and should also satisfy at least one of the following
criteria:
-
-
demonstrated management ability at senior levels in successful organizations;
-
-
current or recent employment in positions of significant responsibility and decision making;
-
-
expertise in leading rapidly growing multi-national organizations; or
-
-
current and prior experience related to anticipated board and committee responsibilities in other areas of importance to our Company.
The
Nominating and Governance Committee receives suggestions for new directors from a number of sources, including independent Board members and our Chairman and Chief Executive Officer. The Committee
may also, at its discretion, employ a third-party search firm to assist in identifying candidates for director.
The
Nominating and Governance Committee will also consider recommendations for Board membership submitted by our stockholders and other sources, and considers director nominees for election so
submitted if the submission is made in accordance with the advance notice provisions of our By-Laws. The qualifications of candidates recommended by stockholders will be reviewed and considered by the
Nominating and Governance Committee with the same degree of care and consideration as candidates for nomination to the Board submitted by independent Board members and our Chairman and Chief Executive
Officer.
In
May 2019, based on engagement with stockholders and benchmarking of corporate governance best practices, the Board amended our By-Laws to add proxy access. Our proxy access By-Law provision
19
Table of Contents
permits
a stockholder, or group of up to 20 stockholders, meeting certain ownership and other requirements to include a nominee for director election in the Company's Annual Proxy Statement. The Board
believes that this change enhances stockholder rights and provides increased accountability of the Company and our Board to our stockholders.
The
full Board is responsible for final approval of new director candidates, as well as the nomination of existing directors for re-election. With respect to existing directors, prior to making its
recommendation to the full Board, the Nominating and Governance Committee, in consultation with the Chairman of the Board, reviews each director's continuation on the Board as a regular part of the
annual nominating process.
Under
the advance notice provisions of our By-Laws, director nominations and proposals to bring any other business before the 2021 Annual Meeting of Stockholders by our stockholders must be received
by our Corporate Secretary at our principal executive offices on or before November 25, 2020. Under the proxy access by-law provisions of our By-Laws, director nominations submitted for
inclusion in our 2021 Annual Proxy Statement must be received no earlier than October 26, 2020 and no later than November 25, 2020. Director nominations by our stockholders must also
satisfy the other procedures and requirements set forth in the advance notice and proxy access provisions of our By-Laws, as appropriate. Should you wish to submit a director recommendation or
nomination, have it addressed to our Corporate Secretary at Boston Scientific Corporation, 300 Boston Scientific Way, Marlborough, Massachusetts 01752.
The
Board has not established any term or age limits to an individual's membership on the Board. While these limits could help ensure that there are fresh ideas and viewpoints
available to the Board, they have the disadvantage of causing the Company to lose the contribution of directors who have been able to develop, over a period of time, increasing insight into the
Company and its operations and, therefore, provide an increasing contribution to the Board as a whole. The Nominating and Governance Committee, as part of its annual assessment of the composition of
the Board, reviews a director's continuation on the Board. The Company believes that, through regular evaluation of performance and the Company's needs, the Company will continue to achieve the
appropriate balance between Boston Scientific experience and fresh ideas and perspectives.
20
Table of Contents
Chief Executive Officer Succession
|
Pursuant
to our Corporate Governance Guidelines, the Nominating and Governance Committee reports to the full Board periodically on succession planning for our Chief Executive Officer
(and other executive officers, as appropriate). Our Chief Executive Officer discusses with the Board and the Nominating and Governance Committee, at least once per year, his recommendations and
evaluations of potential successors to his position, including in the event of an unexpected emergency, and reviews development plans, if any, recommended for such individuals. Additionally, the
Nominating and Governance Committee conducts an annual review of the CEO Succession Plan framework, which outlines certain high-level planning, notification and other actions, and is designed to
minimize disruption in the event of a temporary or permanent absence of the Chief Executive Officer.
Board Leadership Structure
|
Our
Board believes that it is important that it retain flexibility to make the determination as to whether the interests of the Company and our stockholders are best served by having
the same individual serve as both Chief Executive Officer and Chairman of the Board or whether the roles should be separated based on the circumstances at any given time. Under our Corporate
Governance Guidelines, the Board will appoint a Lead Independent Director when the Chief Executive Officer and Chairman of the Board roles are combined or if the Chairman is not otherwise independent.
Pursuant to our Corporate Governance Guidelines, the Lead Independent Director is appointed annually, though is generally expected to serve for a renewable term of three years, subject to annual
re-election to the Board. The Lead Independent Director will preside over meetings of our non-management directors, serve as liaison between our Chairman and the independent directors, work with the
Chairman to establish agendas for Board and committee meetings, raise issues with management on behalf of the independent directors, consult with committee leadership, and carry out other duties as
requested by the Board. The Lead Independent Director also has the authority to call special meetings of independent or non-management directors, as needed.
Mr. Mahoney
has been our President and Chief Executive Officer since November 2012 and the Chairman of our Board since May 2016. In light of the fact that the Chief Executive Officer and
Chairman of the Board roles have been combined since May 2016, the Board appointed Mr. Ludwig at that time to serve as Lead Independent Director, and re-appointed him to serve in that role for
an additional three-year term in February 2019. Mr. Ludwig's qualifications to serve as our Lead Independent Director include his strong leadership experience as Chief Executive Officer and
Chairman of the Board of Becton, Dickinson and Company, his service on the Board of CVS Health Corporation and the Chair of that board's Finance Committee, and as lead director on the Board of
Aetna, Inc. prior to its acquisition by CVS Health Corporation. Our Board believes that this leadership structure, coupled
with a commitment to Board independence, provides effective independent oversight of management, while fostering a constructive and cooperative relationship between the Board and management and
allowing both the Board and management to benefit from Mr. Mahoney's day-to-day familiarity with our business operations.
Our
Board of Directors conducts annual self-evaluations, overseen by the Nominating and Governance Committee in accordance with the committee's charter. The self-evaluations have
been facilitated by a third party and have included in-person and telephonic interviews with directors and presentation of results by the facilitator to our Board and individual directors, as well as
written reports to the Board.
21
Table of Contents
Our
Board oversees an enterprise-wide approach to risk management, designed to support the achievement of our strategic and organizational objectives, to improve long-term
organizational performance and to enhance stockholder value. A fundamental part of risk oversight is to understand the individual risks our Company faces, the steps management is taking to manage
those risks, including the framework used by management for the coordinated oversight, control and continuous improvement of processes used to manage risk, and to assess management's appetite for
risk. It is management's responsibility to manage risk and bring to the Board's attention material risks facing our Company. Our Board receives regular reports from management on matters relating to
strategic and operational initiatives, financial performance and legal developments, which are each integrated with enterprise-risk exposures. The involvement of the full Board in approving our
strategic plan is a key part of its assessment of the risks inherent in our corporate strategy.
While
the Board has the ultimate responsibility for risk oversight, each committee of the Board also oversees risk to the extent that it relates to the committee's responsibilities, as outlined below.
Each committee makes reports in its respective area of responsibility to the Board at the next regularly scheduled Board meeting immediately following the committee meeting.
-
-
The Audit Committee focuses on financial risk, including internal controls, legal and regulatory risks, as well as compliance risks of a
financial nature, including those related to federal healthcare programs and healthcare providers, and receives an annual risk assessment report from our internal auditors. It also assists the Board
in fulfilling its oversight responsibility with respect to compliance risks of a non-financial nature, including those related to federal healthcare programs and healthcare providers, and regulatory,
quality and product safety issues that affect us. The Audit Committee receives an annual risk assessment from our Global Compliance Group.
-
-
The Finance Committee focuses on risk exposure and risk management strategies associated with our strategic initiatives, current and potential
investments, as well as cash, debt and equity management and our ongoing ability to access capital markets. In addition, the Finance Committee consults with the Audit Committee, as necessary, to share
information pertinent to the Audit Committee's consideration and oversight of the Company's risk and risk management programs and policies.
-
-
The Executive Compensation and Human Resources Committee evaluates and sets compensation programs that encourage decision-making predicated
upon a level of risk consistent with our business strategy. The Executive Compensation and Human Resources Committee also reviews compensation and benefit plans affecting employees in addition to
those applicable to executive officers.
-
-
The Nominating and Governance Committee oversees governance and succession risk, including Board and Chief Executive Officer succession, and
evaluates director skills and qualifications to ensure the appropriate appointment of particular directors to our standing committees based upon the needs of that committee.
Given
the Board's role in risk oversight, it believes that any leadership structure that it adopts must allow it to effectively oversee the management of the risks relating to our operations. Although
there are different leadership structures that could allow our Board to oversee risk management effectively, and while our Board believes our current leadership structure will enable it to manage such
risks effectively, it was one factor among many considered by our Board in selecting this leadership
22
Table of Contents
structure
over other potential alternatives. For a discussion of the reasons why our Board has determined that its leadership structure is appropriate, please see the "Board
Leadership Structure" above.
Communications with the Board
|
Stockholders
and other interested parties who wish to communicate directly with any member of our Board, or our non-management directors as a group, may do so by writing to the Board
of Directors or Non-Management Directors, Boston Scientific Corporation, c/o General Counsel, 300 Boston Scientific Way, Marlborough, Massachusetts 01752 or by contacting the Board via email at
BSCboardofdirectors@bsci.com or non-management directors at non-managementdirectors@bsci.com. The Board has authorized the office of our General Counsel to review and organize, but not screen,
communications from stockholders and other interested parties and deliver them to the Board or non-management directors, as applicable. We do screen commercial solicitations for appropriateness.
The
Company is committed to stockholder engagement. In addition to the communication process detailed above, stockholders also have the opportunity to speak at our Annual Meeting of Stockholders,
participate in the annual "say-on-pay" advisory vote and communicate with our active Investor Relations department, among other avenues for engagement. The Board seriously considers the views of
stockholders in its decision-making process. For example, in May 2019, based on
engagement with our stockholders and benchmarking of corporate governance best practices, the Board determined that it was in the best interest of the Company and our stockholders to approve
amendments to the By-Laws to allow for proxy access, a process by which stockholders meeting certain requirements can nominate directors for election using the Company's proxy materials, and to
recommend that stockholders approve amendments to the Corporation's By-Laws implementing a majority voting standard in uncontested director elections. The Board values the input of the stockholders
who engaged with us on these important matters, and believes that the changes enhance stockholder rights and provide increased accountability of the Company and our Board to our stockholders.
Board and Committee Service Limitation
|
Without
the approval of the Nominating and Governance Committee, no director may sit on more than three public company boards (in addition to our Board) and our Chief Executive
Officer may not sit on more than one public company board (in addition to our Board). No director may serve simultaneously on the audit committees of more than three public companies (including the
Company), unless the Board of Directors has determined that such service would not impair the ability of the member to effectively serve on the Company's Audit Committee, such determination to be
disclosed in accordance with applicable NYSE or SEC rules. All of our Board members have complied with these limitations or procedures. In accordance with such procedures, the Nominating and
Governance Committee and/or Board, as required, has reviewed and approved the following service of our directors:
-
-
At the May 2017 Board meeting, the Board made a determination that the then-proposed service of Mr. Dockendorff on the audit committee
of a fourth public company (including the Company) would not impair his ability to effectively serve on the Company's Audit Committee. The Board has reviewed this service on an annual basis thereafter
and determined that it does not impair Mr. Dockendorff's ability to serve on the Company's Audit Committee.
23
Table of Contents
-
-
At a Special Meeting in December 2019, the Nominating and Governance Committee reviewed and made a determination that the then-proposed service
of Mr. Fujimori on the board of a fourth public company (in addition to the Company) would not impair his ability to serve on the Company's Board. In making its determination, the Committee
considered, among other factors, Mr. Fujimori's strong record of attendance at meetings of the Board and the committee of which he is a member, the relative geographic proximity of the other
companies on whose boards he serves, and his capacity to serve on another public company board.
-
-
Following review at its meeting in February 2020, the Nominating and Governance Committee made a determination by unanimous written consent
that the potential service of Ms. Connors on the boards of five public companies for a brief, transitional period, if needed, would not impair her ability to serve on the Company's Board.
Following this period, Ms. Connors would continue to serve on four public company boards, including the Company's Board. In making the determination, the Committee considered, among other
factors, the duration of potential service on five boards, which if any, is anticipated to be brief.
Related Party Transactions
|
Our
Board has adopted a written related party transaction policy to monitor transactions, arrangements or relationships in which the Company and any of the following have an
interest: (i) any person who is or was (since the beginning of 2019, even if they do not presently serve in that role) an executive officer or director or director nominee; (ii) any
person or entity who holds more than a 5% beneficial ownership of our common stock; (iii) any immediate family member of any of the foregoing; or (iv) any entity in which any of the
foregoing persons is employed or is a general partner or principal or acts in any similar position in which such person or persons collectively have a 10% or greater beneficial ownership interest. The
policy covers any related party transaction that meets the minimum threshold for disclosure under relevant SEC rules (generally, transactions involving amounts exceeding $120,000 in which a related
person has a direct or indirect material interest).
Related
party transaction oversight is the responsibility of our Nominating and Governance Committee. Our General Counsel is responsible for identifying any potential related party transactions and,
if she determines that an existing or proposed transaction constitutes a related party transaction under the policy, she will provide relevant details and an analysis of the related party transaction
to the Nominating and Governance Committee. The General Counsel provides an annual summary to the Nominating and Governance Committee of all transactions or relationships which she considered under
this policy, including those that she determined do not constitute a related party transaction. If the General Counsel has an interest in a potential related party transaction, she will provide all
relevant information to the Chairperson of the Nominating and Governance Committee, who will provide the information to the other members of such Committee. The Nominating and Governance Committee
reviews relevant information concerning any existing or proposed transaction contemplated by the Company with an entity that is the subject of a disclosed relationship, and approves or rejects the
transaction, with or without conditions or additional protections for the Company. Our related party transactions policy can be found in our Corporate Governance Guidelines available under
"Governance Overview" in the "Investor Relations" section of our website at www.bostonscientific.com.
The
daughter of Edward F. Mackey, our executive vice president, operations, is employed by the Company as a principal regulatory specialist in our Endoscopy business. During 2019, her total
compensation, including base salary, bonus for 2018 paid in 2019, and taxable income from vesting of a prior year equity award was approximately $121,000. Her compensation was commensurate with
24
Table of Contents
that
of other employees in similar positions within the Company. This transaction was ratified by the Company's Nominating and Governance Committee at its February 24, 2020 meeting.
We
maintain a Code of Conduct, which has been approved by our Board, to ensure that our directors, employees and officers, including our Chief Executive Officer and Chief Financial
Officer, understand the basic principles that govern our corporate conduct. The Code of Conduct is
available under "Governance Overview" in the "Investor Relations" section of our website at www.bostonscientific.com. A stockholder may request a copy of the Code of Conduct by contacting our Corporate Secretary at Boston Scientific
Corporation, 300 Boston Scientific Way, Marlborough, Massachusetts 01752. Any waivers or substantive amendments of the Code of Conduct will be disclosed on our website at www.bostonscientific.com.
In
addition to our corporate governance policies, sustainability is a key focus of our business. We endeavor to reduce our environmental footprint on a global basis, engage with and
support the communities where we operate, conduct our operations in a responsible and ethical manner, advance the growth and capabilities or our employees and develop innovative products that improve
health care worldwide. By proactively addressing energy consumption, carbon output, waste management, and water use, we are making measurable progress toward shaping a better future for our planet,
which directly impacts the wellbeing of our patients, customers, employees, communities, and investors. Using our Global Energy Management System, we implement our C3
strategy Cut, Convert, Compensate to cut energy use, convert to renewable sources instead of fossil fuels, and compensate with carbon offset projects as
needed. This strategy helps us make progress towards our goals including using 100% renewable electricity by 2024, 90% renewable energy (all sources) by 2027, and achieving carbon neutrality in
manufacturing and key distribution sites for all products by 2030.
For
more, please see our sustainability report available at www.bostonscientific.com/performancereport.
25
Table of Contents
MEETINGS AND BOARD COMMITTEES
Board Meetings and Director Attendance
|
The
Board met four times in 2019. In 2019, each incumbent director attended at least 75% of the aggregate of (1) the total number of meetings of our Board of Directors (held
during the period for which he or she has been a director) and (2) the total number of meetings of all committees of our Board of Directors on which the director served (during the periods that
he or she served).
Directors
are expected to prepare for and use reasonable efforts to participate in all Board meetings and meetings of the committees on which they serve. The Board and each committee will meet as
frequently as necessary to properly discharge their responsibilities, provided that the full Board will meet at least four times per year. In addition, directors are expected to use reasonable efforts
to attend Annual Meetings of Stockholders. At our 2019 Annual Meeting of Stockholders, all of our directors were in attendance.
Directors
who qualify as independent directors within the meaning of the NYSE Corporate Governance Standards meet in executive sessions without management at every regularly
scheduled Board meeting and at such other times as they deem appropriate. Our independent directors meet in executive session at least once annually. In 2019, our independent directors met in
executive session without non-independent directors four times. The Chairman of the Board, if independent, or the Lead Independent Director, if the Chairman of the Board is not independent, will
preside at executive sessions of independent directors. In his absence, the Chair of the Nominating and Governance Committee presides at these executive sessions, and, in his absence, the Chair of the
Audit Committee presides.
Committees of the Board of Directors
|
Our
Board currently has standing Audit, Executive Compensation and Human Resources, Nominating and Governance, and Finance Committees. All of the members of the Audit Committee,
Executive Compensation and Human Resources Committee, and Nominating and Governance Committee meet the applicable independence requirements of the NYSE and the SEC. Our Board also establishes special
committees from time to time to address specific issues or discrete matters as the need arises.
Each
of our standing committees is governed by a written charter, which is subject to annual review by each respective committee and approval by the Board. Committee charters are available under
"Governance Overview" in the "Investor Relations" section of our website at www.bostonscientific.com.
In
March 2020, our Board determined that it would be in the best interests of the Corporation and our stockholders to dissolve the Finance Committee and create a Risk Committee, effective
May 6, 2020. In addition, the Board added to the Nominating and Governance Committee's mandate oversight responsibility of environmental and social matters, and directed that corresponding
changes be made to that committee's charter.
26
Table of Contents
Board Committee Membership
|
As
of March 13, 2020, our committee membership was as follows:
|
|
|
|
|
|
|
|
|
Name
|
|
Audit
Committee
|
|
Executive
Compensation
and Human
Resources
Committee
|
|
Nominating and
Governance
Committee
|
|
Finance
Committee
|
|
|
|
|
|
|
|
|
|
Nelda J. Connors
|
|
|
|
*
|
|
|
|
*
|
Charles J. Dockendorff
|
|
+
|
|
|
|
|
|
*
|
Yoshiaki Fujimori
|
|
|
|
|
|
|
|
*
|
Donna A. James
|
|
|
|
+
|
|
*
|
|
|
Edward J. Ludwig
|
|
*
|
|
*
|
|
|
|
|
Stephen P. MacMillan
|
|
|
|
*
|
|
*
|
|
|
Michael F. Mahoney
|
|
|
|
|
|
|
|
|
David J. Roux
|
|
*
|
|
|
|
|
|
+
|
John E. Sununu
|
|
*
|
|
|
|
+
|
|
|
Ellen M. Zane
|
|
*
|
|
|
|
*
|
|
|
|
|
|
*
|
|
Committee Member
|
+
|
|
Committee Chair
|
In
connection with the changes to the committee structure described in the section titled "Committees of the Board of Directors", the Board also
approved the following changes to committee composition, effective May 6, 2020: Mr. Roux will be Chair of the Nominating and Governance Committee, to replace Mr. Sununu;
Mr. Sununu will be Chair of the newly established Risk Committee; and Mr. Ludwig will step down from the Audit Committee.
Our
Audit Committee met eleven times in 2019. Our Audit Committee is comprised of Messrs. Dockendorff, Ludwig, Roux and Sununu and Ms. Zane, each of whom meets the
independence
requirements of the NYSE and the SEC. The Board has also determined that each of Messrs. Dockendorff, Ludwig and Sununu and Ms. Zane is an "audit committee financial expert" as that term
is defined in the rules and regulations of the SEC.
As
outlined in its written charter, the primary purpose of the Audit Committee is to provide oversight of our accounting and financial reporting processes and audits of our financial statements, as
well as of our global compliance program, including matters related to compliance with financial, legal and regulatory requirements. The Audit Committee has responsibility to, among other
things:
-
-
provide assistance to our Board in the areas of corporate accounting, internal control, independent audit and reporting practices;
-
-
maintain, by way of regularly scheduled meetings, a direct line of communication among our directors, management, our internal auditors and our
independent registered public accounting firm;
-
-
appoint our independent registered public accounting firm, evaluate its qualifications, independence and performance, and review its reports
and other services, and has the right to terminate our independent registered public accounting firm;
27
Table of Contents
-
-
pre-approve audit, audit-related and non-audit services performed for us by our independent registered public accounting firm; and
-
-
assist the Board in its oversight of financial, legal and regulatory compliance, including financial reporting, internal controls and financial
risk exposure to the Company resulting from legal and regulatory compliance matters, and all other areas of compliance.
The
Audit Committee Report can be found on page 112 of this Proxy Statement.
Executive Compensation and Human Resources Committee
|
Our
Executive Compensation and Human Resources Committee (Compensation Committee) met five times in 2019. Ms. James, Ms. Connors, and Messrs. Ludwig and
MacMillan are the current members of the Compensation Committee. The Compensation Committee is, and was during 2019, comprised exclusively of "independent directors," as defined by the NYSE, including
under the heightened independence standards applicable to compensation committee members, "non-employee directors" within the meaning of Rule 16b-3 promulgated under the Securities Exchange Act
of 1934, as amended (Exchange Act), and "outside directors" within the meaning of Section 162(m) of the Code.
As
outlined in its written charter, the Compensation Committee has the responsibility to, among other things:
-
-
set the corporate goals and objectives relative to the Chief Executive Officer's compensation and evaluate the Chief Executive Officer's
performance against those goals and objectives;
-
-
determine and approve our Chief Executive Officer's compensation;
-
-
review, oversee and determine (or make recommendations to the Board regarding) the total compensation package for our other executive officers;
-
-
review and approve all new employment, consulting, retirement, severance and change in control agreements, indemnification agreements and other
arrangements proposed for our executive officers, except for employment agreements with the Chief Executive Officer or Chief Financial Officer, with respect to which it shall review and make
recommendations to the Board, and periodically review and evaluate these arrangements for continuing appropriateness;
-
-
review and make recommendations to the Board regarding the compensation of our non-employee directors;
-
-
adopt and periodically review a comprehensive statement of executive compensation philosophy, strategy and principles; and
-
-
review and discuss with management how the Company's compensation policies and programs for all of its employees may create incentives that can
affect risk and the management of that risk, as well as whether the Company's compensation programs are appropriately aligned with the Company's risk management.
The
Compensation Committee may delegate its authority and duties to subcommittees or individual members of the Compensation Committee, as it deems appropriate in accordance with applicable laws
28
Table of Contents
and
regulations. The Compensation Committee has delegated authority to our Chief Executive Officer to make equity grants to new hires and retention awards to existing employees who are not executive
officers within predetermined guidelines. These grants are reviewed with the Compensation Committee at its next regularly scheduled meeting. The Compensation Committee may also delegate authority to
make amendments to the Company's benefit plans and Global Employee Stock Ownership Plan to the Senior Vice President, Human Resources, that he or she determines to be necessary to maintain compliance
with applicable law or other technical amendments that do not materially increase the cost of the plans to the Company.
Pursuant
to its charter, the Compensation Committee has sole authority to retain or obtain advice from any compensation consultant, legal counsel or other advisor, as the Compensation Committee deems
appropriate to assist the Committee in the performance of its duties, including the sole authority to approve the compensation and other terms and conditions of retention. Prior to any such retention,
and on an annual basis, the Compensation Committee considers any factors relevant to such consultant's, legal counsel's or advisor's independence from management, including the factors specified in
the NYSE Corporate Governance Standards or other listing rules, to evaluate whether the services to be performed will raise any conflict of interest or compromise the independence of such consultant,
legal counsel or advisor. Semler Brossy Consulting Group, LLC (Semler Brossy) served as the Compensation Committee's independent compensation consultant in 2019. During 2019, Semler Brossy
provided the following compensation services to the Compensation Committee:
-
-
reviewed and recommended the peer group of companies used in evaluating executive and director compensation;
-
-
provided information and commentary on executive and director compensation market trends;
-
-
collected and analyzed market pay data on director and executive compensation;
-
-
reviewed and provided commentary and recommendations on our executive and director compensation arrangements in comparison to market; and
-
-
reviewed and provided commentary on our proxy disclosures and management proposals concerning executive pay.
For
additional information regarding the services provided by Semler Brossy, please see the Compensation Discussion & Analysis section.
In
2019, Semler Brossy and its affiliates did not provide additional services to the Company other than at the request of the Compensation Committee. After review and consultation with Semler Brossy,
the Compensation Committee determined that Semler Brossy is independent, and there is no conflict of interest resulting from retaining Semler Brossy currently or during 2019. In reaching these
conclusions, the Compensation Committee considered the factors set forth in the SEC rules and the NYSE listing standards.
In
accordance with its annual review of its compensation consultant engagement, the Compensation Committee will evaluate the engagement of Semler Brossy in May 2020.
The
Compensation Committee Report can be found on page 70 of this Proxy Statement.
29
Table of Contents
Nominating and Governance Committee
|
The
Nominating and Governance Committee met five times in 2019. Mr. Sununu, Ms. James, Mr. MacMillan and Ms. Zane are the current members of the
Nominating and Governance Committee, each of whom is a non-employee director and meets the independence requirements of the NYSE.
As
outlined in its written charter, the Nominating and Governance Committee has responsibility to, among other things:
-
-
recommend nominees for election and re-election to the Board;
-
-
ensure that Board nominees are qualified and consistent with our needs;
-
-
monitor significant developments in the law and practice of corporate governance for directors of public companies;
-
-
recommend Board committee assignments;
-
-
review and recommend Board policies and procedures;
-
-
review political contributions made by the Company;
-
-
monitor compliance with our stock ownership guidelines and with our related party transactions and board service policies;
-
-
oversee the Board and each committee of the Board in their annual performance self-evaluations;
-
-
recommend to the Board candidates for Chairman and Chief Executive Officer; and
-
-
review and assess a succession plan for the Chief Executive Officer.
The
Nominating and Governance Committee is also responsible for reviewing with the Board, on an annual basis, the current size, structure and composition of the Board as a whole, and whether the
Company is being well served by the current directors taking into account the following: the directors' degree of independence; business background, including any areas of particular expertise, such
as accounting or related financial management expertise, marketing or technology; record of service (for incumbent directors), including attendance record; meeting preparation; overall contribution to
the Board; employment status; gender; ethnicity; years of experience; availability for service to us; and our anticipated needs.
For
information on the nomination process conducted by the Nominating and Governance Committee and our policies regarding stockholder nominations of directors, please see the Corporate Governance
section titled "Director Nomination Process."
30
Table of Contents
The
Finance Committee met four times in 2019. Mr. Roux, Ms. Connors, Mr. Dockendorff and Mr. Fujimori are the current members of the Finance Committee.
The primary role of the Finance Committee is to provide a forum within the Board to review our overall financing plans and long-term strategic objectives, as well as our shorter-term acquisition and
investment strategies and how these shorter-term activities fit within our overall business objectives.
As
outlined in its written charter, the Finance Committee is charged with providing Board oversight of the financial management of the Company, approving strategic transactions for which the Board has
delegated authority, making recommendations to the Board regarding larger transactions, and evaluating our financial strategies and policies. The Finance Committee has responsibility to, among other
things:
-
-
review periodically with management our strategic business objectives and the manner in which transactional activity can contribute to the
achievement of those objectives;
-
-
review strategic opportunities with management on a regular basis;
-
-
conduct periodic reviews of completed transactions to assess success achieved;
-
-
test the extent to which the projections and other assumptions relied upon in approving past transactions have borne out;
-
-
identify the factors differentiating more successful transactions from less successful ones;
-
-
evaluate the strategic contributions of these transactions; and
-
-
conduct periodic reviews of our cash investments and cash management policies, debt ratings and global financing objectives and strategies,
including the review and approval of certain borrowing arrangements, capital expenditures and dispositions, and activities that may impact our capital structure.
Compensation Committee Interlocks and Insider Participation
|
The
members of our Compensation Committee during 2019 were Ms. Connors, Ms. James, Mr. Ludwig and Mr. MacMillan. None of these Compensation Committee
members is or has ever been an officer or employee of our Company. During 2019, no member of the Compensation Committee had a relationship that must be described under the SEC rules relating to
disclosure of related person transactions. In 2019, none of our executive officers served on the board of directors or compensation committee (or other board committee performing equivalent functions)
of any entity that had one or more of its executive officers serving on the Board or the Compensation Committee of the Company.
31
Table of Contents
DIRECTOR COMPENSATION
Elements of Director Compensation
|
The
Compensation Committee evaluates the appropriate level and form of compensation for non-employee directors at least annually and recommends changes to our Board when appropriate.
Non-employee directors receive a combination of cash and equity compensation for their service on our Board. To determine the level of compensation for 2019, the Compensation Committee relied on the
consulting services of Semler Brossy, as well as publicly available data describing director compensation in our peer group companies, to establish an appropriate and competitive level of
compensation. The Compensation Committee generally aims to provide a level of compensation that is competitive with the median of peer and other similar companies. The Compensation Committee also took
into consideration the significant amount of time and dedication required by our directors to fulfill their duties on our Board and Board committees as well as the need to continue to attract highly
qualified candidates to serve on our Board. Our director compensation is as follows:
Non-Employee Directors
2019 Compensation
For their service for the annual term beginning on the date of the 2019 annual meeting of stockholders, we have compensated our non-employee directors as
described below and in the following sections:
-
-
an annual cash retainer of $115,000;
-
-
an annual grant of equity with a value of $185,000;
-
-
an annual cash fee of $20,000 for the chair of each of our Board committees, other than the chair of our Audit Committee;
-
-
an annual cash fee of $25,000 for the chair of our Audit Committee; and
-
-
an annual cash fee of $40,000 to our Lead Independent Director.
The
annual equity grants are made on the date of each annual meeting of stockholders. If a non-employee director is appointed to the Board on a date other than the annual meeting of stockholders, an
equity grant in an amount equal to the then-current non-employee director annual award, prorated for the time period from the effective date of the appointment to the next annual meeting of
stockholders, is made on the first trading day of the month following the month in which the new director was appointed to the Board. Such awards made to new non-employee directors become free from
restriction upon the expiration of the new director's current term of office on the
date of the annual meeting of stockholders immediately following the date of grant, subject to the director's continuation of service during such term. Additionally, if a non-employee director is
appointed to the Board on a date other than the annual meeting of stockholders, the annual cash retainer for such director will be prorated for the time period from the effective date of the
appointment to the next annual meeting of stockholders.
32
Table of Contents
Cash Compensation
Each non-employee director receives the annual cash retainer and fees on a quarterly basis. For 2019, each non-employee director could elect to receive all or
a portion of his or her cash compensation as one or both of two equity alternatives, each to vest on the date of the annual meeting of stockholders immediately following the date of grant, subject to
the director's continuation of service during such term: (i) restricted stock valued based on the closing price of our common stock on the date of grant; and (ii) deferred stock units,
valued based on the closing price of our common stock on the date of grant (with shares of our common stock to be issued only after a director's separation from Board service in accordance with the
Boston Scientific Non-Employee Director Deferred Compensation Plan, as amended and restated, effective January 1, 2014 (the 2014 Non-Employee Director Deferred Compensation Plan)). Each
non-employee director could also choose to defer receipt of all or a portion of his or her annual cash compensation under the 2014 Non-Employee Director Deferred Compensation Plan, as described
further below.
Equity Compensation
The annual equity grants are made on the date of each annual meeting of stockholders and are subject to the terms and conditions of our 2011 Long-Term
Incentive Plan (2011 LTIP). In 2019, each non-employee director could elect to receive his or her annual equity award as one or both of the following two equity compensation alternatives, each to vest
on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director's continuation of service during such term: (i) restricted stock valued based
on the closing price of our common stock on the date of grant; and (ii) deferred stock units valued based on the closing price of our common stock on the date of grant (with shares of our
common stock to be issued only after a director's separation from Board service in accordance with the 2014 Non-Employee Director Deferred Compensation Plan).
Amendment and Restatement of 2011 LTIP
If stockholders approve an amendment and restatement of the 2011 LTIP, among other amendments, a reasonable annual limit will be imposed on the cash and
equity compensation that may be granted or paid to any non-employee director during a calendar year so that the accounting value of equity awards, when aggregated with cash compensation, granted to a
non-employee director in any calendar year does not exceed $600,000. For more information on the proposed amendment and restatement of the 2011 LTIP, please see "Proposal 3:
Approval of the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan."
Employee Directors
Directors who are also employees of the Company receive no compensation for serving on the Board or its committees.
Other Payments and Benefits
We pay or reimburse our directors for transportation, hotel, meals and other incidental expenses incurred in connection with their performance
of services for us, including attending Board and committee meetings and participating in director education programs. Our corporate aircraft is made available to our directors for travel to and from
our Board meetings, as well as for certain other Company business travel. We also extend directors' and officers' indemnity insurance coverage to each of our directors.
33
Table of Contents
Non-Employee Director Deferred Compensation Plans
Each non-employee director may, by written election, defer receipt of all or a portion of the annual cash retainer, annual cash committee
chair fees and equity compensation under our 2014 Non-Employee Director Deferred Compensation Plan. Cash amounts deferred can be invested in deemed investment options in which we credit the amount
deferred plus any earnings from the chosen investment options. Investment options under the plan are generally the same as those offered under the Company's 401(k) Plan through Vanguard, except that,
among other things, directors may not elect to invest in the BSC Stock Fund. Deferred cash amounts are payable, at the non-employee director's written election, in either a lump-sum or in annual
installments after a director's separation from Board service or in a lump-sum on an earlier fixed date (in all cases, in accordance with the plan).
Director Stock Ownership Guidelines
We believe the stock ownership requirements for our non-employee directors align the interests of our directors with the long-term interests
of our stockholders. Our director stock ownership guidelines provide that each non-employee director should own shares with a value equal to at least five times the director annual cash retainer
within five years of his or her joining the Board. For purposes of satisfying this obligation, stock units and stock or stock unit deferrals under a Company deferred compensation plan may be included
in the aggregate number of shares held by a director. All of our non-employee directors who have served five years or more currently meet our director stock ownership guidelines. The Nominating and
Governance Committee monitors compliance with these guidelines on an annual basis. For information regarding the stock ownership guidelines applicable to our Chairman and Chief Executive Officer,
please see the Compensation Discussion & Analysis section titled "Executive Stock Ownership Guidelines."
Director Compensation Table
|
The
table below summarizes the compensation paid or earned by our non-employee directors for the year ended December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
Name(1)
|
|
Fees
Earned or
Paid in
Cash
($)(2)(3)
|
|
Stock
Awards
($)(2)(4)(5)
|
|
Change in
Pension
Value and
Non-Qualified
Deferred
Compensation
Earnings
($)(6)
|
|
All Other
Compensation
($)(7)
|
|
Total
($)
|
|
|
|
|
|
|
|
|
|
|
|
Nelda J. Connors
|
|
115,000
|
|
184,979
|
|
2,492
|
|
|
|
302,471
|
Charles J. Dockendorff
|
|
140,000
|
|
184,979
|
|
|
|
|
|
324,979
|
Yoshiaki Fujimori
|
|
115,000
|
|
184,979
|
|
|
|
|
|
299,979
|
Donna A. James
|
|
135,000
|
|
184,979
|
|
|
|
|
|
319,979
|
Edward J. Ludwig
|
|
155,000
|
|
184,979
|
|
|
|
130
|
|
340,109
|
Stephen P. MacMillan
|
|
115,000
|
|
184,979
|
|
|
|
|
|
299,979
|
David J. Roux
|
|
135,000
|
|
184,979
|
|
|
|
224
|
|
320,203
|
John E. Sununu
|
|
135,000
|
|
184,979
|
|
|
|
|
|
319,979
|
Ellen M. Zane
|
|
115,000
|
|
184,979
|
|
|
|
|
|
299,979
|
|
|
|
(1)
|
|
Mr. Mahoney, the Chairman of our Board, President and Chief Executive Officer, is not included in this table because Mr. Mahoney did not receive any compensation for his services as a director in 2019. His
compensation as an executive of the Company is discussed in the Compensation Discussion & Analysis and Executive Compensation sections.
|
34
Table of Contents
|
|
|
(2)
|
|
The "Stock Awards" column and, to the extent a director received equity in lieu of cash compensation, the "Fees Earned or Paid in Cash" column, present grant date fair value (and the notes below present the individual
grant date fair values) of each director's equity award computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718. For a description of the assumptions used for purposes of determining
grant date fair value, please see Note L Stock Ownership Plans to our consolidated financial statements included in Item 8 Financial Statements and Supplementary Data of
our Annual Report on Form 10-K for the year ended December 31, 2019.
|
(3)
|
|
Messrs. Ludwig and MacMillan elected to receive equity in the form of deferred stock units for their entire cash retainer earned in 2019. The following table reports the equity granted to Messrs. Ludwig and
MacMillan in lieu of cash for the one-year term beginning after the 2019 Annual Meeting of Stockholders.
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Equity Award
|
|
Grant Date
|
|
Number of
Units(#)
|
|
Grant Date
Fair Value($)
|
|
Vesting Date
|
|
|
|
|
|
|
|
|
|
|
|
Edward J. Ludwig
|
|
Deferred Stock Units
|
|
May 9, 2019
|
|
4,181
|
|
154,990
|
|
May 7, 2020
|
Stephen P. MacMillan
|
|
Deferred Stock Units
|
|
May 9, 2019
|
|
3,102
|
|
114,991
|
|
May 7, 2020
|
|
|
|
(4)
|
|
Each non-employee director elected at our 2019 Annual Meeting of Stockholders was granted an equity award with a value of $185,000. For each director that elected to receive restricted stock, the restricted stock
vests on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director's continued service during such term. For each director that elected to receive deferred stock units, the deferred stock units
vest on the date of the annual meeting of stockholders immediately following the date of grant, subject to continued service during such term, and vested shares of stock will be issued to the director upon his or her separation from Board service in
accordance with the 2014 Non-Employee Director Deferred Compensation Plan.
|
|
|
The annual equity awards to our directors during 2019 are shown below:
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Equity Award
|
|
Grant Date
|
|
Number of
Shares/
Units(#)
|
|
Grant Date
Fair Value($)
|
|
Vesting Date
|
|
|
|
|
|
|
|
|
|
|
|
Nelda J. Connors
|
|
Restricted Stock
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
Charles J. Dockendorff
|
|
Restricted Stock
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
Yoshiaki Fujimori
|
|
Deferred Stock Units
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
Donna A. James
|
|
Deferred Stock Units
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
Edward J. Ludwig
|
|
Deferred Stock Units
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
Stephen P. MacMillan
|
|
Deferred Stock Units
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
David J. Roux
|
|
Restricted Stock
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
John E. Sununu
|
|
Restricted Stock
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
Ellen M. Zane
|
|
Restricted Stock
|
|
May 9, 2019
|
|
4,990
|
|
184,979
|
|
May 7, 2020
|
|
|
|
|
|
The outstanding Restricted Stock, Restricted Stock Deferred and Deferred Stock Units held by the non-employee directors at December 31, 2019 are shown below:
|
|
|
|
|
|
Name
|
|
Outstanding
Restricted Stock
|
|
Outstanding Deferred
Stock Units and
Restricted Stock Deferred
|
|
|
|
|
|
Nelda J. Connors
|
|
4,990
|
|
77,569
|
Charles J. Dockendorff
|
|
4,990
|
|
|
Yoshiaki Fujimori
|
|
|
|
18,111
|
Donna A. James
|
|
|
|
13,484
|
Edward J. Ludwig
|
|
|
|
27,673
|
Stephen P. MacMillan
|
|
|
|
45,694
|
David J. Roux
|
|
4,990
|
|
|
John E. Sununu
|
|
4,990
|
|
81,757
|
Ellen M. Zane
|
|
4,990
|
|
|
|
|
|
|
|
For more information on the beneficial ownership of our directors, please see the section titled "Certain Beneficial Ownership Matters".
|
|
|
|
(5)
|
|
The outstanding, unexercised stock options at December 31, 2019, pursuant to stock option awards previously granted to non-employee directors, all of which have vested, are shown below.
|
|
|
|
Name
|
|
Outstanding
Stock Options
|
|
|
|
Edward J. Ludwig
|
|
16,818
|
Stephen P. MacMillan
|
|
34,493
|
|
|
|
(6)
|
|
The amounts in this column represent the "above-market" portion of 2019 earnings under the interest crediting investment option available under the Non-Employee Director Deferred Compensation Plan. The interest rate
used under the plan each year is the Moody's Composite Yield on Seasoned Corporate Bonds for the month of September of the preceding year. For 2019, the interest rate used under the plan was 4.39%, the Moody's rate in September 2018. Under SEC rules,
interest on non-qualified deferred compensation is considered "above-market" if the interest rate exceeds 120% of the federal long-term interest rate, with compounding at the rate that corresponds most closely to the rate under the plan, at the time
the interest rate or formula is set. For 2019, 120% of the applicable federal long-term interest rate was 3.63%.
|
(7)
|
|
The amount reflected in the "All Other Compensation" column represents the aggregate incremental cost to us for personal use of our corporate aircraft by Messrs. Ludwig and Roux, as well as any incremental costs
associated with persons accompanying them on business travel, if applicable. We calculate the incremental cost to us by dividing the total annual variable operating costs for the corporate aircraft by the number of in-flight hours during the year.
The resulting dollar per hour amount is then multiplied by the number of hours flown for personal use by Messrs. Ludwig and Roux during the year, including the "dead head" costs of flying the aircraft to and from locations for personal use. For
additional details regarding our corporate aircraft, please see the footnotes to the Executive Compensation section titled "Summary Compensation Table." The amount in this column excludes $503 and $1,116
of disallowed Company tax deductions attributable to Messrs. Ludwig and Roux, respectively, for personal use of the corporate aircraft during the year.
|
35
Table of Contents
EXECUTIVE OFFICERS
As
of March 13, 2020, our executive officers were as follows:
|
|
|
|
|
Name
|
|
Age
|
|
Title
|
|
|
|
|
|
Michael F. Mahoney
|
|
55
|
|
Chairman of the Board, President and Chief Executive Officer
|
Kevin J. Ballinger
|
|
47
|
|
Executive Vice President and President, Interventional Cardiology
|
Daniel J. Brennan
|
|
54
|
|
Executive Vice President and Chief Financial Officer
|
Arthur C. Butcher
|
|
49
|
|
Executive Vice President and President, Asia Pacific
|
Wendy Carruthers
|
|
51
|
|
Senior Vice President, Human Resources
|
Jodi Euerle Eddy
|
|
47
|
|
Senior Vice President and Chief Information Officer
|
Joseph M. Fitzgerald
|
|
56
|
|
Executive Vice President and President, Rhythm Management
|
Edward F. Mackey
|
|
57
|
|
Executive Vice President, Operations
|
Professor Ian T. Meredith AM
|
|
63
|
|
Executive Vice President and Global Chief Medical Officer
|
Jeffrey B. Mirviss
|
|
54
|
|
Executive Vice President and President, Peripheral Interventions
|
Maulik Nanavaty
|
|
58
|
|
Senior Vice President and President, Neuromodulation
|
David A. Pierce
|
|
56
|
|
Executive Vice President and President, MedSurg and President, Endoscopy
|
Desiree Ralls-Morrison
|
|
53
|
|
Senior Vice President, General Counsel and Corporate Secretary
|
Meghan Scanlon
|
|
47
|
|
Senior Vice President and President, Urology and Pelvic Health
|
John Bradley Sorenson
|
|
52
|
|
Senior Vice President, Manufacturing and Supply Chain
|
Eric Thépaut
|
|
58
|
|
Executive Vice President and President, Europe, Middle East and Africa
|
Biographical Information About Our Executive Officers
|
For
Michael F. Mahoney, please see his biography in Proposal 1: Election of Directors.
Kevin J. Ballinger is our executive vice president and global president, Interventional Cardiology, a position he has held since March 2017. In his
current role, Mr. Ballinger is responsible for developing and bringing to market innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. Prior to
that, he served as senior vice president from January 2013 to February 2017. Mr. Ballinger has more than 20 years of interventional cardiology experience. Prior to his current role, he
was also president, Interventional Cardiology and held a variety of engineering and general management positions within our Interventional Cardiology and Peripheral Interventions business units,
including vice president and general manager, group program management, cardiology, rhythm and vascular; vice president of research and development, Peripheral Interventions and vice president of
program management, Cardiovascular. Mr. Ballinger earned a B.S. in mechanical engineering from Michigan Technological University and an M.B.A. from the University of Minnesota.
36
Table of Contents
Daniel J. Brennan is our executive vice president and chief financial officer, a position he has held since January 2014. In this role, he is
responsible for several company functions, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations, and corporate business development.
Prior to that, he was the Company's senior vice president and corporate controller, a role he served in since January 2010. Since joining Boston Scientific in December 1996, Mr. Brennan has
held roles with increased responsibilities, including vice president and assistant corporate controller, vice president of finance and information technology for worldwide financial and strategic
planning, investor relations, international finance and Cardiovascular, group controller of the non-vascular business and controller of the Meditech Vascular business. He holds a B.S. degree in
Finance and Investments and an M.B.A from Babson College. Mr. Brennan is also a certified public accountant and a member of the board of overseers of Babson College. He currently is a member of
the board of directors of Nuance Communications.
Arthur C. Butcher is our executive vice president and president, Asia Pacific, a position he has held since February 2020. In this role, he is
responsible for overseeing the continued growth of our
company and the ongoing development of our leadership teams in Asia Pacific. Prior to his current role, Mr. Butcher served as our senior vice president and president, Endoscopy, a position he
held since July 2016. In this role, he was responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions. He also served as vice
president & general manager, Japan Endoscopy from August 2014 to June 2016. Mr. Butcher has held a variety of marketing and strategic planning management positions within the Endoscopy
and Urology and Pelvic Health businesses, including vice president of global marketing, Endoscopy division from April 2011 to August 2014, and vice president of new business development and strategic
planning, Urology & Women's Health. Since joining Boston Scientific in 1997, Mr. Butcher has held management roles with increasing responsibility and has deep experience across
divisions. He holds a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from Columbia University.
Wendy Carruthers is our senior vice president, human resources, a position she has held since December 2012. In this role, she is responsible for
overseeing the Company's human resources activities globally, including human resources operations and services, total rewards, talent management, diversity and inclusion and community engagement.
Prior to her current role, Ms. Carruthers served as the head of human resources on an interim basis from August 2012 to November 2012, as well as our vice president of global talent management
from January 2011 to November 2012. Ms. Carruthers has been with Boston Scientific since 2004 and has held various positions such as, vice president of human resources for our Europe, Middle
East and Africa region; vice president of human resources for Europe and director of human resources for Europe. Prior to joining Boston Scientific, Ms. Carruthers was vice president of human
resources, Europe for Cable & Wireless. Ms. Carruthers holds a B.A. First Class Honors Degree in Modern Languages from the University of Salford and is a Fellow of the Chartered
Institute of Personnel and Development. She is a Board member of Envista Holdings Corporation, the Boston Scientific Foundation and the Greater Boston Food Bank.
Jodi Euerle Eddy is our senior vice president and chief information officer, a position she has held since December 2015. Ms. Eddy joined the
Company in December of 2013 as our vice president, Information Systems. In her current role, Ms. Eddy is responsible for positioning the Company for success across multi-disciplinary
information technology (IT) needs and overseeing the Company's strategy for digital health, data analytics, and cyber security capabilities. Ms. Eddy leads an IT organization of employees and
contractors worldwide focused on continued advancement into complex, integrated IT solutions to address evolving customer and patient data needs. Prior to joining Boston Scientific, Ms. Eddy
progressed through several roles of increasing leadership of information systems positions over 18 years at General Electric, including serving as the commercial chief information
37
Table of Contents
officer
for the Oil and Gas business from October 2012 until December 2013; chief commercial information officer for the Measurement and Control business from October 2011 until February 2012; and
chief information officer for the Engineered Systems business from October 2008 until February 2011. Ms. Eddy earned a B.S. in computer science from Southern Connecticut State University. She
holds certifications in Master Black Belt Six Sigma, CISSP and CISCO CCNA.
Joseph M. Fitzgerald is our executive vice president and president, Rhythm Management, a position he has held since February 2014, having previously
served as senior vice president and president, Cardiac Rhythm Management from July 2011. In this role, he is responsible for developing and bringing to market the most advanced and least invasive
rhythm management technologies. He served as senior vice president and president, Endovascular from February 2010 until July 2011. Prior to that, Mr. Fitzgerald was president and general
manager of Peripheral Interventions and president of Electrophysiology. Mr. Fitzgerald held a variety of management positions in our Neurovascular and Peripheral Interventions businesses. These
included numerous regional and divisional sales management assignments up to and including his roles as vice president, global marketing for the Neurovascular business and vice president of U.S. sales
for the Neurovascular business. Prior to joining Boston Scientific in 1990 as a sales representative, Mr. Fitzgerald was with Anheuser Busch, Inc., where he held a variety of sales,
marketing and training assignments. Mr. Fitzgerald holds a B.S. in Business from Indiana University and an M.B.A. from Southern Illinois University with a concentration in Marketing and
Finance.
Edward F. Mackey is our executive vice president, Operations, a position he has held since February 2015. In this role, he is responsible for global
manufacturing and supply chain, quality and regulatory affairs, IT, global business services, global business excellence, and corporate research and development. Prior to joining Boston Scientific,
Mr. Mackey was worldwide president of DePuy Synthes Power Tools, a division of Johnson & Johnson from November 2012 to January 2015, and vice president of integration for
Johnson & Johnson's acquisition of Synthes from June 2010 to November 2012. Early in his career, Mr. Mackey held management positions in operations, quality and product development at
Raytheon's Mille Systems division. In 1995, he moved to Johnson & Johnson Orthopaedics as a plant manager and progressed through a series of manufacturing and supply chain leadership roles,
becoming worldwide vice president of supply chain and manufacturing for DePuy. Mr. Mackey holds a Bachelor's degree in Mechanical Engineering from Worcester Polytechnic Institute and an M.B.A
from the University of Massachusetts.
Professor Ian T. Meredith AM is our executive vice president and global chief medical officer, a position he has held since January 2017. In this role,
he is responsible for leading clinical science and medical affairs across Boston Scientific and providing global leadership of the company's clinical trial strategy. Prior to joining Boston
Scientific, Professor Meredith served as professor and director of MonashHeart, and executive director of the Monash Cardiovascular Research Centre at Monash University in Melbourne, Australia, from
September 2005 to December 2016. Professor Meredith has over 25 years of experience as a clinical and interventional cardiologist and also served as director of the Cardiac Catheterization
Laboratories and Interventional Cardiology. Professor Meredith has been a member of the Board of the National Heart Foundation (Australia) and a member of the Cardiac Society of Australia and New
Zealand National Board. Professor Meredith received a Ph.D. from the Baker Institute in Melbourne and an Order of Australia (AM) in the General Division for service to medicine in the field of
Cardiology as a clinician and researcher. In 2019, Professor Meredith received a Doctor Laws honoris causa from Monash University for distinguished and exceptional service to the field of medicine and
healthcare.
Jeffrey B. Mirviss is our executive vice president and president, Peripheral Interventions, a position he has held since February 2020. In this role, he
is responsible for developing and bringing to market
38
Table of Contents
innovative
solutions for treating patients with arterial and venous system blockages and cancer. Prior to his current role, he was our senior vice president and president, Peripheral Interventions,
from January 2013 until January 2020, and president, Peripheral Interventions from July 2011 to January 2013. Mr. Mirviss has more than 28 years of experience in medical device and
pharmaceutical general management, marketing and sales. Since joining Boston Scientific in 1997, Mr. Mirviss also served as our vice president, Group Global Marketing, Cardiology, Rhythm and
Vascular and vice president, Global Cardiology Marketing. Prior to joining Boston Scientific, Mr. Mirviss worked for companies ranging in size from a pre-revenue venture-backed medical device
startup to Dow 30 companies. He holds a Bachelor's degree from the University of Minnesota and an M.B.A. from the University of St. Thomas.
Maulik Nanavaty is our senior vice president and president, Neuromodulation, a position he has held since September 2011. In this role, he is
responsible for developing and bringing to market innovative, less-invasive microelectronic implantable technologies used to treat chronic neuropathic pain and neurological diseases such as
Parkinson's disease and other chronic conditions. Prior to his current role, Mr. Nanavaty was our president of Boston Scientific Japan; he also served as vice president and general manager,
Interventional Cardiology, Boston Scientific Japan. Mr. Nanavaty joined Boston Scientific in 2005 as vice president, corporate strategy, Boston Scientific Japan. Prior to joining Boston
Scientific, Mr. Nanavaty spent 16 years working in various executive positions at Baxter International, Inc. and Baxter Japan. Mr. Nanavaty earned a Ph.D. in Pharmaceutical
Sciences from the University of Illinois and an M.B.A. from the University of Chicago.
David A. Pierce is our executive vice president and president, MedSurg a position he has held since April 2018, and president, Endoscopy, a role he has
held since February 2020. In this role, he has direct responsibility for the Endoscopy business, Canada and Latin America regions, and corporate marketing and market access, as well as oversight
responsibility for the Urology and Pelvic Health business. Prior to his current role, Mr. Pierce served as the Senior Vice President and President, Urology and Pelvic Health since July 2016. In
that role, he developed and executed strategies to bring to market industry-leading solutions for treating patients with urological, urogynecological and gynecological diseases. Previously,
Mr. Pierce served as senior vice president and president, Endoscopy since 2011, and vice president, marketing for Endoscopy as well as group marketing director in the Endoscopy business. He
joined Boston Scientific in 1991 as a territory manager before assuming management-level positions of increasing responsibility. Prior to joining Boston Scientific, Mr. Pierce also served as
senior sales representative for Airborne Express and as a Captain in the United States Army. He earned a B.S. in Business Administration from Norwich University and an M.B.A. from Boston University.
Desiree Ralls-Morrison is our senior vice president, general counsel and corporate secretary, a position she has held since November 2017. In this role,
she is responsible for providing global legal leadership across all of our businesses, regions and functions, and overseeing the company's global compliance function. Before joining Boston Scientific,
she was senior vice president, general counsel
and corporate secretary, and head of the global litigation, government affairs and public policy organizations, for Boehringer Ingelheim USA, Inc. since October 2013. Prior to that, she spent
nine years at Johnson & Johnson, most recently as general counsel for the consumer group, and previously progressed through roles of increasing responsibility, including senior counsel,
assistant general counsel, and vice president of law for the women's health, nutritionals and over-the-counter businesses. Earlier in her career, Ms. Ralls-Morrison was a senior attorney and
assistant counsel at Merck & Co, Inc., focusing largely on regulatory and product liability matters, and prior to that, she held litigation roles at the law firms of Kelley Drye &
Warren LLP and Shipman & Goodwin LLP. She recently served on the Danbury Hospital/New Milford Hospital Board of Directors, The Inner-City Foundation for Charity and Education and
the Lawyer's Collaborative for Diversity. Desiree earned her
39
Table of Contents
B.A.
in economics and political science from Wesleyan University and her J.D. from Harvard Law School.
Meghan Scanlon is our senior vice president and president, Urology and Pelvic Health, a position she has held since February 2020. In this role, she is
responsible for developing and bringing to market innovative, industry-leading solutions for urological, urogynecological, and gynecological diseases. Prior to her current role, Ms. Scanlon
served as vice president and general manager for the global Urology and Pelvic Health commercial organization, with responsibility for overseeing the stone, prostate health, prosthetic urology and
women's health franchises. Since joining Boston Scientific in 2014 as vice president, global marketing for Endoscopy, she has progressed through roles of increasing responsibility in Urology and
Pelvic Health and Endoscopy, and played a significant role in driving and shaping the global commercial organization structures and portfolio innovation strategies for both businesses. Prior to
joining Boston Scientific, Ms. Scanlon spent nearly 15 years in leadership roles within the Johnson & Johnson medical device business and started her early career as a design
engineer at Gillette. She holds a B.S. in Mechanical Engineering from Tufts University and both her M.B.A. and M.S.M.E. from Massachusetts Institute of Technology.
John Bradley Sorenson is our senior vice president, manufacturing and supply chain, a position he has held since November 2014. In this role, he is
responsible for the global manufacturing and distribution of our products. Prior to his current role, he served as multi-site vice president, operations from 2008 to 2014. Mr. Sorenson held a
variety of operations positions at Boston Scientific, supporting the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and Structural Heart businesses and
has more than 20 years of medical device manufacturing experience. Before joining Boston Scientific, he was president and chief operating officer of QRS Diagnostic and held manufacturing
management positions at Federal Cartridge. Mr. Sorenson earned a B.A. in Economics from Gustavus Adolphus College and an M.B.A. from the University of Minnesota.
Eric Thépaut is our executive vice president and president, Europe, Middle East and Africa, a position he has held since February 2020.
Prior to his current role, he was senior vice president and president, Europe, Middle East and Africa from December 2017 to January 2020, and senior vice president and president, Europe from January
2015 to December 2017. He also served as vice president Interventional Cardiology & Structural Heart, Europe, from December 2012 to December 2015. He joined Boston Scientific Europe, in 1996,
as a business finance manager and earned roles of increasing responsibility in marketing and finance including vice president, Finance, Europe, general manager and vice president, France, and general
manager and vice president of the France Group, comprised of France, Benelux and Middle East North Africa. Before joining Boston Scientific, Mr. Thépaut held management positions
in treasury operations and auditing at Nestlé and financial planning and analysis at Apple, Inc. (then Apple Computer, Inc.). Mr. Thépaut earned his
M.B.A. at Paris Dauphine University.
40
Table of Contents
CERTAIN BENEFICIAL OWNERSHIP MATTERS
Security Ownership of Principal Stockholders
|
Set
forth below are stockholders known by us to be the beneficial owner of more than 5% of our common stock as of March 13, 2020. As of March 13, 2020, there were
1,399,199,786 shares of our common stock outstanding.
|
|
|
|
|
|
Name and Address
|
|
Number of Shares
Beneficially Owned
|
|
Percent of Shares
Outstanding
|
|
|
|
|
|
|
BlackRock, Inc.
|
|
|
101,603,831
|
(1)
|
7.26%
|
55 East 52nd Street, New York, NY 10055
|
|
|
|
|
|
Capital World Investors
|
|
|
108,071,257
|
(2)
|
7.72%
|
333 South Hope Street, Los Angeles, CA 90071
|
|
|
|
|
|
FMR LLC/Abigail P. Johnson
|
|
|
127,514,507
|
(3)
|
9.11%
|
245 Summer Street, Boston, MA 02210
|
|
|
|
|
|
The Vanguard Group
|
|
|
109,016,849
|
(4)
|
7.79%
|
100 Vanguard Blvd., Malvern, PA 19355
|
|
|
|
|
|
-
(1)
-
Based
solely on an amendment to Schedule 13G filed with the SEC on February 5, 2020. As of December 31, 2019, BlackRock reported that it
possessed sole voting power with respect to 89,114,480 shares and sole dispositive power with respect to 101,603,831 shares. BlackRock reported that it did not possess shared voting or
dispositive power over any shares.
-
(2)
-
Based
solely on an amendment to Schedule 13G filed with the SEC on February 14, 2020. As of December 31, 2019, Capital World Investors
reported that it possessed sole voting power with respect to 107,356,426 shares and sole dispositive power with respect to 108,071,257 shares. Capital World Investors reported that it did not
possess shared voting or dispositive power over any shares.
-
(3)
-
Based
solely on an amendment to Schedule 13G jointly filed by FMR LLC and Abigail P. Johnson with the SEC on February 7, 2020. As of
December 31, 2019, FMR LLC reported sole voting power with respect to 13,292,755 shares and each of FMR LLC and Abigail P. Johnson reported sole dispositive power with
respect to 127,514,507 shares. FMR LLC and Abigail P. Johnson reported that the following subsidiaries of FMR LLC beneficially own shares: (i) FIAM LLC;
(ii) Fidelity Institutional Asset Management Trust Company; (iii) Fidelity Investments Money Management, Inc.; (iv) Fidelity Management & Research (Japan)
Limited; (v) Fidelity Management & Research Company; (vi) Fidelity Personal Trust Company; (vii) FMR Co., Inc.; and (viii) Strategic
Advisors Inc.
-
(4)
-
Based
solely on an amendment to Schedule 13G filed with the SEC on February 12, 2020. As of December 31, 2019, The Vanguard Group
reported that it possessed sole voting power with respect to 2,157,081 shares, shared voting power with respect to 376,859 shares, sole dispositive power with respect to 106,607,732 shares and
shared dispositive power with respect to 2,409,117 shares. Vanguard also reported that (i) Vanguard Fiduciary Trust Company, a wholly owned subsidiary of Vanguard, is the beneficial
owner of 1,662,971 shares as a result of its serving as investment manager of collective trust accounts, and (ii) Vanguard Investments Australia, Ltd., a wholly owned subsidiary
of Vanguard, is the beneficial owner of 1,214,444 shares as a result of its serving as investment manager of Australian investment offerings.
41
Table of Contents
Security Ownership of Directors and Executive Officers
|
The
following table shows, as of March 13, 2020, the amount of our common stock beneficially owned by:
-
-
our directors and director nominees;
-
-
our executive officers named in the Summary Compensation Table; and
-
-
all of our directors and executive officers as a group.
"Beneficial
ownership" includes those shares of our common stock the reporting person has the power to vote or transfer, stock options that are currently exercisable or exercisable within
60 days, and deferred stock units that may vest within 60 days. Unless otherwise indicated, the persons named below have sole voting and investment power over the shares listed.
|
|
|
|
|
|
Name
|
|
Number of Shares
Beneficially Owned
|
|
Percent of Shares
Outstanding
|
|
|
|
|
|
|
Nelda J. Connors(1)
|
|
|
128,001
|
|
*
|
Charles J. Dockendorff(2)
|
|
|
68,203
|
|
*
|
Yoshiaki Fujimori(3)
|
|
|
18,111
|
|
*
|
Donna A. James(4)
|
|
|
35,363
|
|
*
|
Edward J. Ludwig(5)
|
|
|
80,988
|
|
*
|
Stephen P. MacMillan(6)
|
|
|
81,135
|
|
*
|
David J. Roux(7)
|
|
|
55,005
|
|
*
|
John E. Sununu(8)
|
|
|
112,912
|
|
*
|
Ellen M. Zane(9)
|
|
|
27,043
|
|
*
|
Michael F. Mahoney(10)
|
|
|
4,988,359
|
|
*
|
Daniel J. Brennan(11)
|
|
|
581,688
|
|
*
|
Kevin J. Ballinger(12)
|
|
|
294,296
|
|
*
|
Joseph M. Fitzgerald(13)
|
|
|
941,336
|
|
*
|
Edward F. Mackey(14)
|
|
|
267,626
|
|
*
|
All directors and executive officers as a group (25 persons)(15)
|
|
|
9,768,363
|
|
*
|
-
*
-
Reflects
beneficial ownership of less than one percent (1%) of our outstanding common stock.
-
(1)
-
Ms. Connors'
beneficial ownership includes (i) 4,990 shares of restricted stock as to which she has sole voting but not investment power as the
shares are unvested until the Annual Meeting, (ii) 45,442 shares of common stock held in the Nelda J. Connors Trust, of which she is the sole trustee, and (ii) 54,813 shares of
restricted stock and 22,756 deferred stock units, both of which have been deferred pursuant to our Non-Employee Director Deferred Compensation Plan, the underlying shares of which she has
neither voting nor investment power until such shares are distributed in accordance with the plan.
-
(2)
-
Mr. Dockendorff's
beneficial ownership includes (i) 4,990 shares of restricted stock as to which he has sole voting but not investment power as
the shares are unvested until the Annual Meeting and (2) 57,104 shares of common stock held in a grantor retained annuity trust, of which he is the trustee and annuitant.
-
(3)
-
Mr. Fujimori's
beneficial ownership includes 18,111 shares of deferred stock units deferred pursuant to our Non-Employee Director Deferred
Compensation Plan, the underlying shares of which he has neither voting nor investment power until such shares are distributed in accordance with the plan.
-
(4)
-
Ms. James'
beneficial ownership includes (i) 21,879 shares of common stock held through The Donna A James Family Trust, of which she is the
sole trustee, and (ii) 13,484 shares of deferred stock units deferred pursuant to our Non-Employee Director Deferred Compensation Plan, the underlying shares of which she has neither
voting nor investment power until such shares are distributed in accordance with the plan.
42
Table of Contents
-
(5)
-
Mr. Ludwig's
beneficial ownership includes 27,673 deferred stock units deferred pursuant to our Non-Employee Director Deferred Compensation Plan as to
the underlying shares of which he has neither voting nor investment power until such shares are distributed in accordance with the plan, and 16,818 shares of common stock subject to stock
options exercisable within 60 days of March 13, 2020.
-
(6)
-
Mr. MacMillan's
beneficial ownership includes 45,694 deferred stock units deferred pursuant to our Non-Employee Director Deferred Compensation Plan
the underlying shares of which he has neither voting nor investment power until such shares are distributed in accordance with the plan, and 34,493 shares of common stock subject to stock
options exercisable within 60 days of March 13, 2020.
-
(7)
-
Mr. Roux's
beneficial ownership includes 4,990 shares of restricted stock as to which he has sole voting but not investment power as the shares are
unvested until the Annual Meeting.
-
(8)
-
Mr. Sununu's
beneficial ownership includes (i) 4,990 shares of restricted stock as to which he has sole voting but not investment power as the
shares are unvested until the Annual Meeting and (ii) 21,708 shares of restricted stock and 60,049 deferred stock units, both of which have been deferred pursuant to our Non-Employee
Director Deferred Compensation Plan, the underlying shares of which he has neither voting nor investment power until such shares are distributed in accordance with the plan.
-
(9)
-
Ms. Zane's
beneficial ownership includes 4,990 shares of restricted stock as to which she has sole voting but not investment power as the shares are
unvested until the Annual Meeting.
-
(10)
-
Mr. Mahoney's
beneficial ownership includes 2,768,731 shares of common stock subject to stock options exercisable within 60 days of
March 13, 2020.
-
(11)
-
Mr. Brennan's
beneficial ownership includes 318,445 shares of common stock subject to stock options exercisable within 60 days of
March 13, 2020.
-
(12)
-
Mr. Ballinger's
beneficial ownership includes 214,211 shares of common stock subject to stock options exercisable within 60 days of
March 13, 2020.
-
(13)
-
Mr. Fitzgerald's
beneficial ownership includes 645,110 shares of common stock subject to stock options exercisable within 60 days of
March 13, 2020 and 68,401 shares held in his 401(k) Plan account.
-
(14)
-
Mr. Mackey's
beneficial ownership includes 201,917 shares of common stock subject to stock options exercisable within 60 days of
March 13, 2020.
-
(15)
-
This
amount includes 5,437,886 shares of common stock subject to stock options exercisable within 60 days of March 13, 2020 and 70,959 shares
held in the 401(k) Plan accounts of our executive officers. Please refer to footnotes 1 through 14 above for additional details regarding the holdings of our directors, our director nominees
and our Named Executive Officers.
Section 16(a) Beneficial Ownership Reporting Compliance
|
Section 16(a)
of the Exchange Act requires our directors, executive officers and persons beneficially holding more than 10% of our common stock to file with the SEC reports of
their ownership of our common stock and any changes in that ownership. To our knowledge, all of these filing requirements were timely satisfied in 2019. In making this statement, we have relied upon
the written representations of our directors and executive officers and copies of reports that have been filed with the SEC.
43
Table of Contents
COMPENSATION DISCUSSION & ANALYSIS
This discussion and analysis describes material elements of our 2019 compensation program for our Named Executive Officers (NEOs), which
include our Chief Executive Officer (CEO), our Chief Financial Officer (CFO), and our three other most highly-compensated executive officers. NEOs for the year ended December 31, 2019 were as
follows:
|
|
|
Michael F. Mahoney
|
|
Chairman of the Board, President and Chief Executive Officer
|
Daniel J. Brennan
|
|
Executive Vice President and Chief Financial Officer
|
Kevin J. Ballinger
|
|
Executive Vice President and President, Interventional Cardiology
|
Joseph M. Fitzgerald
|
|
Executive Vice President and President, Rhythm Management
|
Edward F. Mackey
|
|
Executive Vice President, Operations
|
Strategic Imperatives Linked to 2019 Executive Compensation
During 2019, we continued to focus on the following five strategic imperatives to help drive innovation, accelerate profitable revenue growth
and increase stockholder value:
-
-
strengthen execution to grow share in our served markets;
-
-
expand into high growth adjacencies that complement our core businesses;
-
-
drive global expansion, including in emerging markets;
-
-
fund the journey to fuel growth through optimization and cost reduction initiatives and a reallocation of spending to support growth
initiatives; and
-
-
develop key capabilities to enable delivery of economic- and customer-focused products and solutions aligned with marketplace needs and to
deliver on our diversity goals.
We
believe that focus on these strategic imperatives will lead to strong performance across key financial metrics, including those incorporated into our short- and long-term incentive programs,
described in further detail below.
44
Table of Contents
Pay for Performance
Our short- and long-term incentive plans incorporate metrics designed to align with the objective of driving profitable growth and reward
Company and individual progress related to the strategic imperatives. Below is a snapshot of 2019 adjusted financial performance metrics used in our short- and long-term incentive programs, as well as
the most directly comparable reported metrics:
|
|
|
Reported Financial
Performance Metrics
|
|
Adjusted Financial
Performance Metrics
|
$10.735 billion
|
|
$10.525 billion
|
GAAP Net Sales
|
|
Adjusted Net Sales(1)(2)
for Annual Bonus Plan
|
$3.33
|
|
$1.58
|
GAAP Net Income Per Share
|
|
Adjusted Net Income Per Share(1)
(Adjusted EPS)
for Annual Bonus Plan
|
$1.836 million
|
|
$2.007 billion
|
GAAP Operating Cash Flow
Provided by Operating Activities
|
|
Adjusted Free Cash Flow(1)
for Free Cash Flow Performance Share
Program
|
102.77%
3-year Total Shareholder Return(3)
For Total Shareholder Return Performance Share Program
|
|
|
|
(1)
|
|
Adjusted net sales, adjusted EPS and adjusted free cash flow are not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For a reconciliation of these non-GAAP financial
measures to the most directly comparable GAAP financial measures and insight into how these non-GAAP measures are considered by management, please see Annex A.
|
(2)
|
|
Adjusted net sales excludes the impact of foreign currency fluctuations. Adjusted EPS excludes the impact of goodwill and intangible asset impairments, acquisition- and divestiture related net charges, restructuring
and restructuring-related net charges, litigation-related net charges, investment impairment charges, EU Medical Device Regulation implementation-related charges, debt extinguishment charges, certain tax-related items, and amortization
expense.
|
(3)
|
|
3-year Total Shareholder Return for the period from January 1, 2017 to December 31, 2019. Please see the Executive Compensation section titled "2019 Total Shareholder Return
Performance Share Program" for how we calculate Total Shareholder Return.
|
CEO's Total Direct Compensation Aligns with Company Performance
Our executive compensation philosophy is to provide appropriate competitive compensation opportunities to our executives with actual pay outcomes tied to
achievement of Company and individual performance targets in support of our business strategy and creation of long-term stockholder value.
Each
year, the Compensation Committee assesses our CEO's actual compensation relative to the Company's performance. The following graph shows the relationship of our CEO's total direct compensation
(as disclosed in the Summary Compensation Table) (TDC) compared against our cumulative total shareholder return (TSR) performance in each of the last three years. The TDC in this
45
Table of Contents
chart
consists of base salary and annual short- and long-term incentives. As illustrated, CEO compensation was generally aligned with Company performance.
CEO Compensation(1)
Summary Compensation Table Total Direct Compensation
versus 3-Year Total Shareholder Return(2)
CEO Pay and 3-Year Indexed Total Shareholder Return
|
|
|
(1)
|
|
Amounts in the 2017, 2018, and 2019 columns were calculated as follows:
|
|
|
the values of the annual
equity awards granted on February 28, 2017, February 15, 2018, and February 21, 2019, were determined in accordance with FASB ASC Topic 718, as described in the footnotes to the Executive Compensation section titled "Summary Compensation Table";
|
|
|
the actual Annual Bonus
Plan award for 2017, 2018, and 2019; and
|
|
|
the annual base salary
earned in 2017, 2018, and 2019.
|
(2)
|
|
Total shareholder return was calculated in accordance with the methodology described in the Executive Compensation section titled "2019 Total Shareholder Return Performance Share
Program" and based on $100 invested on December 31, 2016.
|
The
following chart shows the value of the primary elements of total direct compensation, consisting of base salary and annual short- and long-term incentives, for our CEO in 2019 (i) at
"target" opportunity as considered by our Compensation Committee; (ii) as disclosed in our Summary Compensation Table; and (iii) as "realizable" at December 31, 2019. These values
were calculated using the 2019 base salary, annual equity incentives and Annual Bonus Plan ("ABP") award amounts for our CEO as set forth in the table following the chart below.
46
Table of Contents
2019 CEO Compensation
Target vs. Summary Compensation Table vs. Realizable
|
|
|
|
|
|
|
|
|
Valuation of Compensation Component
|
|
|
Base Salary
|
|
ABP Award
|
|
Long-Term Incentives
|
|
|
|
|
|
|
|
Target
|
|
Annual base salary approved in February 2019
|
|
Target 2019 Annual Bonus Plan award
|
|
Annual equity awards granted on February 21, 2019, with (a) stock options valued in accordance with FASB ASC Topic 718 and (b) service-based deferred stock units (DSUs) and performance-based DSUs valued at target (the number of units
and target units awarded multiplied by the closing price of our common stock on the date of grant).
|
Summary Compensation Table
|
|
Annual base salary earned in 2019
|
|
Actual 2019 Annual Bonus Plan award
|
|
Annual equity awards granted on February 21, 2019, with the value of each award determined in accordance with FASB ASC Topic 718.
|
Realizable
|
|
Annual base salary earned in 2019
|
|
Actual 2019 Annual Bonus Plan award
|
|
Annual equity awards granted on February 21, 2019, with:
(a) stock options valued at their intrinsic value (number of options awarded multiplied by the closing price
of our common stock on December 31, 2019 less the exercise price of such options);
(b) service-based DSUs valued using the number of units awarded multiplied by the
closing price of our common stock on December 31, 2019;
(c) Total Shareholder Return (TSR) performance-based DSUs valued using 142% of the target TSR performance-based
DSUs due to the Company's TSR rank being 23rd out of 60, or 63rd percentile (142% of the target number of units multiplied by the closing price of our common stock on December 31, 2019); and
(d) the free cash flow (FCF) performance-based DSUs valued using 90.1% of the target FCF performance-based DSUs (the actual percentage of target units earned under the program) multiplied by the
closing price of our common stock on December 31, 2019.
|
47
Table of Contents
The
difference in value of the long-term incentive compensation portion of our CEO's TDC reflected in the "Realizable", "Target", and "Summary Compensation Table" columns is primarily due to three
factors:
-
-
the increase in the closing price of our common stock on December 31, 2019 ($45.22) compared to the closing price of our common stock on
February 21, 2019 ($40.12), the date of grant for the 2019 annual equity awards;
-
-
the 2019 FCF performance-based DSUs being earned at 90.1% of target based on FCF achievement of $2.007 billion against a target of
$2.150 billion, which target represents approximately 3.86% growth over 2018 actual performance; and
-
-
the TSR performance-based DSUs granted in 2019 tracking at 142% of target as of December 31, 2019, due to the Company's TSR rank of
23rd out of 60 companies.
The
lower equity value in the "Realizable" column of the chart above relative to that in the "Summary Compensation Table" column is driven by the FCF performance-based DSUs being earned at 90.1% of
target. This demonstrates the sensitivity of CEO pay to the achievement of performance criteria, and, therefore, the linkage between our executive compensation program and the long-term interests of
our stockholders. The long-term incentive portion of the CEO's compensation will remain "at-risk" and the value will vary until the completion of the vesting periods or until the exercise date for
each of the equity awards.
A Significant Portion of our NEOs' 2019 Target TDC is At-Risk, Performance-Based Compensation
Our Compensation Committee ties a significant portion of our executives' target TDC to at-risk, performance-based incentive opportunities. For 2019,
approximately 90.8% of the target value of the primary elements of TDC for our CEO and approximately 80.7% of the target value of the primary elements of TDC for our other NEOs as a group consisted of
at-risk, performance-based incentive compensation, comprised of short-term incentives (Annual Bonus Plan award) and long-term incentives (performance- and service-based equity awards and stock
options). For more details and a breakdown of the elements of TDC, please see the section titled "Elements of 2019 Executive Compensation, Primary Elements of Total Direct
Compensation".
The
percentages above were calculated using the 2019 base salary, target equity values and target Annual Bonus Plan award amounts for our NEOs. The allocation of the target value of the primary
elements of TDC for our CEO and for our other NEOs as a group in 2019 was as follows:
-
*
-
The charts reflect the value of the primary elements of 2019 TDC opportunity as considered by the Compensation Committee. For
details on valuation of components of TDC, please see "Target" in the chart entitled "Valuation of Compensation Component" above.
48
Table of Contents
We believe our emphasis on at-risk, performance-based incentive compensation aligns our executives' financial interests with our business strategy and the
short- and long-term interests of our stockholders, providing "pay for performance" and putting a significant portion of our executives' pay "at risk."
Executive Compensation Program Best Practices
Our Compensation Committee believes that a strong foundation for our compensation program is necessary to execute our executive compensation
philosophy effectively. The following best practices serve as the foundation for our executive compensation program:
At
our 2019 Annual Meeting of Stockholders, we asked our stockholders to approve, on an advisory basis, the 2018 compensation of our then NEOs as disclosed in our 2019 Proxy
Statement, commonly referred to as a "say-on-pay" advisory vote. Our stockholders approved the compensation of our then-NEOs with approximately 94.6% of the votes cast voting in favor of the proposal.
In connection with its review of our compensation program against our executive compensation philosophy, business objectives and peer group practices, our Compensation Committee considered the prior
years' modifications to our compensation programs in support of our executive compensation philosophy and best practices, the results of the say-on-pay advisory vote, as well as prior stockholder
feedback. As a result, our Compensation Committee concluded that it would retain the overall structure and design of our compensation program, including its emphasis on at-risk, performance-based
incentive compensation.
49
Table of Contents
How We Determine Executive Compensation
|
Executive Compensation Philosophy and Objectives
Our philosophy is to provide appropriate competitive compensation opportunities to our executives such that actual pay outcomes are heavily
influenced by achievement of Company, business and individual performance targets and objectives, which are designed to support of our business strategy and create long-term stockholder value. The
core objectives of our compensation program are to:
Participants in the Compensation Process
Our Compensation Committee bears principal responsibility for, among other things, structuring our executive compensation program and making
individual executive compensation determinations. To help facilitate informed determinations with respect to its responsibilities, our Compensation Committee engages an independent compensation
consultant, Semler Brossy Consulting Group, LLC (Semler Brossy), which serves at the direction and under the supervision of our Compensation Committee. For further information about our
Compensation Committee and the services provided by Semler Brossy, please see the Meetings and Board Committees section titled "Executive Compensation and Human Resources
Committee." Semler Brossy and certain members of management support our Compensation Committee with respect to the following, among other things:
|
|
|
Independent Advisor
|
|
|
Semler Brossy
Advisor to the Compensation Committee
|
|
Expertise-based advice,
research and analytical services, including peer group composition, trends and comparative practices in executive compensation, program design and non-employee director compensation.
Commentary and/or recommendations as to the foregoing.
Participation in Compensation Committee
meetings.
|
Management
|
|
|
Senior Vice President, Human Resources, and Total Rewards Management Team
|
|
Proposals, including
regarding compensation and benefits design and pay levels, for executives' employment arrangements for new or promoted executives
Reporting and advisory on diversity and inclusion topics, including pay equity.
Expertise-based advice, research and analytical services, commentary
and/or recommendations as to the foregoing.
Participation in Compensation Committee meetings.
|
Chief Executive Officer and other Executives
|
|
Overview of individual
performance of direct reports.
Recommendations as to compensation of direct reports.
With respect to the CEO and General Counsel, participation in Compensation Committee meetings, except for determinations of their own compensation.
|
50
Table of Contents
Competitive Market Analysis
Our Compensation Committee uses competitive market analysis as a decision-making reference. The Committee primarily considers executive
compensation comparative data for our peer group companies to better understand trends and comparative practices, program design in the market within which we compete for top talent, and competitive
levels and mix of target compensation opportunities provided to our executives. Our peer group includes companies
(i) operating in a comparable industry with respect to customer base and/or product offerings, such as pharmaceuticals, biotechnology and life sciences, and healthcare equipment and services
companies, and (ii) that, in the aggregate, approximate our size as measured by revenue and market capitalization.
Each
year, with the assistance of its independent compensation consultant, our Compensation Committee reviews the composition and appropriateness of our peer group. The Committee considers the size,
performance, and business focus of these companies in comparison to us. The peer companies used to establish 2019 compensation levels include:
2019 Peer Companies(1)(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Shareholder Return
(%)(2)
|
|
|
Revenue
($ in billions)
|
|
Market Cap
($ in billions)
|
|
|
One Year
|
|
Three Year
|
|
|
|
|
|
|
|
|
|
Abbott Laboratories
|
|
$31.9
|
|
$153.1
|
|
22.22%
|
|
127.47%
|
Agilent Technologies, Inc.(3)
|
|
$5.2
|
|
$26.4
|
|
20.26%
|
|
82.52%
|
Baxter International Inc.
|
|
$11.4
|
|
$42.3
|
|
27.10%
|
|
84.68%
|
Becton, Dickinson and Company
|
|
$17.3
|
|
$73.6
|
|
10.87%
|
|
58.30%
|
Danaher Corporation
|
|
$17.9
|
|
$106.7
|
|
42.36%
|
|
87.09%
|
Edwards Lifesciences Corporation
|
|
$4.3
|
|
$48.8
|
|
54.43%
|
|
167.73%
|
Hologic, Inc
|
|
$3.4
|
|
$14.0
|
|
21.47%
|
|
30.18%
|
Intuitive Surgical, Inc.
|
|
$4.5
|
|
$68.6
|
|
15.34%
|
|
168.97%
|
Medtronic plc(4)
|
|
$31.1
|
|
$152.1
|
|
22.02%
|
|
54.19%
|
Quest Diagnostics Incorporated
|
|
$7.7
|
|
$14.3
|
|
18.79%
|
|
26.38%
|
Stryker Corporation
|
|
$14.9
|
|
$78.5
|
|
24.65%
|
|
82.15%
|
Thermo Fisher Scientific, Inc.
|
|
$25.5
|
|
$129.5
|
|
33.03%
|
|
117.12%
|
Zimmer Biomet Holdings, Inc.
|
|
$8.0
|
|
$30.8
|
|
32.13%
|
|
45.36%
|
Boston Scientific Corporation
|
|
$10.7
|
|
$63.1
|
|
20.33%
|
|
102.77%
|
Ranking Relative to Peers(3)
|
|
8 of 14
|
|
8 of 14
|
|
10 of 14
|
|
5 of 14
|
|
|
|
(1)
|
|
Revenue is for the trailing four quarters as of December 31, 2019 and total shareholder return is calculated as of December 31, 2019, other than as otherwise noted. Market cap is calculated using the closing
price of each company's common stock on December 31, 2019 multiplied by the number of outstanding shares of common stock as reported by the company in its most recent periodic report filed with the Securities and Exchange Commission.
|
(2)
|
|
Total shareholder return is calculated in accordance with the methodology described in the Executive Compensation section titled "2019 Total Shareholder Return Performance Share
Program."
|
(3)
|
|
Agilent Technologies, Inc. revenue is provided as of October 31, 2019.
|
(4)
|
|
Medtronic plc revenue is provided for the trailing four quarters as of January 24, 2020.
|
In
establishing 2019 pay levels for our NEOs, the Compensation Committee reviewed comparative pay information for the peer group companies through proxy research and, where peer group information was
unavailable, from 2019 general industry survey data, as reported in the Equilar, Radford, and Willis Towers Watson surveys, which was calibrated to include companies comparable to our size and scope
of each individual's responsibilities. The Company considers market data without regard for any
51
Table of Contents
particular
percentile positioning. This allows us to retain flexibility to make individual decisions that reflect both market and internal considerations, including those described below under
"Internal Pay Equity and Other Considerations."
Internal Pay Equity and Other Considerations
In addition to the competitive market analysis, the Committee considers multiple factors in formulating compensation decisions. These factors
include:
-
-
internal pay equity;
-
-
individual performance and contributions;
-
-
the CEO's recommendations for other NEO compensation;
-
-
the primary elements of each NEO's TDC opportunity compared to the other NEOs;
-
-
the economic and retentive value of prior equity awards; and
-
-
current and prior work experience and future potential.
In
considering internal pay equity, and the elements of an NEO's TDC opportunity compared to the other NEOs, the Committee also considers CEO compensation relative to the other NEOs. The Committee
strives to maintain the appropriate balance in order to motivate the Company's executive team, retain key personnel in a highly competitive labor market, and support a robust succession planning
process. The differences between CEO and NEO pay reflect the foregoing factors, as well as the Company's organizational structure.
Performance Considerations
We utilize a performance, development and coaching (PDC) process to help guide individual development and performance discussions and to
assess annual performance. Our CEO conducts annual PDC reviews for all direct reports, assesses the performance results of those direct reports and makes recommendations to our Compensation Committee
for its consideration. Our Compensation Committee reviews and evaluates our CEO's performance objectives and oversees the evaluation of his performance in relation to those objectives. For 2019, the
overall performance of our executives, including our NEOs, supported a culture of high performance, integrity and accountability with clear expectations. These performance evaluations, among the other
considerations described in this section, influence the Compensation Committee's decisions regarding our executives' base salaries, the individual component of their Annual Bonus Plan awards and, as
an indication of future performance potential, their long-term equity incentive awards.
Chief Executive Officer and Compensation Committee Judgment
The application of CEO and Compensation Committee judgment is an important factor in setting and determining executive pay. We do not employ a
purely formulaic approach to our executive compensation program. Target market guidelines and individual target TDC, financial and operational targets, individual performance objectives and funding
formulae are established in advance; however, other Company and individual performance and other considerations may also be taken into account. For example, while the funding formula tied to
Company-level financial performance targets are set in advance under our Annual Bonus Plan, our Compensation Committee is able to reduce the total
52
Table of Contents
Annual
Bonus Plan funding percentage (Total Bonus Pool), to not less than 50% of the target, based on its assessment of the Company's progress toward achievement of our quality objectives, which are
critical to our commitment to providing high quality products to our customers and patients. Additionally, beginning with our 2019 Annual Bonus Plan program, the Compensation Committee may also reduce
the Total Bonus Pool funding percentage, to not less than 50% of the target, based on performance against operating income margin targets, which takes into consideration the Company's profitability
and commitment to our shareholders, as well as affordability of the proposed bonus funding.
Elements of 2019 Executive Compensation
|
Primary Elements of Total Direct Compensation
We compensate our executives primarily through total direct compensation, namely in the form of base salary and short- and long-term
incentives (the primary elements of TDC). Our primary elements of TDC are heavily weighted towards variable, at-risk performance-based elements, which are reflected below and in the charts under the
section above titled "A Significant Portion of our NEOs' 2019 Target TDC is At-Risk, Performance-Based Compensation."
The
key features and objectives of the primary elements of our NEOs' 2019 TDC are summarized in the table below.
|
|
|
|
|
TDC Elements
|
|
Key Features
|
|
Objectives
|
|
|
|
|
|
Base Salary
|
|
Fixed annual cash amount, paid at regular intervals.
|
|
Attract and retain talented executives and provide stable source of income.
|
Short-Term Incentives
Annual Bonus Plan Awards
|
|
At risk, performance-based annual cash incentive opportunity.
|
|
Align executive compensation with our business strategy, quality, and profitability objectives.
|
|
|
Funding of Total Bonus Pool based on Company performance against two important financial performance targets.
|
|
Focus and reward based on the achievement of important financial, operational and individual performance objectives.
|
|
|
Allocation of funded Total Bonus Pool, based on regional, business and functional performance against specific financial and/or operational performance targets.
|
|
|
|
|
Actual payout based on individual performance.
|
|
|
Long-Term Incentives Equity Awards
|
|
At risk, performance-based equity incentive opportunity.
|
|
Focus talent/organization on important financial measures and long-term stockholder value.
|
|
|
Mix of opportunity comprised of:
|
|
Reward based on:
|
|
|
25% target TSR performance-based DSUs
|
|
our TSR relative to that of other S&P 500 Healthcare Index companies
|
|
|
25% target FCF performance-based DSUs
|
|
our adjusted free cash flow measured against our target performance
|
|
|
25% stock options
|
|
our stock price increase
|
|
|
25% service-based DSUs
|
|
our stock price
|
53
Table of Contents
Base Salary
In determining the 2019 base salaries of our NEOs (other than our Chief Executive Officer), our Compensation Committee also considered the
recommendations of our Chief Executive Officer in light of the general factors discussed above, including their overall performance ratings for the prior year.
The
2019 base salaries (rounded to the nearest thousand) for our NEOs, as well as the percentage increase from their 2018 base salaries for our current NEOs who were also NEOs in 2018, are set forth
below.
|
|
|
|
|
|
|
Name
|
|
2018 Base Salary
|
|
2019 Base Salary
|
|
% Increase
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
$1,240,000
|
|
$1,280,000
|
|
3.2%
|
Daniel J. Brennan
|
|
$625,000
|
|
$660,000
|
|
5.6%
|
Kevin J. Ballinger
|
|
$570,000
|
|
$590,000
|
|
3.5%
|
Joseph M. Fitzgerald
|
|
$650,000
|
|
$670,000
|
|
3.1%
|
Edward F. Mackey
|
|
|
|
$580,000
|
|
|
Short-Term Incentives
Our Compensation Committee annually reviews the design of our Annual Bonus Plan to help ensure that the program continues to support our
executive compensation philosophy and core compensation program objectives. In finalizing the design for 2019, our Compensation Committee retained substantially all of the provisions of our 2018
Annual Bonus Plan, which was designed to reinforce the concept of "pay for performance," align our short-term incentives with important financial and operational measures and the long-term interests
of our stockholders, and to incentivize and reward individual performance. The Compensation Committee also retained the discretion to reduce the Total Bonus Pool funding percentage, to not less than
50% of the target, based on its assessment of the Company's achievement of our quality objectives, and, beginning with our 2019 Annual Bonus Plan, based on performance against the operating income
margin target. This discretion reinforces our commitment to providing quality products for our customers and patients, and takes into consideration the Company's profitability and commitment to our
shareholders, as well as affordability of the proposed bonus funding.
2019 Annual Bonus Plan Awards Paid to Our NEOs
After funding the Total Bonus Pool, the actual amount of an executive's Annual Bonus Plan award is ultimately determined as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Base Salary
x
Target Award Percentage
|
|
x
|
|
Participating Unit
Performance Percentage
(50% - 150%)
|
|
x
|
|
Individual
Performance
Percentage
(0% - 150%)
|
|
=
|
|
Annual Bonus
Plan Award
(0% - 225%)
|
Total Bonus Pool Funded Based on Company Performance
Under the 2019 Annual Bonus Plan, a single Company-wide Total Bonus Pool is funded by the Company's performance measured against important Company-level
financial and
operational performance metric targets, thereby reinforcing the importance of the Company's performance as a whole (which reflects the performance of our regions, businesses and functions). For 2019,
our Compensation Committee selected adjusted EPS and Adjusted Net Sales as our Company-level financial metrics and set performance level targets as follows.
54
Table of Contents
|
|
|
Company-Level Financial Targets
|
|
|
|
Adjusted EPS(1)
|
|
Adjusted Net Sales(1)
|
|
|
|
$1.57
|
|
$10.585 billion
|
|
|
|
(1)
|
|
Adjusted EPS and Adjusted Net Sales are non-GAAP financial measures. For a reconciliation of these non-GAAP measures to the most directly comparable GAAP measures and insight into how these non-GAAP measures are
considered by management, please see the Executive Compensation section titled "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table 2019 Annual Bonus Plan" and Annex A.
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Target FCF
Performance-Based
DSUs(1)(2)
|
|
Target TSR
Performance-Based
DSUs(1)(2)
|
|
Stock
Options(1)
|
|
Service-Based
DSUs(1)
|
|
Total
Long-Term
Incentive
Award Target
Value(3)
|
|
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
67,298
|
|
67,298
|
|
217,917
|
|
67,298
|
|
$10,800,000
|
Daniel J. Brennan
|
|
14,643
|
|
14,643
|
|
47,417
|
|
14,643
|
|
$2,350,000
|
Kevin J. Ballinger
|
|
11,839
|
|
11,839
|
|
38,337
|
|
11,839
|
|
$1,900,000
|
Joseph M. Fitzgerald
|
|
15,578
|
|
15,578
|
|
50,443
|
|
15,578
|
|
$2,500,000
|
Edward F. Mackey
|
|
10,904
|
|
10,904
|
|
35,310
|
|
10,904
|
|
$1,750,000
|
-
(1)
-
Our
NEOs' 2019 long-term equity incentive awards were granted as of February 21, 2019. The stock options have an exercise price of $40.12 per share, the
closing price of our common stock on the date of grant.
-
(2)
-
The
number of shares of our common stock issuable to our NEOs based on our performance under our FCF and TSR performance share programs for the periods ended
December 31, 2019 is discussed below under the section titled "Company Performance-Based DSUs Results for Performance Periods Ended
December 31, 2019."
-
(3)
-
Total
Long-Term Incentive Award Target Value is rounded to the nearest thousand.
The
numbers of FCF and TSR performance-based DSUs and service-based DSUs were calculated by dividing the target dollar value of those awards by the closing price of our common stock on the date of
grant, and the numbers of stock options were determined by dividing the target dollar value of that award by the stock option value determined in accordance with FASB ASC Topic 718, as described in
the footnotes to the Executive Compensation section titled "Summary Compensation Table".
63
Table of Contents
Company Performance-Based DSUs Results for Performance Periods Ended December 31,
2019
In February 2020, our Compensation Committee determined the number of deferred stock units earned pursuant to our performance-based DSUs under the 2017 TSR
Performance Share Program and the 2019 FCF Performance Share Program, presented in the table below.
|
|
|
|
|
|
|
Grant Year
|
|
Performance Metric
|
|
Achievement
|
|
DSUs Earned
|
|
|
|
|
|
|
|
2017
|
|
TSR Percentile Performance Rank for the three-year period ended December 31, 2019
|
|
Tenth relative to that of the other 54 companies in the S&P 500 Healthcare Industry Index (83rd percentile)
165% of target TSR performance based DSUs earned
|
|
Michael F. Mahoney 151,220 DSUs
Daniel J. Brennan 36,964 DSUs
Kevin J. Ballinger 27,246 DSUs
Joseph M. Fitzgerald 29,723 DSUs
Edward F. Mackey 20,161 DSUs
|
2019
|
|
Adjusted FCF for the one-year period ended December 31, 2019
|
|
$2.007 billion or 93.4% of target(1)
90.1% of target FCF performance-based DSUs earned
|
|
Michael F. Mahoney 60,635 DSUs
Daniel J. Brennan 13,193 DSUs
Kevin J. Ballinger 10,666 DSUs
Joseph M. Fitzgerald 14,035 DSUs
Edward F. Mackey 9,824 DSUs
|
|
|
|
|
|
|
All DSUs earned pursuant to our 2019 FCF Performance Share Program are subject to continued service until December 31, 2021.
|
|
|
|
(1)
|
|
Adjusted free cash flow is not prepared in accordance with GAAP. For a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure and insight into how this non-GAAP measure is
considered by management, please see Annex A.
|
Primary Elements of Indirect Executive Compensation
We also compensate our executives, including our NEOs, with indirect compensation, namely in the form of benefits and limited perquisites.
Generally, our benefits and perquisites are targeted to be competitive relative to our peer group companies. The primary elements of and objectives for our NEOs' 2019 indirect compensation are
summarized below.
General Employee Benefits
We provide employee benefits to eligible employees, including our NEOs, to promote personal health and well-being and to provide certain financial security
and protection upon retirement or in the event of death, disability or illness. As U.S.-based employees, our NEOs are eligible to receive employee benefits under our U.S. employee benefits program,
which consists of the following key elements that are generally the same as those provided to our other U.S. salaried employees:
-
-
health and welfare benefits, with a choice between a preferred provider model or a high-deductible plan with a Health Savings Account
(executives share costs within a range of approximately 20% to 35% depending upon the plan and coverage selected);
-
-
Company-paid term life insurance policies that provide a benefit equal to base salary, with a minimum benefit of $50,000 and a maximum benefit
of up to $1 million, payable upon death; and
-
-
a qualified 401(k) retirement plan with a Company match of 6% of eligible salary up to $280,000 in 2019 resulting in a maximum possible match
of $16,800.
64
Table of Contents
In
addition, our executive officers may participate in an annual executive level physical examination program that is designed to encourage the proactive management of executive health. In approving
the program, the Compensation Committee considered the overall cost of the program (estimated to be less than $10,000 per participant) and the importance of good health to an executive's ability to
focus on the short and long-term needs of the Company. Company-paid term life insurance premium amounts (and related imputed income), Company matches of 401(k) Plan contributions for our NEOs,
Company-paid executive level annual physical examination costs, and certain other reimbursements in 2019 are reported in the footnotes to the Executive Compensation section titled
"Summary Compensation Table."
Deferred Compensation Programs
We maintain a Deferred Bonus Plan for certain of our management, including our NEOs, in order to provide them with the opportunity to defer up to 75% of their
annual award under our Annual Bonus Plan until the earlier of termination of employment or an elected distribution date. In 2019, Messrs. Ballinger and Fitzgerald elected to defer 75% of their
2019 Annual Bonus Plan Award, which otherwise would have been paid in 2020, under the Deferred Bonus Plan. For additional
discussion of the Deferred Bonus Plan, please see the narrative to the Executive Compensation section titled "Nonqualified Deferred Compensation."
Relocation Program
We provide tiered relocation benefits under our relocation program to eligible employees, including our NEOs, whom we request to move in connection with their
current position or a promotion and for eligible new hires we require to move in connection with accepting a position with us. Our objectives in providing relocation benefits are to attract and
redeploy top talent. We provide "tax gross-ups" on applicable relocation benefits provided under our relocation program as we believe that this benefit is integral to the Company's ability to attract
and retain employees whose skill or knowledge enhance the Company's competitive position. Participants are generally required to sign a reimbursement agreement that requires them to pay back expenses
incurred by the Company for their relocation in the event that they voluntarily terminate their employment or are terminated for "cause" at a rate of 100% for termination within one year of the date
on which payments were first made and 50% for termination following the first year but within two years of the date on which payments were first made. NEO relocation benefits for 2019 are included in
the footnotes to the Executive Compensation section titled "Summary Compensation Table."
In
accordance with the terms of his offer letter, Mr. Mahoney is eligible for the executive tier of our relocation program. In August 2018, our Compensation Committee approved an additional
time extension of Mr. Mahoney's relocation benefits under the executive tier of our relocation program for up to one year, ending December 31, 2019. In approving the extension, our
Compensation Committee took into consideration the fact that there would be no additional cost to the Company to provide this extension and Mr. Mahoney's desire to maintain stability for his
family at their current residence until the end of the extended period. Mr. Mahoney received approximately $194,468 in relocation benefits in 2019, with certain residual costs for activities
commenced in 2019 to become due and payable in 2020.
Personal Use of Aircraft
Pursuant to Mr. Mahoney's offer letter, he is permitted reasonable personal use of our corporate aircraft up to $100,000 per year in aggregate
incremental cost to the Company. Our other executives are permitted limited personal use of our corporate aircraft with prior approval. These executives are
65
Table of Contents
personally
taxed on their personal use of our corporate aircraft and we do not provide them with income tax gross-up payments. The aggregate incremental cost to the Company (and disallowed tax
deductions of the Company) for our NEOs' personal use of our corporate aircraft in 2019 is included in the footnotes to the Executive Compensation section titled "Summary
Compensation Table."
Financial Planning
In November 2019, our Compensation Committee approved a financial planning perquisite for our executive officers, including our NEOs. The program will provide
financial counseling and planning, investment and retirement management, insurance planning, and income tax planning and preparation services through a single service provider for US-based executive
officers. Executive officers located outside of the United States will be eligible for reimbursement. In approving the program, the Compensation Committee considered the overall cost of the benefit
(up to $12,000 per participant), prevalence of the benefit in the market, and benefit to the Company of reducing potential distraction to executive officers of complex personal financial situations.
Our Post-Employment and Change in Control Arrangements
|
Primary Elements of Post-Employment and Change in Control Arrangements
None of our NEOs has an employment agreement with the Company. However, we provide post-employment and change in control payments and benefits
to our executives under certain circumstances. We believe that offering our executives these payments and benefits facilitates the operation of our business, allows them to better focus their time,
attention and capabilities on our business, and assists the Company in recruiting and retaining key executives. The primary elements of and objectives for our NEOs' 2019 post-employment and change in
control agreements are summarized below.
Executive Retirement Plan
Our executives are eligible to participate in our defined benefit Executive Retirement Plan. For further discussion of our defined benefit Executive
Retirement Plan, please see the narrative to the Executive Compensation section titled "Defined Benefit Retirement Plan."
Severance Plans
We maintain severance plans for eligible employees, including our NEOs, under which participants are entitled to receive certain severance payments,
subsidized COBRA health benefits and dental benefits for specified periods of time. For further discussion of our severance plans, please see the Executive Compensation section titled
"Potential Payments Upon Termination or Change in Control Severance Plans."
Change in Control Agreements
We have entered into change in control agreements to our executives, including our NEOs, and other key employees (Change in Control Agreements). The
possibility of a change in control and the uncertainty that it may raise among our executives as to their continued employment after or in connection with a change in control may result in their
departure or distraction. Our objective in providing Change in Control Agreements is to retain and encourage the continued attention and dedication of our executives during a potentially critical
time, even if they are concerned that their
66
Table of Contents
position
will be eliminated after or in connection with the change in control. Our Change in Control Agreements require both a change in control and termination without cause or resignation for good
reason within two years after the change in control event, commonly referred to as a "double-trigger," for cash payments to be made under the agreement and vesting to be accelerated under the
agreements for equity awards where the surviving or acquiring entity substitutes or assumes outstanding equity awards.
For
further discussion of our Change in Control Agreements, other plans and arrangements under which a change in control and/or termination of employment triggers payments or benefits, and potential
payments to our NEOs under the foregoing, please see the narrative and tables in the Executive Compensation section titled "Potential Payments Upon Termination or Change in
Control Change in Control Agreements."
Our
Compensation Committee has adopted a policy regarding the recovery or adjustment of short-term incentive awards paid to an executive in the event relevant Company performance
measures are restated in a manner that would have reduced the size of a previously granted award. In such an event, and to the extent permitted by applicable law, the Company would seek to recover the
amount of the short-term incentive award paid to such executive that was in excess of the amount that would have been awarded based on the restated financial results, subject to and in accordance with
the terms of the policy. Our Compensation Committee monitors regulatory developments with respect to applicable executive compensation recovery policies required by the Dodd-Frank Wall Street Reform
and Consumer Protection Act and it expects to consider such changes to the Company's current recovery policy as are necessary to comply with final rules (and related guidance, if any) to be issued by
the SEC in accordance with such act.
Our
Compensation Committee has also adopted a policy regarding the recovery of certain short- and long-term incentive compensation awards paid or granted to an executive in the event of executive
misconduct or gross dereliction of duty that resulted in a material violation of Company policy and caused significant harm to the Company. In such an event, and to the extent permitted by applicable
law, the Company may seek reimbursement of all or a portion of cash incentive compensation awards paid within a certain time period and/or recovery of all or a portion of equity incentive awards
granted to such executive over which the Company retains control, subject to and in accordance with the terms of the policy.
Both
of the policies described above are only applicable to awards made after the adoption of the relevant policy. For a discussion of other recovery and forfeiture provisions relating to incentive
compensation awards and other benefits provided to our executives, please see the section titled "Relocation Program" above, and the Executive
Compensation sections titled "Retirement Plan Benefits" and "Narrative Disclosure to Summary Compensation Table and Grants of
Plan-Based Awards Table."
Executive Stock Ownership Guidelines
|
Our
executives are required to have a significant personal investment in the Company through their ownership of shares of our common stock. Our Board has set stock ownership
guidelines for executives, including our NEOs, as a number of shares of Company stock equal in value to at least the following amounts:
-
-
CEO: six times annual base salary; and
-
-
All other executives: three times annual base salary.
67
Table of Contents
Executives
are required to comply with the guidelines at all times. However, if at any time an executive's ownership does not meet or exceed the guideline, he or she is expected to retain ownership of
at least fifty percent of net shares with respect to each vesting of an equity award or stock option exercise until the guideline is met or exceeded. For purposes of satisfying the guidelines, shares
owned outright, shares held in company benefit plans and the intrinsic value of vested "in-the-money" stock options are included in the aggregate number of shares held by an executive. Unvested equity
award shares (including service-based DSUs and performance-based DSUs) and unvested stock options are not included in the aggregate number of shares held by an executive. The Nominating and Governance
Committee monitors compliance with these guidelines on an annual basis. As of December 31, 2019, our CEO and other NEOs were in compliance with these guidelines.
No Tax Gross-Ups (other than for Relocation Benefits)
|
The
Company does not provide tax gross-ups for our executives, except for relocation benefits because the benefit generally applies to all employees eligible to receive relocation
benefits, including our executives, and the Compensation Committee believes it is integral to the Company's ability to attract and redeploy employees whose skill or knowledge enhance the Company's
competitive position.
Our Equity Award Grant Policy and Practices
|
Under
our Equity Award Grant Policy, grants of equity awards to our executives are approved and effective as follows:
-
-
Annual equity awards (if any) for our employees, including our executives, are generally approved by our Compensation Committee at a regularly
scheduled meeting. Such awards are effective on the date of approval or, for administrative reasons, shortly thereafter.
-
-
New hire, promotion, retention and other special or ad hoc awards for our executive officers are generally approved by our Compensation
Committee. New hire or promotion awards for executive officers are effective on the first trading day of the month following both the date of hire or promotion and the date of approval. Retention and
other special or ad hoc awards for our executive officers are effective on the first trading day of the month following approval.
-
-
Stock options are granted with an exercise price equal to the closing price of our common stock on the date of grant.
Tax and Accounting Considerations
|
Section 162(m)
of the Code (Section 162(m)), as amended by the Tax Cuts and Jobs Act, generally disallows a tax deduction to public companies for compensation over
$1 million paid to certain "covered employees," which includes a company's CEO, CFO, and the three other most highly compensated executive officers employed by the company at the end of the
year. Once an officer is a "covered employee," their compensation will remain subject to Section 162(m) for so long as they are receiving compensation from the company. Further, the Tax Cuts
and Jobs Act repealed the exclusion for "qualified performance-based compensation" under Section 162(m) effective January 1, 2018, except for compensation payable pursuant to a written
binding contract in place before November 2, 2017 that is not materially modified thereafter (a grandfathered arrangement). The company may avail itself of this transition rule for
grandfathered arrangements, to the extent applicable and that our existing plans and outstanding awards qualify. To maintain flexibility in compensating executive
68
Table of Contents
officers
in a manner designed to promote varying corporate goals in the best interest of the company, the Committee does not limit its actions with respect to executive compensation to preserve
deductibility under Section 162(m) if the Committee determines that doing so is in the best interests of the Company.
The
Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which requires the Company to recognize compensation expense for share-based payments (including stock options
and other forms of equity compensation). FASB ASC Topic 718 is taken into account by the Compensation Committee in determining to use a portfolio approach to equity grants, awarding both stock options
and DSUs.
Prohibition on Pledging and Hedging the Economic Value of our Common Stock
|
Our
executives, including our NEOs, and our directors, are prohibited from speculating in the Company's securities, engaging in transactions designed to "hedge" the value of our
common stock, and pledging their common stock as collateral for a loan. Examples of hedging and pledging transactions specifically covered by the policy include zero-cost collars and forward sale
contracts, and use of stock as margin to secure borrowings, respectively. To facilitate the implementation of this prohibition, excluded from the policy's general prohibition on hedging and
pledging arrangements are shares held by directors that were subject to hedging or pledging arrangements as of December 31, 2010, and do not in the aggregate for all directors amount to more
than 3.5% of the Company's then outstanding shares. None of our executives or directors is engaged in hedging or pledging arrangements related to the Company's securities.
69
Table of Contents
RISK ASSESSMENT OF OUR COMPENSATION PROGRAMS
With the assistance of the senior members of our Global Compensation and Benefits organization, certain senior executive officers and the
Compensation Committee's independent compensation consultant, Semler Brossy, in February 2020 the Compensation Committee reviewed a risk assessment of our compensation programs and policies to
determine if the provisions and operations of our programs create undesired or unintentional risk of a material nature.
Our
risk assessment included two work streams one focused on reviewing areas of enterprise risk and the other focused on identifying compensation design risk. Our enterprise risk
analysis examined the types and magnitudes of risks our business areas present to the Company so that the Committee could assess the extent to which our compensation programs may mitigate or
exacerbate these risks. Our compensation design risk analysis, which was conducted by management and reviewed by Semler Brossy, examined the potential risks in the design of our performance-based
incentive compensation arrangements. As part of this assessment, we analyzed the mix of fixed and variable compensation; the mix of short- and long-term compensation; the mix of long-term equity
incentives; performance metric mix; weighting, measurement and payout timing; discretion and caps on short-term incentives; award size, vesting schedules and performance and other terms of long-term
equity incentives; and other incentive opportunities and their features. We also analyzed our recovery of incentive awards policy, executive stock ownership guidelines and hedging and pledging
prohibitions. Finally, we evaluated on a combined basis the results of the enterprise and compensation risk assessments, on a business area-by-business area basis.
The
Compensation Committee reviewed and discussed the findings of this analysis with management and concluded that it continues to believe that our compensation programs do not create risks that are
reasonably likely to have a material adverse effect on the Company.
COMPENSATION COMMITTEE REPORT
The Compensation Committee has reviewed and discussed the Compensation Discussion & Analysis contained in this Proxy Statement with
management and, based on such review and discussions, the Compensation Committee has approved the inclusion of the Compensation Discussion & Analysis in this Proxy Statement and in the
Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 for filing with the SEC.
This Compensation Committee Report does not constitute soliciting material and should not be deemed filed or incorporated by reference into any other Boston Scientific filing
with the SEC, except to the extent that Boston Scientific specifically incorporates this Report by reference into another Boston Scientific filing.
THE
COMPENSATION COMMITTEE
Donna
A. James, Chair
Nelda J. Connors
Edward J. Ludwig
Stephen P. MacMillan
70
Table of Contents
EXECUTIVE COMPENSATION
Summary Compensation Table
|
The
table below summarizes the total compensation for each of our named executive officers for the years ended December 31, 2019, 2018 and 2017. For a narrative description of
material factors helpful to understand the information disclosed in the table below for 2019, please see the Compensation Discussion & Analysis and the narrative to this table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Principal Position
|
|
Year
|
|
Salary
($)(1)
|
|
Stock
Awards
($)(2)
|
|
Option
Awards
($)(3)
|
|
Non-Equity
Incentive
Plan
Compensation
($)(4)
|
|
Change in
Pension Value
and
Nonqualified
Deferred
Compensation
Earnings
($)(5)
|
|
All Other
Compensation
($)(6)
|
|
Total
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
2019
|
|
1,274,740
|
|
9,087,249
|
|
2,699,992
|
|
1,996,800
|
|
409,290
|
|
296,069
|
|
15,764,140
|
Chairman of the Board, President
|
|
2018
|
|
1,234,630
|
|
7,643,884
|
|
2,499,993
|
|
2,128,770
|
|
311,932
|
|
151,692
|
|
13,970,901
|
and Chief Executive Officer
|
|
2017
|
|
1,179,452
|
|
7,225,607
|
|
2,249,995
|
|
1,890,000
|
|
417,144
|
|
122,254
|
|
13,084,452
|
Daniel J. Brennan
|
|
2019
|
|
655,437
|
|
1,977,244
|
|
587,497
|
|
583,482
|
|
190,385
|
|
37,241
|
|
4,031,286
|
Executive Vice President and
|
|
2018
|
|
621,637
|
|
1,719,882
|
|
562,495
|
|
626,736
|
|
102,017
|
|
33,058
|
|
3,665,825
|
Chief Financial Officer
|
|
2017
|
|
593,194
|
|
1,766,253
|
|
549,994
|
|
504,037
|
|
198,150
|
|
21,141
|
|
3,632,769
|
Kevin J. Ballinger
|
|
2019
|
|
587,382
|
|
1,598,620
|
|
474,995
|
|
460,205
|
|
227,357
|
|
20,013
|
|
3,368,572
|
Executive Vice President and
|
|
2018
|
|
567,362
|
|
1,337,622
|
|
437,498
|
|
448,918
|
|
4,515
|
|
45,571
|
|
2,841,486
|
President, Interventional Cardiology
|
|
2017
|
|
543,151
|
|
1,316,086
|
|
412,493
|
|
346,500
|
|
171,378
|
|
18,963
|
|
2,808,571
|
Joseph M. Fitzgerald
|
|
2019
|
|
667,416
|
|
2,103,497
|
|
624,989
|
|
546,760
|
|
60,063
|
|
22,732
|
|
4,025,457
|
Executive Vice President and
|
|
2018
|
|
639,958
|
|
1,910,971
|
|
624,994
|
|
582,425
|
|
245,334
|
|
32,636
|
|
4,036,318
|
President, Rhythm Management
|
|
2017
|
|
564,740
|
|
1,435,716
|
|
2,949,992
|
|
595,139
|
|
273,769
|
|
19,641
|
|
5,838,997
|
Edward F. Mackey(7)
|
|
2019
|
|
577,398
|
|
1,472,367
|
|
437,491
|
|
520,282
|
|
156,573
|
|
34,851
|
|
3,198,962
|
Executive Vice President, Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Base salaries for our executive officers are generally effective for one year starting in late February of each year. The amounts in this column for 2019 reflect an amount calculated by prorating 2018 salaries from
January 1, 2019 through February 18, 2019 and 2019 salaries for the remainder of the year. These figures differ from those in the Compensation Discussion & Analysis, which lists amounts approved by the Compensation Committee for
2019.
|
(2)
|
|
The amounts included in the "Stock Awards" column represent the aggregate grant date fair value of all service-based and Company performance-based DSUs granted in 2019, 2018 and 2017 under our 2011 LTIP. These values
have been determined in accordance with FASB ASC Topic 718.
|
|
|
The attainment of the performance-based DSUs awarded to our NEOs in 2019 is based on either (i) the Total Shareholder Return (TSR) of our common stock relative to the TSR of the common stock of the other
companies in the S&P 500 Healthcare Index over a three-year performance and service period, or (ii) our adjusted free cash flow over a one-year performance period measured against our 2019 internal financial plan for the same period,
subject to the satisfaction of the service criteria over a three-year period (inclusive of the performance period). For additional information with respect to these Company performance-based DSUs, including the vesting thereof, please see the
sections titled "2019 Total Shareholder Return Performance Share Program" and "2019 Free Cash Flow Performance Share Program" in the narrative to this
table.
|
|
|
We determined the grant date fair value of the 2019 TSR performance-based DSUs using a Monte Carlo simulation methodology, utilizing the following key assumptions:
|
|
|
|
Stock price on date of grant
|
|
$40.12
|
Risk-free rate
|
|
2.48%
|
Measurement period (in years)
|
|
2.86
|
|
|
|
|
|
The TSR performance metric for the 2019 TSR performance-based DSUs is a market condition as defined under FASB ASC Topic 718. Because these awards do not have performance conditions as defined under FASB ASC Topic 718,
such awards have no maximum grant date fair values that differ from the fair values presented in this Summary Compensation Table.
|
71
Table of Contents
|
|
|
|
|
The grant date fair value of the 2019 FCF performance-based DSUs was determined based on management's evaluation of the Company's 2019 internal financial plan for adjusted free cash flow, assuming target achievement
of the adjusted free cash flow performance criteria and utilizing the closing price of our common stock on the date of grant. The fair values of the 2019 target FCF performance-based DSUs at the grant date assuming achievement of the highest level of
performance (as required to be disclosed by the SEC), which assumes actual adjusted free cash flow for 2019 at or above 125% of the Company's 2019 internal financial plan, are as follows: $4,049,994 for Mr. Mahoney's award, $881,216 for
Mr. Brennan's award, $712,471 for Mr. Ballinger's award, $937,484 for Mr. Fitzgerald's award, and $656,203 for Mr. Mackey's award.
|
|
|
We value service-based DSUs based on the closing price of shares of our common stock on the date of grant.
|
|
|
For more information regarding the stock awards we granted in 2019, please see the Grants of Plan-Based Awards table. For a more detailed description of the assumptions used in determining grant date fair values of
DSUs granted in 2019, please see Note L Stock Ownership Plans to our 2019 consolidated financial statements included in Item 8 of our Annual Report on Form 10-K for the year
ended December 31, 2019.
|
(3)
|
|
The amounts included in the "Option Awards" column represent the aggregate grant date fair value of all stock options granted during each of 2019, 2018 and 2017 under our 2011 LTIP. These values have been determined
in accordance with FASB ASC Topic 718. For a description of the assumptions used for purposes of determining grant date fair value of stock options granted in 2019, please see Note L Stock Ownership
Plans to our 2019 consolidated financial statements included in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2019. For more information regarding the stock option awards we granted in
2019, please see the Grants of Plan-Based Awards table.
|
(4)
|
|
Amounts in the "Non-Equity Incentive Plan Compensation" column represent cash awards made under our Annual Bonus Plan to our NEOs paid in February of the following year. Such amounts may be deferred under the Deferred
Bonus Plan.
|
|
|
For further information regarding the 2019 Annual Bonus Plan awards, please see the Compensation Discussion & Analysis section titled "Short-Term Incentives,"
the narrative to this table and Nonqualified Deferred Compensation.
|
(5)
|
|
The amounts shown in the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" column reflect the change in the actuarial present value of the accumulated benefit under our Executive Retirement
Plan for each retirement plan measurement date used for financial statement reporting purposes with respect to the Company's audited financial statements as compared to the prior retirement plan measurement date.
|
|
|
Please see the narrative and related footnotes to the table in the section titled "Defined Benefit Retirement Plan" for more information regarding the accrued benefits for each NEO under this plan. No amount is
included with respect to nonqualified deferred compensation earnings because there were no above-market or preferential earnings on nonqualified deferred compensation.
|
(6)
|
|
The amounts shown for 2019 in the "All Other Compensation" column are comprised of the following components:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Match
(401(k) Plan)
($)(a)
|
|
Aircraft
($)(b)
|
|
Term
Life
Insurance
($)(c)
|
|
Relocation-
related
Payments
($)(d)
|
|
Other
($)(e)
|
|
Total All
Other
Compensation($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
16,800
|
|
78,152
|
|
3,414
|
|
194,468
|
|
3,235
|
|
296,069
|
Daniel J. Brennan
|
|
16,800
|
|
14,652
|
|
2,190
|
|
|
|
3,599
|
|
37,241
|
Kevin J. Ballinger
|
|
16,800
|
|
|
|
1,434
|
|
|
|
1,779
|
|
20,013
|
Joseph M. Fitzgerald
|
|
16,800
|
|
|
|
3,717
|
|
|
|
2,215
|
|
22,732
|
Edward F. Mackey
|
|
16,800
|
|
14,652
|
|
3,182
|
|
|
|
217
|
|
34,851
|
|
|
|
(a)
|
|
The amounts shown in this column represent matching contributions made by the Company for each NEO under our 401(k) Retirement Savings Plan. All individual and matching contributions to the 401(k) Retirement Savings Plan
are fully vested upon contribution.
|
(b)
|
|
Pursuant to Mr. Mahoney's offer letter, he is permitted reasonable personal use of our corporate aircraft up to $100,000 per year in aggregate incremental cost to us, but he is not entitled to reimbursement by us
for any taxes resulting from imputed income attributable to his personal use of the corporate aircraft. In light of the fact that Mr. Mahoney's travel plans are subject to change on short notice, the Company has agreed that he may use our
corporate aircraft in connection with his service on the board of directors of Baxter International, Inc. so long as he fully reimburses us for the incremental costs associated with such travel or such costs are counted against his annual
personal use amount.
|
72
Table of Contents
|
|
|
|
|
The amount reflected in the "Aircraft" column represents the aggregate incremental costs to us for personal use by the NEO of our corporate aircraft, as well as any incremental costs associated with persons
accompanying such officer on business travel. We calculate the incremental cost to us by dividing the total annual variable operating costs for the corporate aircraft by the number of in-flight hours during the year. The resulting dollar per hour
amount is then multiplied by the number of hours flown for personal use by the executive officer during the year, including the "dead head" costs of flying the aircraft to and from locations for personal use. Our corporate aircrafts are used
predominantly for business travel. We do not include the fixed operating costs, such as pilot salary, general taxes and insurance, in the incremental cost calculation. The incremental cost does not include amounts attributable to the NEO for
increased income taxes we incurred in 2019 as a result of disallowed deductions related to personal use under Internal Revenue Service rules. For 2019, the reflected amounts exclude $287,863, $22,246 and $48,130 of disallowed corporate income tax
deductions attributable to the personal use of the corporate aircraft during the year by Messrs. Mahoney, Brennan and Mackey, respectively. Messrs. Mahoney, Brennan and Mackey were taxed on the imputed income attributable to their
respective personal use of the corporate aircraft and did not receive tax assistance from the Company with respect to this amount.
|
(c)
|
|
Amounts in the "Term Life Insurance" column consist of premiums and the imputed income for Company-paid term life insurance attributable to our NEOs. For Messrs. Mahoney, Brennan, Ballinger, Fitzgerald and Mackey
the premium paid was $792, $519, $466, $529 and $458, respectively.
|
(d)
|
|
Amounts in the "Relocation-related Payments" column represent expenses related to the sale of Mr. Mahoney's former residence. For more information on these expenses, please the Compensation Discussion &
Analysis section titled "Primary Elements of Indirect Executive Compensation Relocation Program."
|
(e)
|
|
Amounts in the "Other" column consist of the costs of annual physical examinations and miscellaneous gifts/prizes.
|
|
|
|
(7)
|
|
Mr. Mackey was not an NEO during 2017 or 2018. In accordance with SEC rules, we are reporting data only for the fiscal year in which he was an NEO.
|
73
Table of Contents
Grants of Plan Based Awards
|
The
table below presents information regarding awards under the Company's 2019 Annual Bonus Plan and 2011 LTIP, including those pursuant to the Company's 2019 Performance Share
Programs, during the year ended December 31, 2019. For a description of material factors helpful for an understanding of the information in the table below, please see the Compensation
Discussion & Analysis and the narrative to this table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All
Other
Stock
Awards:
Number
of
Shares
of Stock
or
Units
(#)(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant
Date
Fair
Value
of
Stock
and
Option
Awards
($)(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)(4)
|
|
Exercise
or Base
Price
of
Option
Awards
($/Sh)
|
|
|
|
|
Estimated Future Payouts
under Non-Equity Incentive Plan
Awards(1)
|
|
Estimated Future Payouts
under Equity Incentive Plan
Awards(2)
|
Name
|
|
Grant
Date(3)
|
|
Threshold ($)
|
|
Target
($)
|
|
Maximum ($)
|
|
Threshold (#)
|
|
Target (#)
|
|
Maximum (#)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
|
|
0
|
|
1,920,000
|
|
4,320,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/21/2019(6)
|
|
|
|
|
|
|
|
26,919
|
|
67,298
|
|
134,596
|
|
|
|
|
|
|
|
3,687,257
|
|
|
2/21/2019(7)
|
|
|
|
|
|
|
|
16,824
|
|
67,298
|
|
100,947
|
|
|
|
|
|
|
|
2,699,996
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67,298
|
|
|
|
|
|
2,699,996
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
217,917
|
|
$40.12
|
|
2,699,992
|
Daniel J. Brennan
|
|
|
|
0
|
|
561,040
|
|
1,262,341
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/21/2019(6)
|
|
|
|
|
|
|
|
5,857
|
|
14,643
|
|
29,286
|
|
|
|
|
|
|
|
802,290
|
|
|
2/21/2019(7)
|
|
|
|
|
|
|
|
3,660
|
|
14,643
|
|
21,964
|
|
|
|
|
|
|
|
587,477
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,643
|
|
|
|
|
|
587,477
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
47,417
|
|
$40.12
|
|
587,497
|
Kevin J. Ballinger
|
|
|
|
0
|
|
442,505
|
|
995,635
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/21/2019(6)
|
|
|
|
|
|
|
|
4,735
|
|
11,839
|
|
23,678
|
|
|
|
|
|
|
|
648,659
|
|
|
2/21/2019(7)
|
|
|
|
|
|
|
|
2,959
|
|
11,839
|
|
17,758
|
|
|
|
|
|
|
|
474,981
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,839
|
|
|
|
|
|
474,981
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,337
|
|
$40.12
|
|
474,995
|
Joseph M. Fitzgerald
|
|
|
|
0
|
|
536,039
|
|
1,206,088
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/21/2019(6)
|
|
|
|
|
|
|
|
6,231
|
|
15,578
|
|
31,156
|
|
|
|
|
|
|
|
853,519
|
|
|
2/21/2019(7)
|
|
|
|
|
|
|
|
3,894
|
|
15,578
|
|
23,367
|
|
|
|
|
|
|
|
624,989
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,578
|
|
|
|
|
|
624,989
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,443
|
|
$40.12
|
|
624,989
|
Edward F. Mackey
|
|
|
|
0
|
|
435,018
|
|
978,791
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/21/2019(6)
|
|
|
|
|
|
|
|
4,361
|
|
10,904
|
|
21,808
|
|
|
|
|
|
|
|
597,430
|
|
|
2/21/2019(7)
|
|
|
|
|
|
|
|
2,726
|
|
10,904
|
|
16,356
|
|
|
|
|
|
|
|
437,468
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,904
|
|
|
|
|
|
437,468
|
|
|
2/21/2019(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35,310
|
|
$40.12
|
|
437,491
|
|
|
|
(1)
|
|
The amounts in these columns reflect target and maximum payouts under the 2019 Annual Bonus Plan. There is no threshold-level payout under the 2019 Annual Bonus Plan. The maximum possible payout under the 2019 Annual
Bonus Plan is 225% of the target payout, representing the product of (i) a maximum of 150% of the target payout based on Company performance metrics and (ii) a maximum of 150% of the target payout based on individual performance objectives.
The actual amount earned by each NEO under the 2019 Annual Bonus Plan is reported under the "Non-Equity Incentive Plan Compensation" column in the Summary Compensation Table. For additional information about our 2019 Annual Bonus Plan and a
discussion of how these amounts are determined, please see the Compensation Discussion & Analysis section titled "Short-Term Incentives" and the section titled "2019
Annual Bonus Plan" in the narrative to this table.
|
(2)
|
|
The amounts in these columns reflect threshold, target and maximum share issuance under our 2019 Total Shareholder Return Performance Share Program (2019 TSR PSP) and 2019 Free Cash Flow Performance Share Program
(2019 FCF PSP). The target performance-based DSUs awarded under these programs were granted to our NEOs in February 2019 as part of our annual review process and were awarded under our 2011 LTIP. For additional details regarding the awards to our
NEOs pursuant to our 2019 TSR PSP and 2019 FCF PSP, please see footnotes 5 and 6 to this Grants of Plan-Based Awards table, respectively.
|
(3)
|
|
The Compensation Committee took action to grant the awards in this table on February 21, 2019.
|
(4)
|
|
The amounts in these columns reflect the number of service-based DSUs and stock options granted to our NEOs under our 2011 LTIP during 2019.
|
74
Table of Contents
|
|
|
(5)
|
|
The amounts in this column have been determined in accordance with FASB ASC Topic 718. See footnotes 2 and 3 to the Summary Compensation Table for a description of the assumptions used in determining the grant date
fair value of these awards.
|
(6)
|
|
These awards were granted pursuant to our 2019 TSR PSP. The threshold award level represents the minimum share issuance for each award that a participant may receive based on performance, which is 40% of the target
TSR performance-based DSUs awarded under the program. The maximum share issuance for each award is 200% of the target TSR performance-based DSUs awarded under the 2019 TSR PSP. For additional information about our 2019 TSR PSP and a discussion of how
these amounts are determined, please see the section titled "2019 Total Shareholder Return Performance Share Program" in the narrative to this table.
|
(7)
|
|
These awards were granted pursuant to our 2019 FCF PSP. The threshold award level represents the minimum share issuance for each award that a participant may receive based on performance, which is 25% of the target
FCF performance-based DSUs awarded under the program. The maximum share issuance for each award is 150% of the target FCF performance-based DSUs awarded under the 2019 FCF PSP. For additional information about our 2019 FCF PSP and a discussion of how
these amounts are determined, please see the section titled "2019 Free Cash Flow Performance Share Program" in the narrative to this table.
|
(8)
|
|
These awards were granted as part of our annual review process and awarded under our 2011 LTIP.
|
Narrative Disclosure to Summary
Compensation Table and Grants of Plan-Based Awards Table
|
The
following provides information about the terms of our 2019 Annual Bonus Plan, 2019 Performance Share Programs and our 2011 LTIP, pursuant to which our NEOs were awarded short-
and long-term incentive compensation, as applicable and detailed in the tables above. For additional information regarding the application of these plans and programs to our NEOs in 2019, please see
the Compensation Discussion & Analysis.
2019 Annual Bonus Plan
Our 2019 Annual Bonus Plan is administered by our Compensation Committee. The plan year for our 2019 Annual Bonus Plan ran from
January 1, 2019 to December 31, 2019. Generally, all U.S. salaried employees not eligible for commissions under sales compensation plans and certain international and
expatriate/inpatriate employees selected for participation were eligible to participate in our 2019 Annual Bonus Plan, provided they had at least two full months of service during the plan year.
Participants generally must be employed with us on the date payments are made in order to receive awards under the plan. However, in the event of death or retirement or certain involuntary
terminations without cause, in each case, as described in the 2019 Annual Bonus Plan, participants may receive their performance incentive awards for the year on a prorated basis based on the
percentage of the year the participant was employed by us and eligible to participate. Participants who have at least two months of eligibility, but less than a full year, similarly may receive awards
under the 2019 Annual Bonus Plan on a prorated basis.
Target Incentive Award Opportunity
Each participant is provided with a target incentive award opportunity under the 2019 Annual Bonus Plan expressed as a percentage of his or her base salary.
For a discussion of the 2019 target incentive award opportunities for our NEOs, please see the Compensation Discussion & Analysis sections titled "Individual Target
Incentive Award Opportunity" and "2019 Annual Bonus Plan Awards Paid to Our NEOs."
75
Table of Contents
Company Performance Funds Total Bonus Pool
Company Performance Metrics and Weighting. Under the 2019 Annual Bonus Plan, after year-end, a single Company-wide annual bonus pool
(Total Bonus Pool) is funded based on the Company's performance measured against important Company-level financial performance metric targets. For 2019, our Compensation Committee selected adjusted
EPS and adjusted net sales as our Company-level performance metrics. Each metric has a 50% weighting.
Company Metrics Defined. For purposes of our 2019 Annual Bonus Plan: (i) adjusted EPS equals adjusted net income (loss) divided
by weighted average diluted shares outstanding for the performance year (adjusted net income (loss) equals GAAP net income (loss) excluding certain charges (credits) from GAAP net income, including,
but not limited to, amortization expense, goodwill and intangible asset impairment charges, acquisition- and divestiture-related net charges (credits), restructuring and restructuring-related net
charges (credits), litigation-related net charges (credits), certain investment impairment charges, EU MDR implementation charges, debt extinguishment charges and discrete tax items); and
(ii) adjusted net sales is calculated at an assumed standard constant currency basis that excludes the impact of foreign currency fluctuations, which are highly variable and difficult to
predict, and other adjustments.
For
a discussion of the Company level targets under the 2019 Annual Bonus Plan, funding of the Total Bonus Pool and the individual performance component of the 2019 Annual Bonus Plan, please see the
Compensation Discussion & Analysis section titled "Short-Term Incentives."
Clawback of Annual Bonus Plan Award
Our 2019 Annual Bonus Plan provides that, to the extent permitted by applicable law, our Board will seek reimbursement of incentive compensation paid to any
executive officer under the plan in the event of a restatement of our financial results that reduced a previously granted award's size or payment. Under such circumstances, and to the extent permitted
by applicable law, we would seek to recover the amount of the 2019 Annual Bonus Plan award paid to such executive that was in excess of the amount that would have been paid based on the restated
financial results. Additionally, our 2019 Annual Bonus Plan provides that to the extent permitted by applicable law, our Board may seek reimbursement of incentive compensation paid to an executive
under the plan in the event of executive misconduct or gross dereliction of duty that resulted in a material violation of Company policy and caused significant harm to the Company. In such an event,
and to the extent permitted by applicable law, the Board may seek reimbursement of all or a portion of cash incentive compensation awards paid within a certain time period under the plan.
2019 Total Shareholder Return Performance Share Program (PSP)
Our 2019 TSR PSP is administered, and the TSR performance-based DSUs awarded pursuant to our 2019 TSR PSP are granted, under our 2011 LTIP.
The TSR performance-based DSUs vest upon the satisfaction of both the Company performance criteria and service criteria under the 2019 TSR PSP, subject to acceleration in the event of certain
qualifying terminations discussed below. Our executives, including our NEOs, are eligible to participate in the 2019 TSR PSP, which is administered by our Compensation Committee. For a discussion of
the TSR performance-based DSUs awarded to our NEOs in 2019, please see the Compensation Discussion & Analysis section titled "2019 Long-Term Incentive Awards for our
NEOs."
76
Table of Contents
Company Performance Criteria
For a discussion of the Company performance criteria under the 2019 TSR PSP, please see the Compensation Discussion & Analysis section titled "2019 Long-Term Incentive Awards for our
NEOs."
Calculation of TSR and Percentile Performance. The TSR for the Company and each other company in the S&P 500 Healthcare Index
for the three-year performance period is determined based on the following formula:
(Change
in Stock Price + Dividends Paid) / Beginning Stock Price
The
change in stock price is determined by subtracting the beginning stock price (the daily average closing price of one share of common stock for the two calendar months prior to the beginning of the
performance period) from the ending stock price (the daily average closing price of one share of common stock for the last two calendar months of the performance period). The dividends paid are the
total of all cash dividends paid on one share of common stock during the performance period.
Following
the calculation of the TSR for the three-year performance period for our Company and each of the other companies in the S&P 500 Healthcare Index, the companies will be ranked in order
of maximum to minimum TSRs for the full three-year performance period. Our percentile performance will be determined by (i) dividing (a) our ranking versus that of the other companies in
the S&P 500 Healthcare Index minus one, by (b) the total number of companies in the S&P 500 Healthcare Index minus one, and (ii) subtracting the result from one.
Service Criteria
Generally under the 2019 TSR PSP, except with respect to termination of employment due to retirement, death or disability, or in connection with a change in
control, in each case, as described in the 2019 TSR PSP and/or the 2011 LTIP, a participant must be employed with us on December 31, 2021 to be eligible to receive shares of our common stock in
respect of his or her TSR performance-based DSUs as to which the performance criteria under the program have been satisfied.
For
information regarding potential payments upon certain terminations of employment or in connection with a change in control, please see "Potential Payments Upon Termination
or Change in Control."
2019 Free Cash Flow Performance Share Program
Our 2019 FCF PSP is administered, and the FCF performance-based DSUs awarded pursuant to our 2019 FCF PSP are granted, under our 2011 LTIP.
The 2019 grants of FCF
performance-based DSUs vest upon the satisfaction of both the one-year Company performance criteria and the three-year service criteria (inclusive of the performance period) under the 2019 FCF PSP,
subject to acceleration in the event of certain qualifying terminations discussed below. Our executives, including our NEOs, were eligible to participate under the 2019 FCF PSP, which is administered
by our Compensation Committee. For a discussion of the 2019 FCF performance-based DSUs awarded to our NEOs and the Company's achievement of the Company performance criteria under the program, please
see the Compensation Discussion & Analysis section titled "2019 Long-Term Incentive Awards for our NEOs."
77
Table of Contents
Company Performance Criteria
For a discussion of the Company performance criteria under the 2019 FCF PSP, please see the Compensation Discussion & Analysis section titled
"2019 Long-Term Incentive Awards for our NEOs."
Service Criteria
Generally under the 2019 FCF PSP, except with respect to termination of employment due to retirement, death or disability, or in connection with a change in
control, in each case, as described in the 2019 FCF PSP and/or the 2011 LTIP, a participant must be employed with us on December 31, 2021 to be eligible to receive shares of our common stock in
respect of his or her 2019 FCF performance-based DSUs as to which the performance criteria under the program have been satisfied.
For
information regarding potential payments upon certain terminations of employment or in connection with a change in control, please see "Potential Payments Upon Termination
or Change in Control."
2011 Long-Term Incentive Plan
Employees, directors and other individuals who provide services to us and our affiliates who, in the opinion of the Compensation Committee,
are in a position to make a significant contribution to our success or that of our affiliates are eligible for Awards under our 2011 LTIP. The purpose of the broad-based equity incentive award
opportunities available for grant under our 2011 LTIP is to attract, retain, engage and focus key employees and other eligible participants on achieving long-term stockholder value by rewarding them
for the increased performance of our common stock underlying such awards. Our 2011 LTIP is administered by our Compensation Committee and provides for the grant of restricted or unrestricted common
stock, deferred stock units, options to acquire our common stock, stock appreciation rights (SARs), performance awards and other stock and non-stock awards (collectively, Awards). Our 2011 LTIP
prohibits repricing or replacement of options or SARs and the issuance of in-the-money options or SARs, and includes limitations on the amounts of grants and payments to any individual within a given
year as well as certain other customary limitations. Our existing 2011 LTIP will terminate on March 1, 2021 (unless terminated sooner by our Board), and no further Awards may be granted
following that date. Therefore, we are asking our stockholders to approve an amendment and restatement of the 2011 LTIP to, among other things, extend the ability to continue to grant awards beyond
March 1, 2021 and to increase to the number of shares of our common stock available for issuance under the plan. For information regarding the proposed changes to our 2011 LTIP, please see
"Proposal 3: Approval of the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan."
Generally,
the DSUs granted to our executives, including our NEOs, vest in five equal annual installments (for DSUs granted in 2017 and 2018) or, beginning in 2019, four equal annual installments, in
each case from the first anniversary of the date of grant, subject to continued service on each applicable vesting date, and stock options vest in four equal annual installments, subject to continued
service on each applicable vesting date. The stock options that we granted to our executives expire on the tenth anniversary of the date of grant.
Certain Separations from Service
Generally under the 2011 LTIP, except with respect to termination of employment due to retirement, death or disability, or in connection with a change in
control, in each case, as described therein or as otherwise provided for in the applicable award agreement, all equity awards terminate to the extent
78
Table of Contents
not
vested immediately prior to the cessation of employment, and to the extent vested but not exercised at such time, remain exercisable for the lesser of one year or until the expiration of the
stated term of the award. Further, in the event of a termination for "cause" (defined as conviction of, or a failure to contest prosecution for, a felony, or misconduct or dishonesty that is harmful
to our business or reputation), or as a result of reasons that cast such discredit on the individual as to justify immediate termination of the award, in each case, as determined in the Compensation
Committee's sole discretion, all outstanding equity awards (including unexercised stock options, whether vested or unvested) terminate immediately upon notice of such termination.
For
a discussion of our plans and arrangements under which a change in control and/or termination of employment triggers payments or benefits, including our 2011 LTIP, please see the narrative to the
tables appearing in "Potential Payments Upon Termination or Change in Control." Potential payments to our NEOs in 2019 under such plans or arrangements
are included in the tables appearing in "Potential Payments Upon Termination or Change in Control."
2019 Equity Awards
With respect to our executives, including our NEOs, our Compensation Committee set the mix of equity award opportunities under our 2019 Long-Term Incentive
Program at 25% target TSR performance-based DSUs, 25% target FCF performance-based DSUs, 25% stock options and 25% service-based DSUs. The service-based DSUs granted in 2019 vest in four equal annual
installments beginning on the first anniversary of the date of grant, subject to continued service on each applicable vesting date and except as set forth under "Certain
Separations from Service." For a discussion of the 2019 equity awards made to our NEOs, please see the Compensation Discussion & Analysis section titled
"Long-Term Incentives."
79
Table of Contents
Outstanding Equity Awards at Fiscal Year End
|
The
following table provides information with respect to outstanding unexercised non-qualified stock options and unvested DSUs for each NEO as of December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
Name
|
|
Grant Date
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable(1)
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable(1)
|
|
Option
Exercise
Price
($)
|
|
Option
Expiration
Date
|
|
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)(2)
|
|
Market
Value of
Shares or
Units of
Stock that
Have Not
Vested
($)(3)
|
|
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
(#)
|
|
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
($)(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
2/27/2012
|
|
674,941
|
|
0
|
|
6.28
|
|
2/27/2022
|
|
|
|
|
|
|
|
|
|
|
2/28/2013
|
|
660,536
|
|
0
|
|
7.39
|
|
2/28/2023
|
|
|
|
|
|
|
|
|
|
|
2/24/2014
|
|
346,083
|
|
0
|
|
13.08
|
|
2/24/2024
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
334,051
|
|
0
|
|
16.31
|
|
2/23/2025
|
|
|
|
|
|
|
|
|
|
|
2/22/2016
|
|
252,951
|
|
84,317
|
|
17.26
|
|
2/22/2026
|
|
|
|
|
|
|
|
|
|
|
2/28/2017
|
|
148,220
|
|
148,222
|
|
24.55
|
|
2/28/2027
|
|
|
|
|
|
|
|
|
|
|
2/15/2018
|
|
69,521
|
|
208,565
|
|
27.09
|
|
2/15/2028
|
|
|
|
|
|
|
|
|
|
|
2/21/2019
|
|
0
|
|
217,917
|
|
40.12
|
|
2/21/2029
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
|
|
|
|
|
|
|
|
23,759
|
|
1,074,382
|
|
|
|
|
|
|
2/22/2016
|
|
|
|
|
|
|
|
|
|
46,350
|
|
2,095,947
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
54,990
|
|
2,486,648
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
89,449(4)
|
|
4,044,884
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
151,220(5)
|
|
6,838,168
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
73,828
|
|
3,338,502
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
108,797(6)
|
|
4,919,800
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
67,298
|
|
3,043,216
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
60,635(7)
|
|
2,741,915
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
184,568(8)
|
|
8,346,165
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
134,596(9)
|
|
6,086,431
|
Daniel J. Brennan
|
|
2/16/2010
|
|
20,463
|
|
0
|
|
7.41
|
|
2/16/2020
|
|
|
|
|
|
|
|
|
|
|
2/28/2011
|
|
24,846
|
|
0
|
|
7.16
|
|
2/28/2021
|
|
|
|
|
|
|
|
|
|
|
2/27/2012
|
|
12,187
|
|
0
|
|
6.28
|
|
2/27/2022
|
|
|
|
|
|
|
|
|
|
|
2/28/2013
|
|
15,144
|
|
0
|
|
7.39
|
|
2/28/2023
|
|
|
|
|
|
|
|
|
|
|
2/24/2014
|
|
40,984
|
|
0
|
|
13.08
|
|
2/24/2024
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
60,345
|
|
0
|
|
16.31
|
|
2/23/2025
|
|
|
|
|
|
|
|
|
|
|
2/22/2016
|
|
46,374
|
|
21,080
|
|
17.26
|
|
2/22/2026
|
|
|
|
|
|
|
|
|
|
|
2/28/2017
|
|
36,231
|
|
36,232
|
|
24.55
|
|
2/28/2027
|
|
|
|
|
|
|
|
|
|
|
2/15/2018
|
|
15,642
|
|
46,927
|
|
27.09
|
|
2/15/2028
|
|
|
|
|
|
|
|
|
|
|
2/21/2019
|
|
0
|
|
47,471
|
|
40.12
|
|
2/21/2029
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
|
|
|
|
|
|
|
|
5,365
|
|
242,605
|
|
|
|
|
|
|
2/22/2016
|
|
|
|
|
|
|
|
|
|
11,588
|
|
524,009
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
13,443
|
|
607,892
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
21,865(4)
|
|
988,735
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
36,964(5)
|
|
1,671,512
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
16,612
|
|
751,195
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
24,479(6)
|
|
1,106,940
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
14,643
|
|
662,156
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
13,193(7)
|
|
596,587
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41,528(8)
|
|
1,877,896
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29,286(9)
|
|
1,324,313
|
80
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
Name
|
|
Grant Date
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable(1)
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable(1)
|
|
Option
Exercise
Price
($)
|
|
Option
Expiration
Date
|
|
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)(2)
|
|
Market
Value of
Shares or
Units of
Stock that
Have Not
Vested
($)(3)
|
|
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
(#)
|
|
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
($)(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kevin J. Ballinger
|
|
2/24/2014
|
|
34,153
|
|
0
|
|
13.08
|
|
2/24/2024
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
51,724
|
|
0
|
|
16.31
|
|
2/23/2025
|
|
|
|
|
|
|
|
|
|
|
2/22/2016
|
|
41,104
|
|
13,702
|
|
17.26
|
|
2/22/2026
|
|
|
|
|
|
|
|
|
|
|
3/3/2017
|
|
26,408
|
|
26,408
|
|
24.98
|
|
3/3/2027
|
|
|
|
|
|
|
|
|
|
|
2/15/2018
|
|
12,166
|
|
36,499
|
|
27.09
|
|
2/15/2028
|
|
|
|
|
|
|
|
|
|
|
2/21/2019
|
|
0
|
|
38,337
|
|
40.12
|
|
2/21/2029
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
|
|
|
|
|
|
|
|
3,679
|
|
166,364
|
|
|
|
|
|
|
2/22/2016
|
|
|
|
|
|
|
|
|
|
7,532
|
|
340,597
|
|
|
|
|
|
|
3/3/2017
|
|
|
|
|
|
|
|
|
|
9,909
|
|
448,085
|
|
|
|
|
|
|
3/3/2017
|
|
|
|
|
|
|
|
|
|
16,116(4)
|
|
728,766
|
|
|
|
|
|
|
3/3/2017
|
|
|
|
|
|
|
|
|
|
27,246(5)
|
|
1,232,064
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
12,920
|
|
584,242
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
19,038(6)
|
|
860,898
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
11,839
|
|
535,360
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
10,666(7)
|
|
482,317
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32,298(8)
|
|
1,460,516
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23,678(9)
|
|
1,070,719
|
Joseph M. Fitzgerald
|
|
2/28/2011
|
|
77,640
|
|
0
|
|
7.16
|
|
2/28/2021
|
|
|
|
|
|
|
|
|
|
|
2/27/2012
|
|
70,306
|
|
0
|
|
6.28
|
|
2/27/2022
|
|
|
|
|
|
|
|
|
|
|
2/28/2013
|
|
79,264
|
|
0
|
|
7.39
|
|
2/28/2023
|
|
|
|
|
|
|
|
|
|
|
2/24/2014
|
|
56,921
|
|
0
|
|
13.08
|
|
2/24/2024
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
58,189
|
|
0
|
|
16.31
|
|
2/23/2025
|
|
|
|
|
|
|
|
|
|
|
2/22/2016
|
|
44,265
|
|
14,756
|
|
17.26
|
|
2/22/2026
|
|
|
|
|
|
|
|
|
|
|
3/3/2017
|
|
28,808
|
|
28,810
|
|
24.98
|
|
3/3/2027
|
|
|
|
|
|
|
|
|
|
|
12/1/2017
|
|
153,186
|
|
153,186
|
|
26.15
|
|
12/1/2027
|
|
|
|
|
|
|
|
|
|
|
2/15/2018
|
|
17,380
|
|
52,141
|
|
27.09
|
|
2/15/2028
|
|
|
|
|
|
|
|
|
|
|
2/21/2019
|
|
0
|
|
50,443
|
|
40.12
|
|
2/21/2029
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
|
|
|
|
|
|
|
|
4,139
|
|
187,166
|
|
|
|
|
|
|
2/22/2016
|
|
|
|
|
|
|
|
|
|
8,112
|
|
366,825
|
|
|
|
|
|
|
3/3/2017
|
|
|
|
|
|
|
|
|
|
10,809
|
|
488,783
|
|
|
|
|
|
|
3/3/2017
|
|
|
|
|
|
|
|
|
|
17,581(4)
|
|
795,013
|
|
|
|
|
|
|
3/3/2017
|
|
|
|
|
|
|
|
|
|
29,723(5)
|
|
1,344,074
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
18,457
|
|
834,626
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
27,199(6)
|
|
1,229,939
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
15,578
|
|
704,437
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
14,035(7)
|
|
634,663
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46,142(8)
|
|
2,086,541
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,156(9)
|
|
1,408,874
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
81
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
Name
|
|
Grant Date
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable(1)
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable(1)
|
|
Option
Exercise
Price
($)
|
|
Option
Expiration
Date
|
|
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)(2)
|
|
Market
Value of
Shares or
Units of
Stock that
Have Not
Vested
($)(3)
|
|
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
(#)
|
|
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
($)(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward F. Mackey
|
|
2/23/2015
|
|
32,327
|
|
0
|
|
16.31
|
|
2/23/2025
|
|
|
|
|
|
|
|
|
|
|
3/2/2015
|
|
68,106
|
|
0
|
|
17.06
|
|
3/2/2025
|
|
|
|
|
|
|
|
|
|
|
2/22/2016
|
|
31,618
|
|
10,540
|
|
17.26
|
|
2/22/2026
|
|
|
|
|
|
|
|
|
|
|
2/28/2017
|
|
19,762
|
|
19,763
|
|
24.55
|
|
2/28/2027
|
|
|
|
|
|
|
|
|
|
|
2/15/2018
|
|
10,428
|
|
31,285
|
|
27.09
|
|
2/15/2028
|
|
|
|
|
|
|
|
|
|
|
2/21/2019
|
|
0
|
|
35,310
|
|
40.12
|
|
2/21/2029
|
|
|
|
|
|
|
|
|
|
|
2/23/2015
|
|
|
|
|
|
|
|
|
|
2,300
|
|
104,006
|
|
|
|
|
|
|
3/2/2015
|
|
|
|
|
|
|
|
|
|
19,227
|
|
869,445
|
|
|
|
|
|
|
2/22/2016
|
|
|
|
|
|
|
|
|
|
5,794
|
|
262,005
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
7,332
|
|
331,553
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
11,925(4)
|
|
539,249
|
|
|
|
|
|
|
2/28/2017
|
|
|
|
|
|
|
|
|
|
20,161(5)
|
|
911,680
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
11,074
|
|
500,766
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
16,318(6)
|
|
737,900
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
10,904
|
|
493,079
|
|
|
|
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
9,824(7)
|
|
444,241
|
|
|
|
|
|
|
2/15/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,684(8)
|
|
1,251,870
|
|
|
2/21/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,808(9)
|
|
986,158
|
|
|
|
(1)
|
|
All stock options are non-qualified stock options and vest in four equal annual installments beginning on the first anniversary of the date of grant, subject to continued service on each applicable vesting
date.
|
(2)
|
|
Unless otherwise noted, all service-based DSUs granted in 2017 and 2018 vest in five equal annual installments and beginning in 2019 all service-based DSUs will vest in four equal annual installments, in each case
beginning on the first anniversary of the date of grant, subject to continued service on each applicable vesting date.
|
(3)
|
|
Unless otherwise noted, the amounts reflected in this column are based on the closing price of our common stock on December 31, 2019, which was $45.22.
|
(4)
|
|
In February 2017, each of our NEOs was awarded FCF performance-based DSUs under our 2017 FCF PSP. Our adjusted free cash flow performance over the one-year performance period that ended December 31, 2017 was
98.8% relative to target performance for the same period. Accordingly, in February 2018, the Compensation Committee determined that pursuant to the terms of the 2017 FCF PSP, 97.6% of the target number of FCF performance-based DSUs had satisfied the
performance criteria under the program. These awards were settled in January 2020.
|
(5)
|
|
In February 2017, each of our NEOs was awarded TSR performance-based DSUs under our 2017 TSR PSP. Our total shareholder return performance was ranked 10th relative to that of the other companies in the
S&P 500 Healthcare Index over the performance cycle comprising the three-year period that ended December 31, 2019. Accordingly, in February 2020 the Compensation Committee determined that pursuant to the terms of the 2017 TSR PSP, 165%
of the target number of TSR performance-based DSUs had been earned based on the performance criteria under the program. Amounts for these awards represent the number of shares of our common stock that were delivered or otherwise made available to our
NEOs on February 14, 2020 in settlement of the units awarded to them in 2017.
|
(6)
|
|
In February 2018, each of our NEOs was awarded FCF performance-based DSUs under our 2018 FCF PSP. Our adjusted free cash flow performance over the one-year performance period that ended December 31, 2018 was
108.9% relative to target performance for the same period. Accordingly, in February 2019, the Compensation Committee determined that pursuant to the terms of the 2018 FCF PSP, 117.9% of the target number of FCF performance-based DSUs had satisfied
the performance criteria under the program. Amounts for these awards represent the number of shares of our common stock that will be delivered or otherwise made available to our NEOs no later than January 15, 2021 in settlement of the units
awarded to them in 2018 so long as the service criteria is also satisfied. As of December 31, 2019, such units were unearned and remained subject to forfeiture under the terms of the 2018 FCF PSP.
|
82
Table of Contents
|
|
|
(7)
|
|
In February 2019, each of our NEOs was awarded FCF performance-based DSUs under our 2019 FCF PSP. Our adjusted free cash flow performance over the one-year performance period that ended December 31, 2019 was
93.4% relative to target performance for the same period. Accordingly, in February 2020, the Compensation Committee determined that pursuant to the terms of the 2019 FCF PSP, 90.1% of the target number of FCF performance-based DSUs had satisfied the
performance criteria under the program. Amounts for these awards represent the number of shares of our common stock that will be delivered or otherwise made available to our NEOs no later than January 15, 2022 in settlement of the units awarded
to them in 2019 so long as the service criteria is also satisfied. As of December 31, 2019, such units were unearned and remained subject to forfeiture under the terms of the 2019 FCF PSP.
|
(8)
|
|
In February 2018, each of our NEOs was awarded TSR performance-based DSUs under our 2018 TSR PSP. In accordance with the SEC rules, the number of performance-based DSUs shown represents the number of units that may be
earned as of December 31, 2019 based on maximum performance. The SEC rules require that the maximum number of units be disclosed because the number of units that would have been earned based on actual results under the performance conditions for
the two-year period from January 1, 2018 through December 31, 2019 (instead of through the end of the performance period on December 31, 2020) was between target and the maximum level of performance under the program.
|
(9)
|
|
In February 2019, each of our NEOs was awarded TSR performance-based DSUs under our 2019 TSR PSP. In accordance with the SEC rules, the number of performance-based DSUs shown represents the number of units that may be
earned as of December 31, 2019 based on maximum performance. The SEC rules require that the maximum number of units be disclosed because the number of units that would have been earned based on actual results under the performance conditions for
the one-year period from January 1, 2019 through December 31, 2019 (instead of through the end of the performance period on December 31, 2021) was between target and the maximum level of performance under the program.
|
Options Exercised and Stock Vested
|
The
following table sets forth information regarding stock options that were exercised and DSUs that vested for our NEOs during the year ended December 31, 2019:
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
Name
|
|
Number of Shares
Acquired on
Exercise (#)
|
|
Value Realized on
Exercise ($)(1)
|
|
Number of Shares
Acquired on
Vesting (#)
|
|
Value Realized on
Vesting ($)(2)
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
|
|
|
|
476,848
|
|
18,524,661
|
Daniel J. Brennan
|
|
20,462
|
|
655,417
|
|
116,542
|
|
4,523,259
|
Kevin J. Ballinger
|
|
|
|
|
|
76,003
|
|
2,951,934
|
Joseph M. Fitzgerald
|
|
151,928
|
|
5,450,423
|
|
84,904
|
|
3,302,204
|
Edward F. Mackey
|
|
|
|
|
|
75,142
|
|
2,949,232
|
|
|
|
(1)
|
|
The amounts shown in this column represent the number of shares acquired on exercise multiplied by the difference between the option exercise price and the closing price of our common stock on the date of
exercise.
|
(2)
|
|
The amounts shown in this column represent the number of shares vested or earned multiplied by the closing price of our common stock on the vesting date.
|
Defined Benefit Retirement Plan
|
All
of our executive officers, including our NEOs, are eligible to participate in our defined benefit Executive Retirement Plan, as amended effective August 1, 2016. The
Executive Retirement Plan is a defined benefit plan that is intended to provide a clear and consistent approach to managing retirement-eligible executive departures with a standard, mutually
understood separation and post-employment relationship. The plan provides retiring executives with a lump sum benefit of 2.5 months of salary for each year of service, up to a maximum of
36 months' pay. The lump sum payments are made in the first payroll period after the last day of the six-month period following
83
Table of Contents
retirement.
Receipt of payment is conditioned upon the retiring employee entering into a separation agreement with us that includes a release of claims and customary non-disclosure, non-competition,
non-solicitation and non-disparagement clauses in favor of the Company. The plan provides that in the event the executive breaches the non-competition or non-solicitation provision of his or her
separation agreement, the executive must, in addition to any other court-ordered relief, repay to the Company all amounts paid under the plan.
To
receive benefits under the plan, upon his or her retirement an executive's age plus his or her years of service with us must exceed 65 years (provided that the executive is at least
55 years old and has been employed by us for at least five years). For purposes of the plan, "retirement" means any separation from service (as defined in the plan) other than a termination for
"cause" (defined as conviction of, or failure to contest prosecution for, a felony, or misconduct or dishonesty that is harmful to our business or reputation). In addition, if an executive dies and is
otherwise eligible for benefits under the plan on the date of his or her death, benefits under the plan will be paid within 60 days of the executive's death.
For
retirement-eligible NEOs as of December 31, 2019 (Mr. Fitzgerald), the present value of accrued benefits is calculated as the value of their lump sum benefit under the plan based on
the NEO's base salary, age and number of years of credited service as of December 31, 2019. For NEOs who were not eligible for retirement (Messrs. Mahoney, Brennan, Ballinger and Mackey)
as of December 31, 2019, the present value of accrued benefits is calculated based on the respective NEO's base salary, age and number of years of credited service as of December 31,
2019, discounted to December 31, 2019 from the earliest retirement eligibility date, using a discount rate of 2.7% per year. This valuation methodology is consistent with the methodology we use
for financial statement accounting purposes, except that NEOs are assumed to remain employed by us until their earliest retirement age under the plan (or their age on December 31, if eligible
for retirement on that date). For financial statement
accounting purposes, the valuation considers the probability that the executives will achieve retirement age. For a more detailed description of the assumptions used in valuing accrued benefits under
the plan, please see Note A Significant Accounting Policies to our 2019 consolidated financial statements included in
Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2019.
The
table below shows the present value of accumulated benefits payable to each of our NEOs, including the numbers of years of service credited to each NEO, under our Executive Retirement Plan as of
December 31, 2019.
|
|
|
|
|
|
|
|
|
Name
|
|
Plan Name
|
|
Number of Years
Credited Service
(#)(1)
|
|
Present Value of
Accumulated Benefit
($)(2)
|
|
Payments
During Last
Fiscal Year ($)
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
BSC Executive Retirement Plan
|
|
8.20
|
|
2,130,314
|
|
|
Daniel J. Brennan
|
|
BSC Executive Retirement Plan
|
|
23.06
|
|
1,940,969
|
|
|
Kevin J. Ballinger
|
|
BSC Executive Retirement Plan
|
|
24.07
|
|
1,435,984
|
|
|
Joseph M. Fitzgerald
|
|
BSC Executive Retirement Plan
|
|
29.21
|
|
2,010,147
|
|
|
Edward F. Mackey
|
|
BSC Executive Retirement Plan
|
|
4.91
|
|
568,557
|
|
|
|
|
|
(1)
|
|
The numbers of years of credited service reflect the NEO's actual years of service as of December 31, 2019. We do not credit additional years of service under the plan. Rather, the plan provides that the number of
years of credited service is calculated through the NEO's last day worked. Partially completed years of service are prorated based on calendar days and calculated to the second decimal point.
|
(2)
|
|
Amounts are computed as of December 31, 2019, the same retirement plan measurement date used for financial statement reporting purposes for our audited financial statements for the year ended December 31,
2019.
|
84
Table of Contents
Nonqualified Deferred Compensation
|
The
Boston Scientific Corporation Deferred Bonus Plan (the Deferred Bonus Plan) provides certain of our management, including our NEOs, an opportunity to defer a portion of their
annual award under our Annual Bonus Plan. The Deferred Bonus Plan provides participants the opportunity to defer up to 75% of their annual award under our Annual Bonus Plan until the earlier of
(i) termination of employment or (ii) an elected distribution date, such election to be made by June 30th of each year. Investment choices under the plan are generally the
same as those under our 401(k) Retirement Savings Plan, except that, among other things, participants may not elect to invest in the BSC Stock Fund. Distributions under the plan are in either lump sum
payments or annual installments over a period of two to five years, as specified by the participant. Under the Deferred Bonus Plan, Messrs. Ballinger and Fitzgerald elected to defer 75% of
their 2017, 2018 and 2019 Annual Bonus Plan Awards.
In
September 2004, we committed to fund a special one-time contribution to our 401(k) Retirement Savings Plan for the benefit of our employees. In June 2005, we adopted an Excess Benefit Plan, a
non-qualified deferred compensation plan designed to provide specific supplemental benefits to those employees who would have exceeded the 2004 Code contribution limits if the special contribution had
been made to their 401(k) plan accounts. Accordingly, the historic Excess Benefit Plan was established to accept the "overflow" contributions resulting from the special one-time contribution on behalf
of participating employees, including certain of our NEOs. Investment choices under the historic Excess Benefit Plan are generally the same as those under our 401(k) Retirement Savings Plan, except
that, among other things, executive officers may not elect to invest in the BSC Stock Fund. The investment elections are made by each participant and may be changed daily. Generally, a lump sum cash
payment of their respective account balances under the plan is made to participants determined to be "specified employees," including certain of our NEOs, commencing no earlier than six months and one
day following their "separation from service."
The
table below shows the aggregate earnings and balances for each of our NEOs under our historic Excess Benefit Plan and Deferred Bonus Plan as of December 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Plan Name
|
|
Executive
Contributions
in Last Fiscal
Year
($)
|
|
Registrant
Contributions
in Last Fiscal
Year
($)
|
|
Aggregate
Earnings
in Last
Fiscal
Year
($)(1)
|
|
Aggregate
Withdrawals/
Distributions
($)
|
|
Aggregate
Balance at
Last Fiscal
Year End
($)(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney(2)
|
|
Excess Benefit Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred Bonus Plan
|
|
|
|
|
|
140,272
|
|
|
|
720,601
|
Daniel J. Brennan
|
|
Excess Benefit Plan
|
|
|
|
|
|
13,260
|
|
|
|
60,801
|
|
|
Deferred Bonus Plan
|
|
|
|
|
|
|
|
|
|
|
Kevin J. Ballinger
|
|
Excess Benefit Plan
|
|
|
|
|
|
2,645
|
|
|
|
31,558
|
|
|
Deferred Bonus Plan
|
|
|
|
336,688
|
|
479,277
|
|
65,305
|
|
1,439,572
|
Joseph M. Fitzgerald
|
|
Excess Benefit Plan
|
|
|
|
|
|
18,773
|
|
|
|
78,902
|
|
|
Deferred Bonus Plan
|
|
|
|
436,819
|
|
519,788
|
|
452,395
|
|
2,563,537
|
Edward F. Mackey
|
|
Excess Benefit Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred Bonus Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
No portion of the amounts in this column is included in the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" column for 2019, 2018 or 2017 in the Executive Compensation section titled
"Summary Compensation Table," as the earnings were neither above-market nor preferential.
|
(2)
|
|
Messrs. Mahoney and Mackey were not employed by us when the one-time 401(k) contribution was made to our historic Excess Benefit Plan.
|
85
Table of Contents
The
investment choices under the historic Excess Benefit Plan and the Deferred Bonus Plan and their annual rates of return for the year ended December 31, 2019 are contained in the following
table.
|
|
|
Name of Investment Option
|
|
2019 Rate of Return
|
|
|
|
American Funds EuroPacific Growth Fund Class R-6
|
|
27.40%
|
Metropolitan West Total Return Bond Fund Class I
|
|
9.09%
|
PRIMECAP Odyssey Growth Fund
|
|
23.97%
|
T. Rowe Price Institutional Small-Cap Stock Fund
|
|
33.96%
|
T. Rowe Price Value Fund I Class
|
|
26.38%
|
Vanguard Extended Market Index Fund Institutional Plus Shares
|
|
28.07%
|
Vanguard Federal Money Market Fund Investor Shares
|
|
2.14%
|
Vanguard Institutional Index Fund Institutional Plus Shares
|
|
31.48%
|
Vanguard Total Bond Market Index Fund Institutional Shares
|
|
8.73%
|
Vanguard Total International Stock Index Fund Institutional Shares
|
|
21.56%
|
Vanguard Wellington Fund Admiral Shares
|
|
22.61%
|
Potential Payments Upon Termination or Change In Control
|
Executive Retirement Plan
All of our executives, including our NEOs, are eligible to participate in our Executive Retirement Plan. The Executive Retirement Plan is
intended to provide a clear and consistent approach to managing executive departures with a standard mutually-understood separation and post-employment relationship. The benefits payable to our
executives upon "retirement" under the Executive Retirement Plan, as well as the present value of amounts accrued thereunder as of December 31, 2019, are reflected in the table and the related
footnotes and narrative to the section titled "Defined Benefit Retirement Plan." In addition, changes in the present value of the benefits under the
Executive Retirement Plan from December 31, 2018 to December 31, 2019 are reflected in the
"Change in Pension Value and Nonqualified Deferred Compensation Earnings" column of the Summary Compensation Table. For further discussion of our Executive Retirement Plan, please see the footnotes
and narrative to the table appearing in the section titled "Defined Benefit Retirement Plan."
Change in Control Agreements
We have entered into Change in Control Agreements with our executives, including our NEOs, and other key employees. Our Change in Control
Agreements for our executives are limited to a three-year term and provide that if both a change in control occurs during the term of the agreement and the executive's employment is terminated either
by us without "Cause" or by the executive for "Good Reason" (each as described below) during the two-year period following the change in control, then the executive would be entitled to receive a lump
sum payment of three times the sum of (i) the executive's base salary and (ii) target incentive bonus (or prior year's bonus, if higher). Additionally, an executive would be entitled to
receive a prorated target incentive bonus for the year in which his or her termination occurred, continuation of health, life insurance and other welfare benefits for up to three years, and
reimbursement for up to $100,000 in legal fees and expenses incurred by an executive in disputing termination or enforcing rights under his or her Change in Control Agreement. Our Change in Control
Agreements further provide that all equity awards granted to executives require both a change in control and a termination without Cause or resignation by the executive for Good Reason within two
years after the change in control in order to accelerate vesting; provided, however, that if the surviving or acquiring entity in a change in control transaction does not provide for the substitution
or assumption of outstanding equity awards, such outstanding awards will immediately become fully vested.
86
Table of Contents
The
Change in Control Agreements include a "best net" provision that requires a reduction in the amount of the severance paid to an executive if the reduction would result in a greater after-tax
amount. In exchange for the benefits afforded under our Change in Control Agreements, our executives agree to certain non-disclosure restrictions, a two-year non-solicitation obligation and to execute
and not revoke a release in favor of the Company. Executives, including our NEOs, who receive payments under our Change in Control Agreements cannot also receive payments and benefits under our
Executive Retirement Plan or Severance Plan For Exempt Employees (the Severance Plan).
For
purposes of our Change in Control Agreements, "Cause" generally means willfully engaging in criminal or fraudulent acts or gross misconduct that is demonstrably and materially injurious to us.
"Good Reason" generally means, among other things, assignment of duties inconsistent with the executive's status as an executive or an adverse alteration of the executive's duties; a reduction in
annual base salary or bonus or failure to increase salary at a rate commensurate with that of other key executives; an adverse change in long-term incentive opportunities; failure by the Company to
continue to provide comparable benefits or continue in effect, or continue the executive's participation in, any compensation plan in which the executive participates; the relocation of the
executive's principal place of work more than 50 miles; or failure by the Company to obtain a satisfactory agreement from any successor entity to agree to perform the Change in Control Agreement.
Long-Term Incentive Plan
Equity awards granted to our executives under our 2011 LTIP require both a change in control and a subsequent termination without Cause or for
Good Reason pursuant to the terms of our Change in Control Agreements for accelerated vesting where the surviving or acquiring entity assumes outstanding awards.
The
terms of all service-based DSUs granted in 2019 to our employees, including our NEOs, provide that in the event that the employee's employment terminates:
-
(i)
-
due
to retirement (as defined in the 2011 LTIP) prior to the first anniversary of the equity award grant date, the unvested service-based DSUs will immediately lapse
and be forfeited;
-
(ii)
-
due
to death or disability (in each case as defined in the 2011 LTIP) prior to the first anniversary of the equity award grant date, the unvested service-based DSUs
will vest in full; or
-
(iii)
-
due
to retirement, death or disability after the first anniversary of the equity award grant date, the unvested service-based DSUs will vest in full.
Our
2011 LTIP is more fully described under the section titled "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table
2011 Long-Term Incentive Plan."
TSR Performance Share Programs
Our TSR PSPs cover our executives, including our NEOs, and are administered by the Compensation Committee. Under our 2017, 2018 and 2019 TSR
PSPs, if a participant's employment terminates due to death or disability prior to the end of the three-year performance period, shares of our common stock will be issued in respect of the TSR
performance-based DSUs as to which the performance criteria under the program have been satisfied at the end of the three-year performance period as if the participant had been employed until the end
of the three-year performance period. Under our 2017, 2018 and 2019 TSR PSPs, if a participant's employment terminates due to retirement after
87
Table of Contents
December 31
in the year of grant and prior to the end of the three-year performance period, shares of our common stock will be issued in respect of the TSR performance-based DSUs as to which
the performance criteria under the program have been satisfied at the end of the three-year performance period, on a prorated basis through the date of retirement; however, such awards will be
forfeited in their entirety in the event that retirement occurs on or prior to December 31 in the year of grant.
Pursuant
to the terms of our Change in Control Agreements, the TSR performance-based DSUs awarded to our executives require both a change in control and a subsequent termination without Cause or for
Good Reason for accelerated vesting where the surviving or acquiring entity assumes outstanding awards. Under our TSR PSPs and our Change in Control Agreements, if a change in control and a subsequent
termination without Cause or for Good Reason occurs after December 31 in the year of grant, but prior to the end of the three-year performance period, shares of our common stock will be issued
in respect of the TSR performance-based DSUs as to which the performance criteria under the program have been satisfied on the last day of the month preceding the date on which the change in control
is consummated, on a prorated basis.
Our
2019 TSR PSP is more fully described under the section titled "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table
2019 Total Shareholder Return Performance Share Program."
FCF Performance Share Programs
Our FCF PSPs cover our executives, including our NEOs, and are administered by our Compensation Committee. Under our 2017, 2018 and 2018 FCF
PSPs, if a participant's employment terminates (i) due to retirement after the end of the one-year performance period but prior to the end of the three-year service period, shares of our common
stock will be issued in respect of the FCF performance-based DSUs as to which the performance criteria under the program have been satisfied, on a prorated basis through the date of retirement
(however, such awards will be forfeited in their entirety in the event that retirement occurs prior to the end of the one-year performance period), or (ii) due to death or disability at any
time before the end of the three-year service period, shares of our common stock will be issued in respect of the FCF performance-based DSUs as to which the performance criteria under the program have
been satisfied as if the participant had been employed until the end of the three-year service period.
Pursuant
to the terms of our Change in Control Agreements, the FCF performance-based DSUs awarded to our executives require both a change in control and a subsequent termination without Cause or for
Good Reason for accelerated vesting where the surviving or acquiring entity assumes outstanding awards. However, such awards will be forfeited in their entirety in the event of a change of control
that occurs prior to the end of the one-year performance period.
Our
2019 FCF PSP is more fully described under the section titled "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table
2019 Free Cash Flow Performance Share Program."
2019 Annual Bonus Plan
Our 2019 Annual Bonus Plan is generally available to all U.S. salaried personnel not eligible for commissions under sales compensation plans,
including our NEOs, and certain international and expatriate/inpatriate employees working in positions designated by the Company as eligible to participate in the plan. To be eligible to receive their
incentive award, participants generally must be employed by us on the date payments are made under the 2019 Annual Bonus Plan. However, in the
88
Table of Contents
event
of death, retirement or certain involuntary terminations without cause, in each case, as described in the 2019 Annual Bonus Plan, participants may receive their performance incentive awards for
the year on a prorated basis based on the percentage of the year the participant was employed by us and eligible to participate (subject to certain minimum months of service requirements). Grants of
performance incentive awards to our NEOs under our 2019 Annual Bonus Plan are reflected in the Summary Compensation Table in the "Non-Equity Incentive Plan Compensation" column, and our 2019 Annual
Bonus Plan is more fully described under the section titled "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table 2019
Annual Bonus Plan," as well as the Compensation Discussion & Analysis section titled "Short-Term Incentives."
Severance Plans
We maintain severance plans for eligible employees, including our NEOs, under which participants are entitled to receive certain payments and
benefits for specified periods of time following a qualifying termination. Such benefits are only available in the event of certain involuntary terminations either (i) due to an anticipated
facility relocation or closing or a reduction of staffing levels where the employee has not refused a similar position with us, or (ii) resulting from a sale, merger or reorganization of our
Company where the employee is not provided an opportunity to be employed in a similar position with the acquiring or resulting entity. Executives, including our NEOs, who are eligible to receive
payments under our Executive Retirement Plan or who receive severance payments under a Change in Control Agreement are not also eligible to receive payments and benefits under our severance plans.
The
Severance Plan provides that director level and above exempt employees, including certain of our NEOs, are eligible for:
-
(i)
-
two
weeks of payments for each completed year of service to the Company, based on the weekly rate of the employee's salary in effect on the date of his or her
termination, with a minimum benefit of 26 weeks and a maximum benefit of 52 weeks;
-
(ii)
-
one
month of subsidized health and dental coverage for each completed year of service to the Company with a minimum benefit of six months and a maximum benefit of
twelve months; and
-
(iii)
-
outplacement
services, in each case, in the event of certain involuntary terminations described above.
Additionally,
the Severance Plan provides that, in the event of certain involuntary terminations, employees eligible to participate in our Annual Bonus Plan may be entitled to a prorated bonus if such
involuntary termination occurs on or after October 1 of a calendar year. The prorated bonus is calculated by multiplying the amount of the bonus an employee would have received for the calendar
year, had he or she remained employed by the Company until the bonus payment date (or, if less, the target bonus) (Bonus), times a fraction, as follows:
|
|
|
|
|
|
Bonus
|
|
|
×
|
|
number of days in which employee was bonus eligible during calendar year
number of days in the calendar year
|
Under
the Severance Plan, the payment of severance benefits is subject to the Company's receipt of a release of claims. In addition, the maximum severance payment available under the plan is limited
to twice the Code dollar limitation in effect for qualified plans for the calendar year immediately preceding the calendar year in which the termination occurs.
89
Table of Contents
The following tables show potential payments to Messrs. Mahoney, Brennan, Ballinger, Fitzgerald and Mackey under existing agreements, plans or other arrangements, for
various scenarios involving a change in control or termination of employment, in each case assuming the termination was effective before the end of the day on December 31, 2019 and, where
applicable, using the closing price of our common stock of $45.22 per share on December 31, 2019. In each case, amounts in these tables do not include amounts payable, if any, to our NEOs who
were not retirement eligible on December 31, 2019 pursuant to our Executive Retirement Plan, which are described in the table and accompanying narrative and footnotes in the section titled
"Defined Benefit Retirement Plan."
Michael F. Mahoney
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due
Upon
Termination:
|
|
Termination
for
Cause
($)(1)
|
|
Voluntary
Termination
($)(2)
|
|
Involuntary
Termination
Without
Cause
($)(3)
|
|
Change in
Control
($)(4)
|
|
Termination
Following
Change in
Control
($)(4)
|
|
Disability
($)
|
|
Death
($)
|
|
Retirement
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Severance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Salary
|
|
|
|
|
|
550,000
|
|
|
|
3,840,000
|
|
|
|
|
|
|
Bonus
|
|
|
|
|
|
|
|
|
|
6,386,310
|
|
|
|
|
|
|
Pro rata Target Bonus(5)
|
|
|
|
|
|
1,920,000
|
|
|
|
1,920,000
|
|
|
|
1,920,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Cash Severance
|
|
|
|
|
|
2,470,000
|
|
|
|
12,146,310
|
|
|
|
1,920,000
|
|
|
Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits(6)
|
|
|
|
|
|
8,906
|
|
|
|
47,468
|
|
|
|
|
|
|
Post-Termination Life Insurance
|
|
|
|
|
|
|
|
|
|
2,376
|
|
|
|
|
|
|
Executive Retirement Plan(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Benefits(8)
|
|
|
|
|
|
2,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Benefits
|
|
|
|
|
|
10,906
|
|
|
|
49,844
|
|
|
|
|
|
|
280G or Other Tax Adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of Accelerated Stock Options(9)
|
|
|
|
|
|
|
|
|
|
10,313,912
|
|
10,313,912
|
|
10,313,912
|
|
|
Value of Accelerated Deferred Stock Units(10)
|
|
|
|
|
|
|
|
|
|
31,431,943
|
|
42,750,316
|
|
42,750,316
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
|
|
|
|
|
|
|
41,745,855
|
|
53,064,228
|
|
53,064,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value: All Benefits
|
|
|
|
|
|
2,480,906
|
|
|
|
53,942,009
|
|
53,064,228
|
|
54,984,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90
Table of Contents
Daniel J. Brennan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due
Upon
Termination:
|
|
Termination
for
Cause
($)(1)
|
|
Voluntary
Termination
($)(2)
|
|
Involuntary
Termination
Without
Cause
($)(3)
|
|
Change in
Control
($)(4)
|
|
Termination
Following
Change in
Control
($)(4)
|
|
Disability
($)
|
|
Death
($)
|
|
Retirement
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Severance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Salary
|
|
|
|
|
|
550,000
|
|
|
|
1,980,142
|
|
|
|
|
|
|
Bonus
|
|
|
|
|
|
|
|
|
|
1,880,208
|
|
|
|
|
|
|
Pro rata Target Bonus(5)
|
|
|
|
|
|
561,040
|
|
|
|
561,040
|
|
|
|
561,040
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Cash Severance
|
|
|
|
|
|
1,111,040
|
|
|
|
4,421,390
|
|
|
|
561,040
|
|
|
Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits(6)
|
|
|
|
|
|
13,360
|
|
|
|
47,306
|
|
|
|
|
|
|
Post-Termination Life Insurance
|
|
|
|
|
|
|
|
|
|
1,557
|
|
|
|
|
|
|
Executive Retirement Plan(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Benefits(8)
|
|
|
|
|
|
2,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Benefits
|
|
|
|
|
|
15,360
|
|
|
|
48,863
|
|
|
|
|
|
|
280G or Other Tax Adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of Accelerated Stock Options(9)
|
|
|
|
|
|
|
|
|
|
2,430,925
|
|
2,430,925
|
|
2,430,925
|
|
|
Value of Accelerated Deferred Stock Units(10)
|
|
|
|
|
|
|
|
|
|
7,362,953
|
|
9,857,214
|
|
9,857,214
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
|
|
|
|
|
|
|
9,793,878
|
|
12,288,139
|
|
12,288,139
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value: All Benefits
|
|
|
|
|
|
1,126,400
|
|
|
|
14,264,131
|
|
12,288,139
|
|
12,849,179
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
91
Table of Contents
Kevin J. Ballinger
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due
Upon
Termination:
|
|
Termination
for
Cause
($)(1)
|
|
Voluntary
Termination
($)(2)
|
|
Involuntary
Termination
Without
Cause
($)(3)
|
|
Change in
Control
($)(4)
|
|
Termination
Following
Change in
Control
($)(4)
|
|
Disability
($)
|
|
Death
($)
|
|
Retirement
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Severance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Salary
|
|
|
|
|
|
544,620
|
|
|
|
1,770,018
|
|
|
|
|
|
|
Bonus
|
|
|
|
|
|
|
|
|
|
1,346,754
|
|
|
|
|
|
|
Pro rata Target Bonus(5)
|
|
|
|
|
|
442,504
|
|
|
|
442,504
|
|
|
|
442,504
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Cash Severance
|
|
|
|
|
|
987,124
|
|
|
|
3,559,276
|
|
|
|
442,504
|
|
|
Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits(6)
|
|
|
|
|
|
15,758
|
|
|
|
55,213
|
|
|
|
|
|
|
Post-Termination Life Insurance
|
|
|
|
|
|
|
|
|
|
1,396
|
|
|
|
|
|
|
Executive Retirement Plan(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Benefits(8)
|
|
|
|
|
|
2,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Benefits
|
|
|
|
|
|
17,758
|
|
|
|
56,609
|
|
|
|
|
|
|
280G or Other Tax Adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of Accelerated Stock Options(9)
|
|
|
|
|
|
|
|
|
|
1,774,851
|
|
1,774,851
|
|
1,774,851
|
|
|
Value of Accelerated Deferred Stock Units(10)
|
|
|
|
|
|
|
|
|
|
5,524,739
|
|
7,511,913
|
|
7,511,913
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
|
|
|
|
|
|
|
7,299,590
|
|
9,286,764
|
|
9,286,764
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value: All Benefits
|
|
|
|
|
|
1,004,882
|
|
|
|
10,915,475
|
|
9,286,764
|
|
9,729,268
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
92
Table of Contents
Joseph M. Fitzgerald
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due
Upon
Termination:
|
|
Termination
for
Cause
($)(1)
|
|
Voluntary
Termination
($)(2)
|
|
Involuntary
Termination
Without
Cause
($)(3)
|
|
Change in
Control
($)(4)
|
|
Termination
Following
Change in
Control
($)(4)
|
|
Disability
($)
|
|
Death
($)
|
|
Retirement
($)
|
|
Cash Severance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Salary
|
|
|
|
|
|
|
|
|
|
2,010,146
|
|
|
|
|
|
|
Bonus
|
|
|
|
|
|
|
|
|
|
1,747,275
|
|
|
|
|
|
|
Pro rata Target Bonus(5)
|
|
|
|
536,039
|
|
536,039
|
|
|
|
536,039
|
|
536,039
|
|
536,039
|
|
536,039
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Cash Severance
|
|
|
|
536,039
|
|
536,039
|
|
|
|
4,293,460
|
|
536,039
|
|
536,039
|
|
536,039
|
Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits(6)
|
|
|
|
|
|
|
|
|
|
47,312
|
|
|
|
|
|
|
Post-Termination Life Insurance
|
|
|
|
|
|
|
|
|
|
1,587
|
|
|
|
|
|
|
Executive Retirement
Plan(7)
|
|
|
|
2,010,147
|
|
2,010,147
|
|
|
|
|
|
2,010,147
|
|
2,010,147
|
|
2,010,147
|
Other Benefits(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Benefits
|
|
|
|
2,010,147
|
|
2,010,147
|
|
|
|
48,899
|
|
2,010,147
|
|
2,010,147
|
|
2,010,147
|
280G or Other Tax Adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of Accelerated Stock Options(9)
|
|
|
|
4,862,265
|
|
4,862,265
|
|
|
|
5,119,524
|
|
5,119,524
|
|
5,119,524
|
|
4,862,265
|
Value of Accelerated Deferred Stock Units(10)
|
|
|
|
6,144,054
|
|
6,144,054
|
|
|
|
6,848,492
|
|
9,547,258
|
|
9,547,258
|
|
6,144,054
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
|
11,006,319
|
|
11,006,319
|
|
|
|
11,968,016
|
|
14,666,782
|
|
14,666,782
|
|
11,006,319
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value: All Benefits
|
|
|
|
13,552,505
|
|
13,552,505
|
|
|
|
16,310,375
|
|
17,212,968
|
|
17,212,968
|
|
13,552,505
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
93
Table of Contents
Edward F. Mackey
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due
Upon
Termination:
|
|
Termination
for
Cause
($)(1)
|
|
Voluntary
Termination
($)(2)
|
|
Involuntary
Termination
Without
Cause
($)(3)
|
|
Change in
Control
($)(4)
|
|
Termination
Following
Change in
Control
($)(4)
|
|
Disability
($)
|
|
Death
($)
|
|
Retirement
($)
|
|
Cash Severance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Salary
|
|
|
|
|
|
290,012
|
|
|
|
1,740,073
|
|
|
|
|
|
|
Bonus
|
|
|
|
|
|
|
|
|
|
1,305,054
|
|
|
|
|
|
|
Pro rata Target Bonus(5)
|
|
|
|
|
|
435,018
|
|
|
|
435,018
|
|
|
|
435,018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Cash Severance
|
|
|
|
|
|
725,030
|
|
|
|
3,480,145
|
|
|
|
435,018
|
|
|
Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health and Welfare Benefits(6)
|
|
|
|
|
|
4,882
|
|
|
|
35,470
|
|
|
|
|
|
|
Post-Termination Life Insurance
|
|
|
|
|
|
|
|
|
|
1,373
|
|
|
|
|
|
|
Executive Retirement
Plan(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Benefits(8)
|
|
|
|
|
|
2,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Benefits
|
|
|
|
|
|
6,882
|
|
|
|
36,843
|
|
|
|
|
|
|
280G or Other Tax Adjustment
|
|
|
|
|
|
|
|
|
|
(647,034)
|
|
|
|
|
|
|
Long Term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of Accelerated Stock Options(9)
|
|
|
|
|
|
|
|
|
|
1,450,477
|
|
1,450,477
|
|
1,450,477
|
|
|
Value of Accelerated Deferred Stock Units(10)
|
|
|
|
|
|
|
|
|
|
5,288,297
|
|
7,070,966
|
|
7,070,966
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Accelerated Equity Grants
|
|
|
|
|
|
|
|
|
|
6,738,774
|
|
8,521,443
|
|
8,521,443
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value: All Benefits
|
|
|
|
|
|
731,912
|
|
|
|
9,608,728
|
|
8,521,443
|
|
8,956,461
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Employees, including NEOs, are not entitled to any benefits upon termination for cause. All unvested equity awards, as well as all vested but unexercised stock options, are forfeited as of the date of termination for
Cause.
|
(2)
|
|
Other than for Mr. Fitzgerald, who was retirement eligible, no benefits were payable upon voluntary termination by our NEOs as of December 31, 2019.
|
(3)
|
|
Amounts in this column represent benefits payable upon involuntary termination by the Company on December 31, 2019 (other than termination for cause or in connection with a change in control). Amounts for
Messrs. Mahoney, Brennan, Ballinger and Mackey represent benefits payable pursuant to our 2019 Annual Bonus Plan and the Severance Plan only in the event of certain involuntary terminations under the plans where each is not otherwise offered
similar employment within the Company. Amounts for Mr. Fitzgerald represent benefits payable pursuant to our 2019 Annual Bonus Plan and Executive Retirement Plan. Because Mr. Fitzgerald is eligible to receive benefits under the Executive
Retirement Plan, he is not eligible for any payments of benefits under the Severance Plan.
|
(4)
|
|
All equity awards granted to our executives require both a change in control and subsequent termination (without Cause or by the executive for Good Reason) in order to accelerate vesting; provided, however, that if
the surviving or acquiring entity in a change in control transaction does not provide for the substitution or assumption of outstanding equity awards, such outstanding awards will immediately become fully vested. Amounts in the "Change in Control"
column assume that the executive is not terminated subsequent to a change in control and that the surviving or acquiring entity in a change in control transaction provides for the substitution or assumption of outstanding equity awards.
|
|
|
Amounts in the "Termination Following Change in Control" column represent benefits payable under our Change in Control Agreements following termination without Cause or resignation by the executive for Good Reason on
December 31, 2019 in connection with, and within two years of, a change in control of the Company. For a further description of our Change in Control Agreements, please see the section titled "Change in Control
Agreements" in the narrative to these tables.
|
94
Table of Contents